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Abstract 
Correction of blood genetic disorders requires permanent gene transfer into self-
renewing, hematopoietic stem cells (HSC), and regulation of transgene expression in 
specific cell lineages. HIV-derived lentiviral vectors are very effective in transducing 
rare, non-dividing stem cell populations without altering their long-term repopulation 
and differentiation capacity. We developed a strategy for transcriptional targeting' of 
lentiviral vectors based on replacing the viral LTR control elements with cell lineage-
specific, genomic control elements. An upstream enhancer (HS2) of the erythroid-
specific GATA-l gene was cloned in a second-generation lentiviral vector to replace 
most of the U3 region of the LTR, immediately upstream of the HIV-l promoter. The 
modified LTR was used to drive the expression of a reporter gene (GFP), while a 
second gene (~LNGFR) was placed under the control of an internal, constitutive 
promoter to monitor cell transduction, or immunoselect transduced cells, independently 
from the expression of the targeted promoter. The vector was used to transduce cell 
lines, human CD34+ hematopoietic stem/progenitor cells, and murine bone marrow 
HSCs. Gene expression was analyzed in the differentiated progeny of transduced stem 
cells in vitro and in vivo, after transplantation into lethally irradiated co-isogenic (for 
murine cells) or NOD/SCID (for human cells) mice. The transcriptionally targeted HIV 
LTR allowed very high level of transg'ene expression specifically in mature 
erythroblasts, in a tat-independent fashion and with no alteration in titer, infectivity, and 
genomic stability of the lentiviral vector. Expression from the targeted LTR was higher, 
better restricted, and showed significantly less position effect variegation than that 
obtained by the same combination of enhancer/promoter elements placed in the 
conventional, internal position. Cloning of the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) at a defined position in the targeted vector, 
allowed selective accumulation of the genomic with respect to the internal RNA 
transcript, with no l,oss of cell-type restriction. A critical advantage of this targeting 
strategy is the use of the spliced, major viral transcript to express a therapeutic gene, 
and that of an internal, independently regulated promoter to express an additional gene 
for either cell marking or in vivo selection purposes. 
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Chapter 1 . 
INTRODUCTION 
15 
1.1 Haematopoiesis: an overview. 
All the cells that circulate in the periphe~al blood are derived from primitive 
mesenchymal cells referred to as pluripotential hematopoietic stem cells (HSCs). In the 
adult, most of these cells are located in the bone marrow, but they are capable of 
circulating freely in the peripheral blood. Indeed, small numbers of these cells are 
always present in the peripheral bloodstream in transit from one site in the marrow to 
another via hematogenous spread; in this manner, the marrow is continuously "seeded" 
with these cells in a homogenous fashion. In the marrow of a healthy person, most stem 
cells are neither" dividing nor differentiating. These cells are considered to be in a 
prolonged intermitotic interval and comprise the reserve stem cell pool that can be 
called into division during times of hematopoietic stress. Another smaller fraction of the 
total hematopoietic population is composed of cells that are dividing but not 
differentiating. Finally, at any given moment in time, a relatively tiny portion of the 
total stem cell pool is made up of cells that are beginning to differentiate along one the 
several pathways of hematopoietic development through a process that ultimately gives 
rise to the wide diversity of cells that circulate in the peripheral blood. This elegant 
process, which generally is restricted to the bone marrow, is referred to as 
haematopoiesis (Fig. 1.1). 
In vertebrates, the site of hematopoiesis shifts during development from the yolk sac 
site to the fetal liver, then to the bone marrow in the perinatal period (Fig. 1.2). 
Primitive haematopoiesis, that is associated with the production of large nucleated 
embryonic erythroblasts, occurs in blood islands that emerge from extraembryonic 
mesoderm in the yolk sac, at murine embryonic day 7.5 (E7.5) or day 15-18 in humans 
(Orkin and Zon, 1997). Definitive hematopoiesis, characterised by well-defined 
enucleated erythrocytes first takes place in the fetal liver beginning at mouse E9.5; it is 
multilineage, generating myeloid, megakaryocyte and lymphoid cells (Dzierzak and 
Medvinsky, 1995). It is generally believed to initiate in the aorto-gonad-mesonephros 
(AGM) region (Dzierzitk et a!., 1998), though a more recent study suggests that the yolk 
sac is the predominant source of both primitive and definitive hematopoietic progenitors 
(Palis et a!., 1999). Hema~opoietic progenitors migrate through the blood stream to seed 
the fetal liver. Late in fetal life, bone marrow assumes hematopoietic activity and 
becomes the predominant hematopoietic organ in postnatal life (Medvinsky and 
Dzierzak, 1996) (Fig.l.2). 
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Figure 1.1. Haematopoiesis. This illustration describes the development of mature blood 
cells through the sequential restriction of the cell fate potential of oligopotent progenitor 
cells derived from multi potent HSC. 
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Figure 1.2. Models of ontogeny of mammalian haematopoiesis. The two main sources of 
haematopoietic progenitor cells are the yolk sac and the AGM region. At day 9, the yolk sac 
contributes an early line of CFU-C cells that probably does not last long after birth, and which 
makes a population of predominantly red blood cells. This cell population is thought to be the 
major source of the first wave of haematopoiesis in the liver. At day 10, the AGM-derived 
cells provide CFU-S cells and pluripotential haematopoietic stem cells. These constitute the 
major cells of the second wave. Definitive progenitor cells present in circulation colonize the 
liver at 5-6 weeks and full development of liver haematopoiesis is established by 8-9 weeks 
and maintained until about 12 weeks, when bone marrow and spleen are colonized. Bone 
marrow is the exclusive site of haematopoiesis in the adult animal. · . 
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1.1.1 Organization of Hematopoiesis: cell compartments 
Hematopoietic cells can be broadly classified a~ transiting through three compartments: 
(1) stem cell compartment, (2) committed progenitor cells, and (3) mature functional-
end cells (Fig. 1.1). The cells in each succeeding compartment are the progeny of, and 
more numerous than, the cells of the preceeding compartment. 
The stem cell compartment is composed of very rare cells endowed with certain 
fundamental properties (discussed in detail in section 1.1.2), but mainly their ability to 
both self-renew and provide multilineage hematopoiesis for the life of the animal. 
Several physical ·characteristics have been ascribed to stem cells, and these have aided 
both their purification and the assay used to define them in different transplantation 
systems (Morrison et aI., 1995). Lineage markers are absent from these cells, and they 
normally are found in a quiescent state or are turning over very slowly. Stem cells are 
also equipped with a regimen of critical transcription factors that are important in the 
execution of their fundamental cellular functions of cell renewal and multilineage 
differentiation (see section 1.1.3.2). 
The progenitor cell compartment contains cells that are found at a higher frequency than 
the stem cell pool and, like the stem cell, are not morphologically distinguishable. Their 
existence is revealed by their ability to give rise to differentiated progeny in vitro in 
well-defined functional assays (see section 1.1.2.2). The progenitor cell compartment is 
derived from stem cells trough a process of commitment to different lineage pathways. 
Transition of stem cells to cells of the committed compartment is achieved not by 
acquisition of new characteristics or new proteins but by enhancement of certain 
molecular pathways, already primed in these cells, and abrogation of others (Hu et aI., 
1997). Within each lineage, a spectrum of progenitor cells exists, and these are 
hierarchically categorized on the basis of their proliferative potential, maturation time, 
response to a set of cytokines and type of differentiated progeny as revealed through in 
vitro clonogenic cultures. For example, multilineage progenitors giving rise to multiple 
lineages in vitro (e. g., colony-forming unit- granulocytic, erythroid, eosinophil, 
macrophage, megakariocyte [CFU-GEMM]) are presumed to be more primitive than 
unilineage progenitors committed only to a single lineage. 
As progenitor cells differentiate, they acquire more distinctive features characteristic of 
each lineage and move away from shared primitive progenitor characteristics: they 
show the enhancement of lineage-specific features, with a diminished or absence of 
expression of multilineage properties. Progenitor cells of each lineage are internally 
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programmed to ensure their own survival, but external cues are frequently impinged on 
these internal program that control differentiation, maturation, survival and migration 
(Wagers et aI., 2002) (see section 1.1.3). 
The precursor cell compartment, in contrast to stem and progenitor compartments, is 
defined by morphological criteria and contains cells at different maturation stages; the 
cells may be capable of undergoing a few rounds of cell division, or they may be end:-
stage, non-mitotic cells with a finite life span. The morphological characteristics of 
these cells reflect the accumulation of lineage-specific proteins, and organelles and the 
decline of nucleoar activity, which gives them a unique appearance. Furthermore, 
precursor cells for each lineage follow a unique maturation sequence; for example, in 
erythroid cells, the end product is an enucleated red cell, as the nuclei are expelled 
before terminal maturation. By contrast, terminally mature white cells remain nucleated. 
Also, cells of megakaryocytic lineage undergo unique endoreduplication cycles, 
forming large cells with multilobulated nuclei. The maturation sequence for each 
lineage requires a specific time frame, but there is enough plasticity to allow for faster 
than normal production of end-stage effector cells. Such deviations from the normal 
sequence are dictated by stress, which demands quick delivery of specialized (mainly 
white) cells into the periphery. 
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1.1.2 The Hematopoietic stem cell 
Hematopoietic stem cells (HSCs) are prob~bly the best characterized stem cell 
population. The properties that define these cells are: (i), they have the capacity to 
generate differentiated progeny of multiple blood cell lineages; (ii), they have the 
potential to produce more stem cells through a process known as self-renewal. It is this 
capacity to self-renew that enables the stem cell population to sustain hematopoiesis 
over extended periods of time (perhaps indefinitely) in vivo and, in fact, distinguishes 
them from virtually all other cells within the hematopoietic system (Abruzzese et aI., 
1999; Jordan and -Lemischka, 1990; Keller and Snodgrass, 1990; Morrison et aI., 1996). 
The theory of HSCs was first put forward in 1964 (Till et ai, 1964), but to date it has not 
been comprehensively identified and isolated. Indeed, the only means of assaying stem 
cells is by their ability to reconstitute the bone marrow of an irradiated host and give 
rise to the hematopoietic system (radioprotection assay). This has been demonstrated 
primarily in humans undergoing bone marrow transplantation and also in experimental 
animal models, where the endogenous hematopoietic system was ablated by a lethal 
dose of radiation (Aguila et aI., 1997). The frequency of HSCs in the bone marrow is 
argued to be 1x10-4 to 1x10-5 (Murray et aI., 1994). Due to its rarity, a robust effort has 
been dedicated to enrich HSCs to allow further characterization studies. HSCs have 
been enriched using a varieties of techniques, including density centrifugation, 
activation and/or cell-cycle status and surface antigen expression, but no unique 
characteristics have been found to identify these elusive cells specifically. A crucial 
point in the isolation of the HSCs is the one-to-one correspondence between physically 
purified cells and their potential ability to function as stem cells (see below). 
1.1.2.1 Phenotypic characterization of HSC 
Although the history of the application of BM transplants to humans involved the use of 
a large number of animal pre-clinical models, including the dog, pig and non-human 
primates, many of the relevant experiments leading to the isolation and characterization 
-
of HSC were derived from studies using mice~ Thus, particular attention has been 
dedicated to principles of HSC isolation, characterization and transplantation in the 
mouse, providing correlative experiments in human. 
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Properties of mouse HSClprogenitor subsets 
Limiting dilution reconstitution experiments in congenic mice using inbred strains that 
differed only at the CD45 molecule by two known alleles, CD45.1 and CD45.2, allowed 
the isolation of at least two classes of multi potent stem cells: long term (LT-HSCs) and 
short term (ST-HSCs) reconstitutive cells (Morrison and Weissman, 1994; Smith et aI., 
1991; Uchida et aI., 1997). The long-term subset self-renews for the entire lifespan of 
the host, while the short-term subset retained self-renewal capacity for approximately 8 
weeks. A third, more abundant and less completely characterized population of 
multipotent progenitors (MPPs) include multi potent cells of limited productive lifespan 
and, probably, without any self-renewal (Morrison and Weissman, 1994). The three 
classes of cells are arranged in a lineage from LT-HSCs to ST-HSCs, which in tum give 
rise to MPPs (Fig. 1.3) (Morrison et aI., 1997). Each stage of differentiation of 
multi potent cells involves functionally irreversible maturation steps. ST-HSCs and 
MPPs do not produce LT-HSCs, and MPPs do not produce ST-HSCs. Included in the 
progeny of mouse HSCs are two kinds of oligolineage-restricted cells: common 
lymphocyte progenitors (CLPs), which at a clonal level are restricted to give rise to T 
lympocytes, B lymphocytes, and Natural Killer (NK) cells (Kondo et aI., 1997) and 
CMPs, which are progenitors for the myeloerythroid lineages (Akashi et aI., 1999). 
CMPs give rise to myelomonocytic progenitors (GMPs) and megakaryotic/erythroid 
progenitors (MEPs). All of these populations (LT-HSCs, ST-HSCs, MPPs, CLPs, 
CMPs, GMPs and MEPs) are separable as pure populations using cell surface markers 
(Fig. 1.3) (Akashi et aI., 1999; Weissman, 2000). The total population of mouse 
multi potent progenitors is contained within cells that are c-kit+ Thy 1. 1 10 Lin-/lo Sca-1 + 
(KTLS cells) (Spangrude et aI., 1988). The Lin designation is for markers found on the 
surface of blood cells of known committed lineages, such as T cells, B cells, 
granulocytes, monocytes, erythrocytes and natural killer cells. Of the Lin markers, two 
are important for the separation of the different multi potent progenitor populations: 
Mac-1 and CD4. The most primitive population of LT-HSCs are contained in the Mac-
1- and CD4- subset of KTLS cells, while their immediate descendants, the ST -HSCs, are 
Mac-1 low and CD4-. The" other population of MPPs is characterized by a Mac-1 low 
and CD4 low phenotype (Morrison and Weissman, 1994). Common lymphocyte 
progenitors (CLPs) has been found to be represented at about 0.02% of mouse BM and 
can be isolated with the phenotyp~ Lin- IL7R+ Thy-1- Sca-1-lo c-kirlo (Fig. 1.3). 
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In 1996, Goodell et aI. reported a new method of obtaining enriched populations of 
HSCs from adult mouse bone marrow (Goodell et aI., 1996). This procedure exploits 
the ability of HSCs to efflux the fluorescent dye, which like the activity of P-
glycoprotein (encoded by the MDR gene), is verapamil-sensitive. The Hoechst 33342 
low cells thus isolated were called the side population (SP) cells and were found to have 
the same Lin- Scal+ CD34- phenotype independently identified in adult murine HSCs 
(Yusa and Tsuruo, 1989). SP cells have since been identified in adult bone marrow from 
several species including humans (Miller and Eaves, 1997). 
Properties of human HSClprogenitor subsets 
As with isolation of mouse HSC, human HSC and progenitor isolation has been 
characterized by enriching a rare cell population with a combination of monoclonal 
antibodies. Over the past decade, various cell surface and metabolic markers have been 
identified and used to isolate human HSC and progenitors. Among them, CD34, 
originally identified by the My 10 monoclonal antibody (Civin et aI., 1984), became the 
most critical cell surface marker to define the phenotype of human HSCs. For most 
experimental purposes purification of CD34 high expressing cells from peripheral blood 
(0.1 % of total cells), bone marrow (1-3% of total cells), or umbilical cord blood (0.3-
1 % of total cells), in association with low granularity and/or low levels of CD45 
expression, can reliably give rise to a population of CD34+ cells that include HSCs. 
However, CD34 expression is not restricted to the most early hematopoietic progenitors 
but is also present on many of the intermediate cells, between the most primitive 
hematopoietic cells to more committed progenitors. Furthermore, several groups 
provided evidence of various types of human HSCs that do not express detectable levels 
of CD34 (Zanjani et aI., 1998). Therefore, intense research has focused on identifying 
other characteristics, in either association or not with CD34 expression, which may 
serve as more reliable indicators of the HSC. The most widely used associated antigen 
is CD38. This is typically a marker for thymocytes, but is also found on plasma cells, 
and activated T-Iympocytes. Cells that do not express, or express low levels of this 
antigen in association witry high levels of CD34 (CD34+CD38-nO), constitute a widely 
accepted phenotype for identification of primitive HSC. During differentiation, the cells 
up-regulate expression of CD38, therefore serving as a useful marker to distinguish 
between CD34+ primitive HSC a~d CD34+ progenitor HSC. Other associated antigens 
th.at can be used to identify primitive HSC include the type 2 major histocompatibility 
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antigen, HLA-DR, which is absent from the most primitive HSC, but is acquired during 
stem cell ontogenesis. Another intringuing marker for primitive HSC is Thy-I. More 
than 25% of hematopoietic cells express this marker, but if combined with CD34 
expression, it is argued that a cell expressing both these antigens at high levels 
represents a very rare and early HSC (Chen et aI., 1997). 
In conclusion, it is clear that the HSC has a wide range of phenotypes, however, the· 
CD341'hy-l + Lin- designation identifies human HSC in fetal liver and BM, umbilical 
cord blood, adult bone marrow and mobilized peripheral blood (Baum et aI., 1992; 
Murray et aI., 1995). 
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Figure 1.3. Model of HSC differentiation. Included in the progeny of mouse HSCs are 
two kinds of oligolineage-restricted cells: common lymphocyte progenitors (CLPs), 
which can be isolated with the phenotype Lin-IL-7R1'hyl.l-Sca-l l°c-KitIO, and which at 
the clonal level are restricted to give rise to T lymphocytes, B lymphocytes, and natural 
killer (NK) cells; and CMPs, which are progenitors for the myeloerythroid lineages. 
CMPs give rise to cells that include myelomonocytic progenitors (GMPs) and 
megakaryotic/erythroid progenitors (MEPs). All of these populations are separable as 
pure popUlations using cell surface markers (adapted from Weissman, Cell 2000). 
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1.1.2.2 Assays for the HSC 
Human HSC functional activity can be analyzed quantitatively by in vitro and in vivo 
assays. 
In vitro assays 
A number of in vitro assays have been described that assess primitive human· 
progenitors. These include colony forming cell (CFC), long-term culture initiating cell 
(LTC-IC) (Sutherland et aI., 1990) and the cobblestone area-forming cell (CAFC) 
(Baum et aI., 1992) assays. 
CFC assays are typically performed after the initial collection of the hematopoietic cells 
from either the whole bone marrow or an isolated CD34+ cell population. Plating of a 
defined number of cells within a semi-solid (methylcellulose) media results in the 
formation of discrete colonies of various morphology, which are easily visible and 
distinguishible under a microscope. The assay requires two weeks and results obtained 
can represent either progenitor or early progenitor cells. The output colonies are divided 
into 4 different types: colony forming unit-erythroid (CFU-E), burst forming unit-
erythroid (BFU-E), colony forming unit-granulocyte/macrophage (CFU-OM) and 
colony forming unit- granulocyte/erythroid/macrophage/megakaryocyte (CFU-OEMM 
or CFU-MIX). 
LTC-IC assays utilise bone marrow stromal monolayers to support the maintenance 
and/or growth of primitive hematopoietic progenitors over at least 5 weeks (Sutherland 
et aI., 1990). Only primitive cells can be maintained over this time period and once 
plated in methylcellulose, following the CFC-based assay, will give rise to colonies. 
The CAFC assay is very similar to the LTC-IC assay (Baum et aI., 1992). The plating of 
HSC on preformed stromal monolayers results in the formation of small groups of cells 
attached to the stroma, which are visible after 28-32 days. 
These assays enumerate primitive myeloid progenitors, but not. cells with multi-lineage 
differentiation or self-renewal potential. More recently, several groups have developed 
cultures that allow the differentiation of single human Lin-CD34+ cells into cells with 
myeloid, natural killer (NK), B-Iymphoid, dendritic, and/or T -lymphoid phenotypes, 
showing that a single cell can differentiate in vitro into multiple lineages (Hao et aI., 
1998; Miller et aI., 1999). However, all of these assays have some limitation. First of 
all, none of these assays are able t~ generate secondary primitive progenitors that again 
have multilineage differentiation potential, thus arguing that they select for certain 
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populations, raising doubts as to whether if it is the HSC is in fact being selected. 
Secondly, there is a poor correlation between results obtained in vitro and the results 
obtained in vivo. 
In vivo assays 
Demonstrations of hematopopoietic activity in vivo are much more revealing, but much' 
more difficult to perform, than in vitro assays. Most assays involve the use of murine 
animal models but assays involving sheep and non-human primates have also been used 
to demonstrate the long-term repopulating behaviour of these cells (Donahue et aI., 
1996; Dunbar et aI., 1996; Ziegler et aI., 1999). 
An in vivo model for human HSC/progenitor cell engraftment was developed using 
xenogenic transplantation of human cells into immunodeficient mice. The two main 
types of immunodeficient mice are bnx (beige/nude/xid), which lack both T and NK 
cells (Nolta et aI., 1996) and SCID, which lack functional T and B cells (Kamel-Reid 
and Dick, 1988). In the SCID-hu bone marrow model, candidates for human HSC 
populations can be examined for their ability to reconstitute allogeneic human fetal bone 
giving rise to B-, myeloid and CD34+ progenitor cells (Kyoizumi et aI., 1992; McCune 
et aI., 1988). The T-cell potential of such candidate populations can be characterised in 
the SCID-hu thymus model (Peault et aI., 1991):' Human HSC/progenitors can engraft 
and differentiate into myeloid and CD3+ cells in bnx mouse BM (Nolta et aI., 1996). 
Most of the earlier studies used SCID mice, which were not ideal as they still possessed 
significant antigen-non-specific immunity. As a result, high cell doses were required to 
overc()me any residual host resistance, ruling out the development of quantitative assays 
and any purification strategies. A new mouse strain, generated by crossing SCID into 
the non-obese diabetic (NOD) background, proved to be a better recipient. Compared 
with SCID mice, this new NOD/SCID strain appears to have lower NK and complement 
activities and a defect in macrophage function.·A lower numbe~ of cells (10 to 20-fold 
less) were necessary to engraft NOD/SCID mice when compared with SCID mice. 
Overall, these mice showed high levels of engraftment for normal and leukaemic human 
transplants and, more import~ntly, enabled engraftment with .lower cell doses, rendering 
purification strategies possible (Larochelle et aI., 1996). The only limitation. of these 
NOD/SCID mice is their inability to support human T-cell development. On the 
contrary, beige-nude-SCID (Bnx) mice allow T-cell development, but not B-cell 
differentiation. Other strains have also become available recently: B2-microglobulin 
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knockout/NOD/SCID, Ragl knockout/NLD, and the nude/NOD/SCID mice. The 
capabilities of each of these new strains still need to be explored. 
1.1.2.3 Correlation of phenotype and function 
Although CD34+ cells represent a large section of the hematopoietic microenvironment, 
they have been demonstrated to posses reconstitution potential (Peault et aI., 1991) .. 
CD34+ cells injected into a SCID-hu (thymus model) mouse gives rise to engraftment 
and generation of CD3, CD4, CD8 and T cells. More importantly, this population of 
cells was also shown to repopulate baboons. Additionally, they are routinely used for 
humans, thus confirming their potential. However, whether they represent long-term or 
short-term repopulating cells is still not clear. 
CD34+ Thy-l+ Lin-, CD34+ Thy-I+' CD34+ HLA-DR- and CD34+ CD38+ CD33+ cells 
have all been demonstrated to reconstitute mice and sheep. The CD34+IHLA-DR- cell 
population was demonstrated to reconstitute sheep, giving rise to virtually all the 
hematopoietic lineages over at least 7 months. The CD34+/Thy-l + cell population is 
routinely used for SCID and SCID-hu experiments, giving rise to both myeloid and B-
lymphoid cells. The CD34+ CD38+ CD33+ cell population has obtained popularity for 
reliably reconstituting NOD/SCID mice (Larochelle et aI., 1996). However, all of these 
phenotypes are rare, and it is difficult to plan extensive experiments employing these 
cell types, due to the difficulty and low efficiency in obtaining them. 
The most widely used phenotype for animal experiments, belivied to represent the 
repopulating stem cell, is the CD34+/CD38- cell, which has been used extensively for 
the reconstitution of mice (reviewed in Verfaillie et aI., 2002). 
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1.1.3 Molecular control of Hematopoiesis 
The complex orchestration of hematopoiesis through which the elaborate array of blood 
cells described above is produced requires three physiological components, each of 
which is essential. These are: (1) the stem cell pool itself; (2) hematopoietic cytokines, 
that regulate hematopoiesis through both endocrine and paracrine mechanisms; and (3) 
the hematopoietic inductive microenvironment, which is made up of the bone marrow· 
stroma and vasculature. In addition to these extracellular cues, it is evident that critical 
steps in the control of HSC fate, from the very earliest swiching of mesenchymal cells 
to the hematopoietic lineage to differentiation into the various lineages, are 
transcri ptionall y regulated. 
Most studies of HSC fate determination focus on the choice between stem cell self-
renewal or differentiation. Over the years, several models have been advanced 
proposing that hematopoietic lineage determination is driven extrinsically (through 
growth factors, stroma or other external influences), intrinsically (as described in 
stochastic models), or both. While several studies support an instructive role for 
cytokines in the maturation of terminally differentiated cells from progenitor and 
precursor cells (Kaushansky et aI., 1995; Kondo et aI., 2000; Metcalf and Burgess, 
1982) the initial divisions of HSC are likely to involve stochastic fate choices (Ogawa, 
1993; Ogawa, 1999). In fact, it has been postulated that stochastic determination of 
HSC cell fate may be important for HSC function, in that this scheme allows for the 
maintenance of production of all blood cell lineages even in the face of substantial 
demand for one particular lineage (Enver and Greaves, 1998). Supporting the stochastic 
model for HSC differentiation, in vitro culture of Bcl-2 transgenic HSC with stem cell 
factor (SCF) alone induces these cells to proliferate, but does not preserve their 
primitive status (Domen and Weissman, 2000). This induction of HSC differentiation in 
the absence of any overt differentiating signals, suggests that lineage choice need not be 
initiated by particular cytokine signals. Similarly, lineage-res~ricted progenitors can 
develop from HSC at normal frequency, even in the absence of lineage-specific 
cytokines (Kondo et aI., 1997). 
Overall, it appears that th~ regulation of hematopoiesis. is the result of multiple 
processes involving cell-cell and cell-extracellular matrix i'nteractions, the ~ction of 
specific growth factors and other cytokines, as well as intrinsic modulators of 
hematopoietic development. 
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1.1.3.1 Role of the microenvironment in HSC fate determination 
Regulation of HSC fate involves multiple highly. orchestrated pathways that determine 
cell cycle status and gene expression profile. This complexity is due in large part to the 
fact that HSCs do not grow as independent autonomous units. Rather, these cells are 
surrounded in all dimensions by the marrow microenvironment, the so-called "stem cell 
niche". The hypothetical function of the HSC niche is to provide HSC survival and self-
renewal factors, either through direct contact with HSC or through secreted factors. 
HSC niches are formed from a subset of mesenchymal cells within the bone marrow. 
These so-called "stromal cells", which include specialized fibroblasts, endothelial cells, 
osteoblasts, and perhaps adipocytes, may playa further role in "translating" external 
signals to influence HSC developmental decisions (Muller-Sieburg and Deryugina, 
1995). 
HSC are exposed in situ to many different growth factors, some soluble, some bound to 
extracellular matrix (ECM) and others bound to adjacent cells. Due to the inherent 
diffculty in studying these cells in their microenvironment, most of what we know about 
how different soluble growth factors control HSC fate has been deduced from in vitro 
studies (Em a et aI., 2000; Goff et aI., 1998). The primary question that has been 
addressed is whether we can simulate in vitro the conditions that tell the HSC to self-
renew. If this were completely understood and could be performed in vitro, we could 
then expand small numbers of highly pluripotent HSC for clinical transplantation as 
well as for other scientific studies. Due to their fundamental role in mediating in vitro 
maintenance and expansion of stem cells, growth factors and cytokines will be 
described in detail in Section 1.1.3.3. 
Within the context of a supportive microenvironment, cell adhesion and extracellular 
matrix molecules also play an important role in HSC development. Within the adult 
bone marrow, these molecules mediate interactions between stromal and hematopoietic 
cell components that in tum regulate cell proliferation, differentiation and migration. 
Extracellular matrix (ECM) is composed of three major classes of molecules: structural 
proteins such as collagen and elastin, specialized proteins such as fibronectin and 
laminin, and proteoglycans Which consist of a protein core ,to which is attached long 
chains of repeating disaccharide units, termed glycosamin'oglycans (GAGs). ECM 
proteins in the BM include fibronectin, collagen, laminin and cytokines, which can bind 
to ECM proteins. The ECM acts in concert with cell-cell interactions and soluble factors 
to regulate the HSC. In general, adhesion of hematopoietic stem and progenitor cells to 
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the marrow ECM inhibits cellular proliferation and prevents apoptosis, both of which 
lead to long-term survival of quiescent hematopoietic stem cells. Clues are beginning to 
emerge regarding how these effects are mediated. For example, binding of integrins on 
hematopoietic stem or progenitor cells has been shown to lead to increased p27 
expression, and p27 halts progression of the cell cycle by inhibiting a cyclin dependent 
kinase (Cheng et aI., 2000). 
1.1.3.2 Transcriptional regulation of HSC fate 
Transcription factors represent a nodal point of hematopoietic control through the 
integration of the various signaling pathways and subsequent modulation of the 
transcriptional machinery. Transcription factors can act both positively and negatively 
to regulate the expression of a wide range of haematopoiesis-relevant genes including 
growth factors and their receptors, other transcription factors, as well as various 
molecules important for the function of developing cells. It is the alternative expression 
of specific combinations of transcription factors that determines the survival, 
proliferation, commitment, and differentiation responses of hematopoietic progenitors 
to such signals, whether they arise from extrinsic or intrinsic regulatory factors. 
Increasing evidence suggests that different families of transcription factors regulate the 
developmental program of stem cells (Shivdasani and Orkin, 1996) and when their 
expression is disrupted, leukaemic proliferation is initiated (Rabbitts, 1994). 
Since purifying and biochemically investigating very rare HSC populations is so 
difficult, knowledge of the role of specific transcription factors in HSC fate decisions 
has been derived largely from genetic strategies, primarily gene-targeting (knockout) 
and retroviral infection/overexpression experiments. From this growing body of 
literature, 'several transcription factors have been found to play critical roles in HSC 
physiology, and some of them are described in the sections below depending on the 
time and the influence of their expression during different steps of HSC development. 
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1.1.3.2.1 Transcription factors required during early stem cell decisions 
Lying at the top of a regulatory hierarchy would appear to be those genes that are 
required for the formation of all hematopoietic lineages. Such genes might act at the 
pre-HSC level, for example, within mesoderm or the hemangioblast, to specify a 
hematopoietic fate or within the HSC to foster survival or proliferation. Genes in this 
general class include the transcription factors known as SCL/Tal-1, GATA-2, and 
LMO-2, which are essential for primitive and definitive hematopoiesis, and AML-1 that 
is required for definitive hematopoiesis (Fig. 1.4). 
SCL/Tal-1 protein shares homology within a restricted region of 56 amino acids with a 
number of bHLH transcription factors, and it is capable of binding to the E-box motif of 
DNA (CANNTG) in vitro and forms heterodimers with other HLH factors such as 
E47/E2A and E12. SCL homozygous null embryos die at around 9.5 d.p.c. and 
histological studies showed complete absence of recognizable hematopoiesis in the yolk 
sac, with GAT A-I and c-Myb expression being undetectable (Robb et aI., 1995). Very 
recently, the group of Orkin reported that SCL/Tal-1 is dispensable for HSC 
engraftment, self-renewal and differentiation into myeloid and lymphoid lineages, while 
proper differentiation of erythroid and megakaryocytic precursors is dependent on 
SCL/Tal-1 (Mikkola et aI., 2003). Thus, SCL/Tal-1 is essential for the genesis of HSCs, 
but its continued expression is not essential for HSC function. 
Both primitive hematopoiesis in the yolk sac and definitive hematopoiesis in fetal liver 
and spleen as well as adult bone marrow are greatly affected by deficiency in GAT A-2. 
Deficient primitive haematopoiesis, evident by severe anemia, results in most GATA-2-
deficient embryos dying before 10.5 p (Tsai et aI., 1994). GATA-2 may also be one 
major mediator of the ability of BMP-4 to specify hematopoietic mesoderm, since 
BMP-4 expression in the embryo is polarized to the ventral wall· of the aorta, 
immediately underlying the site of initial hematopoiesis (Maeno et aI., 1996; Marshall 
et aI., 2000). 
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Figure 1.4. Transcriptional regulation of early HSC development. HSCs, as one progeny 
of hemangioblasts or hemogenic endothelium, are faced with the cell fate choice either to 
self-renew or to differentiate into committed common lymphoid or common myeloid 
haematopoietic precursors. The transcription factors involved in each development 
direction are depicted (see text for details. Adapted from Zhu J and Emerson SG, 
Oncogene, 2(02). 
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Lim-finger protein LM02, also known as Rbtn2, was originally found to be activated in 
T cell leukemia by chromosomal translocation. Embryogenic LM02 expression was 
found localized to hematopoietic sites (Manaia et aI., 2000). LM02 does not bind DNA 
by itself, but acts as a bridge between DNA-binding transcription factors such as SCL 
and GATA-1. LM02 null mice die around E9 from severe anemia, with a lack of any 
yolk sac haematopoiesis, identifying an essential role for LM02 in early haematopoiesis 
(Yamada et aI., 1998). However, LM02 may also participate in the lineage-specific 
mechanisms that regulate erythropoiesis, as it takes part in an erythroid transcription-
activation complex, together with SCL, E2A, GATA-1 and Lbd1 (Wadman et aI., 1997; 
Warren et aI., 1994). The complex recognizes an E box motif approximately one helix 
tum (10 bp) upstream from a GATA site (Fig. 1.5). 
The AML-1 gene is the most frequent target for chromosomal translocations in human 
acute leukemias. Homozygous AML-l knockout mice showed an absence fetal liver 
haematopoiesis and failed to contribute to definitive hematopoiesis in chimeric mice, 
but primitive yolk sac erythropoiesis was unaffected (Okuda et aI., 1996). 
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Figure 1.S. Pentameric complex formed between SCL, E2A, LM02, Ldbl and GATA-l. 
schematic representation of cis-acting regulatory DNA from a hypothetical erythroid 
target gene containg an E box motif (CAGGTG) and GATA-binding motif separated by 
10 nuc1eotides (adapted from Wadman et al., 1997). 
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1.1.3.2.2 Transcription factors regulating self-renewal of HSCs 
The transcriptional machinery governing p~imitive stem cell biology is undoubtedly 
very complex. While the transcription factors described above are absolutely essential 
for the survival and proliferation of HSCs, other molecules clearly impact strongly on 
the cell fate decisions of stem cells, both for symmetric expansion and lineage 
commitment. While we are still at the beginning of uncovering these key molecular 
regulators, several pieces of work indicate that transcription factors HOXB4 and Ikaros, 
activated nuclear form of Notch1, cell cycle inhibitor p21 and TGF/BMP-4 family 
members are likely to be involved in the maintenance or promotion of hematopoietic 
stem cell renewal (Fig. 1.4). 
Homeobox (HOX) gene family members encode DNA-binding transcription factors 
characterized by a conserved 60-amino acid homeodomain which is homologous to 
Drosophila homeobox proteins and also plays a crucial role in mammalian embryonic 
axis formation. Human HOX genes are organized on different chromosomes in four 
major clusters, A, B, C and D, each of which consists of nine to 12 tandem genes (Scott, 
1992). While their role in embryonic axis formation has been well studied, their 
potential function in regulating haematopoiesis is less clear, although several recent 
studies point to a major role (Sauvageau et aI., 1994). For example, it was first noticed 
that in vitro differentiation of human Lin-, non-adherent peripheral blood cells to either 
the erythroid or granulocytic fate was accompanied by a remarkable and persistent 
increase in HoxB4 mRNA levels, and that the administration of HoxB4 antisense 
oligonucleotides inhibited colony formation to these two lineages in vitro (Giampaolo et 
aI., 1994). Then it was shown that the long-term repopulating ability of murine bone 
marrow cells was increased by at least 10-fold when HoxB4 cDNA was overexpressed 
by retroviral infection (Sauvageau et aI., 1995; Thorsteinsdottir et aI., 1999). More 
recently, the same group also reported that Hox B4 is able to induce ex vivo expansion 
of adult HSCs (Antonchuk e~ aI., 2002). 
The Ikaros gene product belongs to the zinc finger family of transcription factors. The 
long form of Ikaros mainly consists of. two zinc fingers, an N-terminal finger domain 
mediating DNA binding and a C-terminal domain mediating dimerization. Generally, 
.. 
Ikaros proteins modulate transcription by recruiting a co-repressor complex .to the 
promoters of target genes and/or. sequestering these genes to the vicinity of 
heterochromatin (Koipally et at, 1999; Sabbattini et aI., 2001; Trinh et aI., 2001). 
Intriguingly, different isoforms of Ikaros are differentially expressed at different stages 
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of hematopoiesis (Klug et aI., 1998), suggesting that regulated expression of Ikaros 
isoforms could provide fine regulation of the. expression of lineage specific transcription 
factors. Mice lacking all isoforms of Ikaros display a severe deficiency in B, T and NK 
cell development (Georgopoulos et aI., 1994). 
In contrast to the transcription factors described above, which are believed to be directly 
regulated by only intracellular events, Notch1-Jagged may provide a key pathway to 
integrate extracellular regulatory signals with stem cell cycling control. Notch and 
jagged are members of a superfamily of highly evolutionarily conserved transmembrane 
receptors that influence numerous cell-fate decisions in both invertebrates and 
vertebrates. Members of both the Notch and Jagged superfamilies are predominantly 
transmembrane molecules. When a Notch family member binds to its ligand (a Jagged 
family member), a signal is transferred to cleave the intracellular domain of Notch, 
which then translocates to the nucleus where it interacts with cofactors to affect the 
transcriptional program. By constitutively overexpressing the intracellular domain of 
Notch1, several immortalized cell lines were established from murine BM SKL cells, 
which still maintained the potential to reconstitute myeloid and lymphoid cell lines both 
in vivo and in vitro (Varnum-Finney et aI., 2000). This phenomenon may reflect the in 
vivo physiology of Notch/Jagged interactions, as the addition of Notch ligand jagged-1 
into an in vitro expansion system of human CD34+ CD38- Lin- cord blood cells, 
prompted their ability to repopulate pluripotently in SCID mice (Karanu et aI., 2000). 
1.1.3.2.3 Transcriptional regulation of lineage commitment 
Several transcription factors characterized to date exhibit restricted patterns of 
expression among the maturing precursor cells and are specifically required for 
development of one or more hematopoietic lineages. Some of these factors act in very 
different lineage decisions, such as PU.1 and Notch1 and their influence on HSC fate 
may vary depending on the ,time and the level of their expression during hematopoietic 
development (see Figs. 1.6 and 1.7). 
Once HSCs divide and generate more differentiated daughter cells, within 10-15 
divisions the genetic programs of the descendent cells become fixed toward a single 
lineage. How are lineage commitment decisions from HSCs initiated and reg!llated? 
This critical but most difficult question has been the subject of intense and creative 
debate and equally intense and creative experimentation. Among the most intriguing set 
of relevant data are those suggesting that HSC, CLP and CMP fate decisions might not 
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be instantly made, but rather preceded by a phase of promiscuousness or hesitation 
(Enver and Greaves, 1998; Rothenberg, 200.0). The alternative differentiation potential 
might not be immediately eliminated, but rather repressed in a graded or gradual way in 
the cells that are committing to a given lineage. 
Presumably, the differential expression of transcription factors triggers the determination 
of HSC fate: renewal or commitment to either CLP or CMP. By using differential cDNA 
library screening and sensitive RT-PCR methods, a number of candidate transcription 
factors that are preferentially expressed in cells destined to' one of those fates have been 
found. Of the transcription factors studied to date, the largest body of published 
evidence relates to the transcription factor PU.1. Predominance of PU.l could be among 
one of earliest events biasing HSCs to lineage commitment. The co-upregulation of 
PU.l and GATA-l heralds the commitment to CMPs (see Fig. 1.6), PU.l expression is 
maintained in CLPs and is also absolutely required for lymphoid development (see Fig. 
1.7), while knock-out of PU.l spared the development of primitive erythropoiesis (Scott 
et aI., 1994). 
Whereas PU.l and GATA-l are co-expressed in CMPs, their mutually exclusive 
expression coincides with further commitment to either granulocytic/monocytic or 
megakaryocytic/erythroid differentiation. The expression of GAT A-I decreases in 
granulocytic/monocytic differentiation while that of PU.l decreases with differentiation 
to either megakaryocytic or erythroid direction (see Fig. 1.6). Moreover, gene targeting 
experiments have shown that PU.l is absolutely required for monocytic and B 
lymphocytic development while GAT A-I for erythroid and megakaryocytic 
development. If hematopoietic lineage commitment is preceded by a state of 
transcriptional promiscuity, one may ask what is the mechanism that reinforces and 
stabilizes commitment to specific lineages. Studies suggest that the expression of a 
transcription factor, above a threshold level, has two reinforcing lineage directing 
effects: (1) auto-upregulation of itself (Chen etaI., 1995; Tsai et aI., 1991) and (2) 
down-regulation of alternative transcription factor pathways. In the clearest system 
studied to date, PU.l was found to inhibit the transcriptional activity of GAT A-I upon 
its target genes and vice versa;' The overexpression of PU.l inhibited DNA binding of 
GAT A-I to its consensus element on target gene promoters and this inhibiting effect 
could be relieved by the over-expression of GATA-l (Nerlov et aI., 2000; Zhang et aI., 
1999). Taken together, these data suggest that the initial ratio of GATA-l/PU.l protein 
at an"early, critical time point in the CMP determines the subsequent lineage-restricted 
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fate of the cell (Cantor and Orkin, 2001; Rekhtman et aI., 1999; Zhang et aI., 1999; 
Zhang et aI., 2000). 
A sea of transcription factors regulating the subsequent lineage choice of the CMP and 
CLP has been identified. This is beyond the immediate scope of this study, but the 
reader is referred to any pubblication, by the guru in this field, S. Orkin (Cantor and 
Orkin, 2001; Shivdasani and Orkin, 1996). 
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Figure 1.6. Transcriptional regulation of common myeloid precursor (CMP) 
commitment. CMPs differentiate into either common precursors for granulocytic and 
monocytic lineages (GMPs) or common precursors for both erythroid and megakaryocytic 
lineages (EMPs). A separate, possible, pathway leading to eosinophils is depicted by 
dotted line. Dual expression of PU.l and GATA-l leads HSCs to CMPs, but then 
dominant expression ofPU.l is restricted to GMPs, while unopposed GATA-l expression 
directs differentiation to EMPs (from Zhu J and Emerson SG, Oncogene, 2(02). 
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Figure 1.7. Transcription regulation of common lymphoid precursor (CLP) commitment. 
B lymphocytes and T lymphocytes are derived from a common lymphoid precursor 
(CLP). The early development of B cell is distinguished into distinct stages by the 
sequential expression of different transcription factors that direct Ig gene recombination 
and the expression of B cell specific cell surface phenotypes. A proposed differentiation 
pathway of macrophages from pro-B is also indicated by a dotted line (from Zhu J and 
Emerson SG, Oncogene, 2(02). 
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1.1.3.3 In vitro maintenance of the HSC: citokines and growth factors 
The HSC is not only plastic in its characteristic, but also delicate. This is hard to believe 
when considering the manipulation it is exposed to in bone marrow transplant, but even 
short ex vivo culture periods, in the absence of appropriate growth stimuli, quickly 
results in its extinction. Growth in vitro can only be sustained if the cell is exposed to 
growth factors, cytokines or feeder layers, whereas in vivo all the necessary factors for 
controlled and regulated growth are provided by the microenvironment of the host (see 
Section 1.1.3.1). 
For the in vitro study, or ex vivo maintenance of either the HSC or its progeny, 
cytokines and growth factors are absolutely required. The effects elicited by them range 
from maintenance of phenotype and function, to specific signals directing the cells to 
differentiate towards a certain lineage. A large number of cytokines and growth factors 
regulate hematopoiesis, both in positive and negative ways, and this section is dedicated 
to the major cytokines that have been or are used in vitro to study and maintain the HSC 
(Alexander, 1998; Dexter and Heyworth, 1994). 
Interleukin-3 (lL-3), also known as multi-CSF, is a multilineage stimulator'- directly 
giving rise to megakaryocytes, mast-celllbasophils, B-cells and eosinophils. Interleukin-
6 (IL-6) has a direct proliferative effect on hematopoietic cells, including the growth of 
both Band T cells, but in synergy with other factors can induce myeloid cell 
proliferation. If used with IL-3, it can induce the proliferation of primitive 
hematopoietic progenitors. Stem cell factor (SCF, also known as Kit-ligand and Steel 
factor) contributes to the maintenance of normal stem cell numbers. Direct in vitro 
addition appears to elicit no response on the HSC, and requires synergy with other 
cytokines. Knock-out mice for either the factor or its receptor results in a large 
reduction of marrow repopulating cells, whilst the addition of SCF to normal mice 
results in the expansion of transplantable HSC (Kaushansky, 1998). Thrombopoietin 
(TPO) is the sole ligand for c-mpl, a transforming oncogene. It stimulates 
megakaryocytes, platelet growth, differentiation and maturation. However, addition to 
umbilical cord blood derived HSC can result in expansion of the HSC pool and also 
expansion of LTC-IC in serum free culture (Kaushansky, 1998). However, the same 
. . 
effect has not been observed for mobilised peripheral blood derived CD34~ cells 
(Murray et aI., 1999), but has been observed for bone marrow derived CD34+/fhy+/Lin-
cells (Young et aI., 1996). Flt-3 is a class III tyrosine kinase receptor, expressed almost 
exclusively on human CD34+ HSC. Flt-3 Ligand can recruit primitive CD34+/CD38-
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HSC into cycle to a greater extent than combination of cytokines (Haylock et aI., 1997), 
although the receptor expression is low on the most primitive HSC, but higher on 
intermediates between it and committed progenitors. 
Very few cytokines act alone, most of them synergistically with other cytokines, to 
produce an effect. Any combination of different cytokines can result in the growth and 
maintenance of the HSC, however more specific approaches to determine which 
cytokines are best for the ex vivo maintenance of in vivo repopulating cell are constantly 
being tested. The use of IL-3, IL-6 and SCF was a standard for HSC culture and has 
been used in combination or substitution with other colony stimulating factors during in 
vitro culture. The culture of CD34+/CD3S- cells for 3 weeks in SCF, TPO, Flt3-L give 
rise to higher levels of engraftment compared to a TPO, Flt3-L, IL-6 supplemented 
culture. The addition of IL-6 to the SCF, TPO, Flt3-L culture combination gave no 
benefit, indicating that SCF was absolutely required, for ex vivo maintenance of the 
repopulating HSC. 
Studies analysing a large variety of cytokine combinations or cytokines alone 
demonstrated that the induction of cycling, and maintenance of the CD34+ phenotype 
did not vary greatly between the combinations used (Murray et aI., 1999). Prevention of 
apoptosis, the percent of cell viability and the percent of primitive phenotype were 
better controlled using the SCF, TPO, Flt3-L alone or in combination, compared to 
combinations containing LIF, IL-3, or IL-6 (Murray et aI., 1999). However, an 
important role of HSC and hematopoietic control is attributed to its environment and 
particularly to the stroma. 
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1.1.4 The Hematopoietic System as a Target for Gene Therapy 
Gene therapy employs various methods to deliver foreign genes into somatic cells with 
the ultimate goal of incorporation and stable expression of the gene of interest in a 
manner which will result in a therapeutic effect. Methods used for gene therapy are 
categorized into non-viral and viral. Non-viral methods of gene delivery include 
cationic and cholesterol-containing liposomes, peptide lipid vectors, activated 
dendrimers, bacteria, artificial chromosomes and artificial viruses. Most of the current 
gene therapy approaches make use of the viral methods. The viral vectors used for gene 
transfer include retroviruses, adenoviruses, adeno-associated viruses, herpes simplex 
virus and flaviviruses. For gene therapy to be successful, an appropriate amount of a 
therapeutic gene must be delivered into the target tissue without substantial toxicity. 
Each viral vector system is characterized by an inherent set of properties that affect its 
suitability for specific gene therapy applications. For some disorders, long-term 
expression from a relatively small proportion of cells would be sufficient (for example, 
genetic disorders), whereas other pathologies might require high, but transient, gene 
expression. In other cases, such as diabetes and thalassemias, gene therapy will require 
tightly regulated gene expression (Clackson, 2000). No single vector system is likely to 
be optimal for all the potential gene therapy applications. However, for a specific 
application, an "ideal" vector will be administered by non-invasive delivery routes, 
target to the desired number of cells within target tissue and express a therapeutic 
amount of transgene product with the desired regulation for a defined length of time. 
Though we are likely to see gene therapy successes in the near future, the true fruition 
of gene therapy cannot be realized until the current vectors are perfected or new vectors 
developed with the properties described above. 
Over the last two decades, it has been proposed that the transfer of genes into 
hematopoietic stem cells could be a tool for the treatment of genetically inherited 
diseases as well as a number of acquired diseases, including cancer; AIDS, autoimmune 
and neurodegenerative disorders. With the clinical application of gene therapy 
progressing in parallel with a better understanding of stem cell biology, the number of 
different target cells, tissues and' organs used in gene therapy has increased significantly. 
.. . 
However, HSCs remain the main cellular target for genetic intervention in a number of 
clinical settings of primary medical and scientific relevance, especially, but not only, 
those that aim to correct or modulate the immune system. 
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1.1.4.1 Viral vectors for gene transfer into HSC 
All viral and synthetic vectors developed for different gene therapy models have been 
tested for their ability to transduce HSCs with most of the data being generated with 
viral vectors, predominantly murine onco-retroviruses (Kay et aI., 2001). These vectors 
permanently integrate the transferred gene into the genome of the host cell, which 
should maintain transgene expression during proliferation, differentiation and 
maturation in all cell lineages. However, target cell division is required for gene 
transduction with these' vectors, whereas immature HSCs are naturally quiescent. To 
overcome this initial obstacle, a large body of research focused on inducing cell division 
while preserving the self-renewal ability of stem cells and their potential to expand and 
differentiate into all blood lineages. Strategies involved the use of different 
hematopoietic growth factors in various combinations, with or without the additional 
use of bone marrow stromal cell layers and human recombinant fibronectin fragments. 
The abilities of these strategies to favour gene transfer efficiency while preserving 
"stem cell potential" of the transduced population were explored. This massive effort 
resulted in significant progress in the development of animal models of HSC gene 
transfer. However, for several years this research had no impact on gene therapy for 
human diseases. Data on the feasibility of stem cell gene therapy in humans only 
became available a few years ago in a small number of clinical settings, including 
severe-combined immunodeficiencies (SCIDs) and several gene-marking studies in the 
context of bone marrow transplantation (Bordignon et aI., 1995; Kohn, 1999). But either 
the clinical relevance of these results was difficult to evaluate or transgene expression 
was below the threshold required for clinical benefit. Only very recently, a clear clinical 
benefit has been observed in the treatment of two different types of SCID diseases 
(Ai uti et aI., 2002); Cavazzana-Calvo et aI., 2000). However, in both these cases the 
relevance of the outcome was partially attributed to the selective advantage that the 
transduced cells shared with respect to the untransduced cells. 
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The discovery and development of new vectors derived from HIV sharply accelerated 
progress in the field of HSC gene transfer. This family of lentiviral vectors can 
transduce dividing and nondividing cells from different lineages, tissues and organs, 
including HSCs, with great efficiency (Naldini et aI., 1996). Lentiviral vectors 
efficiently transduce nondividing cells after direct in vivo injection, thus making genetic 
engineering easier and more suitable for large-scale medical application. However, 
safety concerns related to the use of vectors derived from a human pathogen and 
technical problems associated with large-scale production and validation have hindered 
their application as a new gene transfer tool. 
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1.2 Lentiviruses, HIV -based vectors and lentiviral packaging cell system 
Lentiviruses are a family of complex retroviruses typically associated with infection of 
macrophages and lymphocytes. Lentiviruses include a variety of primate (e.g. human 
immunodeficiency viruses [HIV-l and 2], and simian immunodeficiency viruses [SIV]) 
and non-primate (e.g. maedi-visna virus [MVV], feline immunodeficiency virus [FIV], 
equine infectious anemia virus [EIA V], caprine arthrithis encephalitis virus [CAEV] 
and bovine immunodeficiency virus [BIV]) viruses (Coffin et aI., 1997). The ability to 
integrate into the genome of non-dividing cells makes lentiviruses particularly attractive 
in human gene therapy. 
1.2.1 Lentiviral genome structure and vector elements 
The lentiviral genome is a diploid, plus stranded RNA that is reverse transcribed into 
DNA (called a provirus) and integrated into the host cell chromosomes (Fig. 1.8). Like 
other retoviruses, the provirus contains the long terminal repeat (LTR) elements at both 
5' and 3' ends. The LTRs contain the left and right integration attachment sites (att) and 
are required for integration into the host genome. The LTRs also serve as enhancer-
promoter sequences, controlling expression of the viral genes. ,Each LTR contains U3 
(unique 3), R (repeat), and U5 (unique 5) regions. T~e U3 contains the core promoter 
and adjacent regulatory sequences, both of which recruit the cellular transcriptional 
machinery to the start site of viral RNA synthesis. The R region contains the sequence 
for the trans-acting response (TAR) element and signals for polyadenilation. The U5 
region contains sequences that contribute to the packaging of progeny RNA genomes 
during virus assembling. 
HIV-l encodes three structural genes: gag, pol and env. The product of gag is translated 
from un spliced mRNA as a precursor protein and cleaved into the following protein 
subunits: matrix (MA), essential for virion assembly and infection of non-dividing cells 
(GaBay et aI., 1996; GaBay et aI., 1995) capsid (CA), which forms the hydrophobic core 
of the virion and is essential for virion assembly and maturation; nucleocapsid (NC), 
which coats viral RNA stochiometricallyand remains tightly associated with viral RNA 
in virions; p6 which is important for Vpr incorporation during v~ral assembly (Selig et 
aI., 1999) and for the efficient particle release (Huang et aI., 1995). The pol-gene 
encodes three enzymes required for viral replication: protease (PRO), reverse 
transcriptase (RT) and integrase (IN). PRO cleaves Gag and Gag-Pol polyproteins 
which are essential for the maturation of the virion. RT contains three enzymatic 
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Figure 1.S. Genetic organization of generalized provirus. The proviral DNA as it is 
inserted into host DNA is shown at the top, with the long terminal repeats (LTRs) 
composed of U3, R, and U5 elements at each end abutting cellular sequences. Sequences 
in the LTR that are important for transcription, for example, enhancers, the promoter, and 
the poly(A) addition signal, are marked. The gag, pro, pol, and env sequences are located 
invariably in the positions shown in all retroviruses. Accessory genes are located as 
shown, and also overlapping env and U3 and each other, and occasionally in other 
locations. The RNA that is the primary transcriptional product is shown on the second 
line. Sequences that are important for replication and gene expression are shown in the 
approximate locations in which they are typically found. (PBS) Primer-binding site; ('I') 
encapsidation sequence; (SD) splice donor site; (SA) splice acceptor site; (PPr) 
polypurine tract; (A)O polyadenylation signal; (AAA ... ) poly(A) tail. 
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activities: RNA-dependent DNA polymerase, RNAase H and DNA-dependent DNA 
polymerase. The env gene is essential for viral binding and entry into 
the host cells. It encodes the precursor glycoprotein, gp160, which is cleaved into a 
surface moiety, gp120 (SU), and a transmembrane moiety, gp41 (TM). The surface 
glycoprotein is required for binding to cellular receptors, whereas the transmembrane 
glycoprotein is responsible for fusion with the cellular membrane. 
All lentiviral regulatory and accessory proteins are encoded by variously spliced viral 
mRNAs that are generated from this full-length viral transcirpt using different 5' and 3' 
splice site signals. The two essential regulatory genes tat and rev encode transactivator 
proteins essential for viral replication. Doubly spliced viral mRNAs encoding Rev, Tat 
and Nef proteins are the first ones to be synthesized de novo following viral integration. 
Once synthesized, Rev and Tat augment production of viral mRNAs. Rev contains a 
nuclear export signal (NBS) and allows nuclear export of unspliced and singly spliced 
mRNAs that encode viral structural proteins. In the absence of Rev the only mRNAs 
detected in the infected cells are those that are doubly-spliced. Two interactions of Rev 
are required for attaining this function. First, Rev interacts with the Rev Responsive 
Element (RRE) overlapping the env coding sequence. Second, Rev interacts with the 
nuclear pore proteins, nucleoporins. Rev, therefore, ac~~ as a shuttle between the nucleus 
and cytoplasm, mediating the nuclear export of the RRE-containing viral mRNAs. The 
viral protein Tat upregulates viral transcription at the level of elongation via interaction 
with the Tat activation region (TAR) located at the 5' end of all viral mRNAs. In 
addition to interacting with TAR, the binding to the cyclin-dependent kinase-9 (CDK-
9)-Cyclin Tl complex has also been shown to be required for the activity of Tat (Wei et 
aI., 1998). Tat interacts through its activation domain (AD) with the cyclin Tl subunit 
of a preexisting TAK (Tat-associates Kinase) complex. The interaction of Tat with the 
cyclin Tl alters the conformation of Tat to enhance greatly the affinity and specificity of 
the TatTAR interaction. Subsequent to the binding to TAR, CDK-9" phosphorylates the 
C-terminal domaIn (CTD) of RNA polymerase II ensuing an efficient elongation of the 
viral transcription (Kim et aI., 2002). 
The accessory genes include vif~ vpr, vpu and nef. These genes·.~ere named accessory 
because they are nonessential for virus replication in cell culture (Luciw, 1996). Vif 
(virion infectivity factor) is not essential for mv -1 replication in permissive cells such 
as HeLa-CD4 or SupTI (Gabuzda et aI., 1992; Sakai et aI., 1993). However, it is 
necessary for production of infectious virions by cells that are natural targets for 
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infection, including CD4-positive T-Iymphocytes, macrophages, and H9 cells (Fouchier 
et aI., 1996; von Schwedler et aI., 1993). A recent study has suggested that 
nonpermissive cells contain an endogenous inhibitor of HIV -1 production that is 
overcome by the virus-encoded Vif protein (Madani and Kabat, 1998). The potential 
role of Vif in an HIV-1-derived vector was directly examined and it was concluded that 
vif is dispensable (Kim et aI., 1998; Zufferey et aI., 1997). It may be inferred that the 
vector producing cells utilized in these studies may have a "permissive" phenotype with 
respect to Vif, and that the presence of Vif in a replication-defective vector may not be 
necessary because target cells will not produce viral progeny. Vpr (viral protein R) is a 
virion-associated protein present only in primate lentiviruses. The first function of Vpr 
to be documented was its ability to act as a weak transcriptional transactivator of the 
viral LTR (Ogawa et aI., 1989). In addition, HIV-1 Vpr participates in viral infection of 
non-dividing cells (Balotta et aI., 1993; Bukrinsky and Haffar, 1997; Heinzinger et aI., 
1994). Vpr has also been shown to cause cell cycle block in G2 and apoptosis (Jowett et 
aI., 1995; Po on et aI., 1998; Stewart et aI., 1997). Despite its role in the transduction of 
non-dividing cells, vpr is not required in an HIV-1 packaging construct (Kim et aI., 
1998; Zufferey et aI., 1997), due largely to the existence of the ()ther mechanisms (MA 
and IN) allowing the nuclear transport of pre-integr~tion complexes. The vpu gene 
encodes a cytoplasmic viral protein and is present exclusively in HIV-l. It promotes 
degradation of CD4 in the endoplasmic reticulum of target cells. Degradation of CD4 
allows transport of Env to the cell surface and its incorporation into virions. Vpu is able 
to stimulate the release of viral particles from certain types of cells including T-
lymphocytes, HeLa and colonic carcinoma SW480 cells (Klimkait et aI., 1990). Another 
function of Vpu is to downregulate the expression of MHC I molecules on the surface 
of infected cells (Kerkau et aI., 1997). This prevents recognition by cytotoxic T-cells. 
Despite its multiple functions, vpu is a dispensable gene in a vector system as its 
exclusion does not not seem to influence the properties of the 'vpu-negative viral 
particles (Kim efaI., 1998; Zufferey et aI., 1997). The nef gene is only found in primate 
lentiviruses and it is essential for viral infectivity in vivo, but not in vitro (Kestler et aI., 
" 1991). Nef reduces interactions between Env and intracellular. CD4 by inducing 
internalization and degradation of CD4 (Piguet 'et aI., 1999). Nef also downregulates 
cell surface expression of MHC I molecules and protects infected cells from killing by 
cytotoxic T-Iymphocytes (Collins et aI., 1998). Nef was also shown to enhance the 
infectivity of viral particles, independently of the effects on CD4 (Goldsmith et aI., 
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1995). This Nef-dependent enhancement of infectivity occurs at the level of proviral 
DNA synthesis, early in the infectious cyc1e'(Aiken and Trono, 1995). However, later 
studies demonstrated that the dependence on Nef for achieving optimal infectivity in a 
vector system could be overcome by the use of VSV -G glycoprotein-pseudotypes 
(Aiken, 1997). This observation suggested that Nef only increases infectivity of virions 
entering the cells by direct fusion with the cellular membrane, but not via receptor-
mediated endocytosis. These results are in agreement with ~ther studies which directly 
demonstrate that Nef is entirely dispensable in lentiviral vectors when pseudotyed with 
VSV-G (Zufferey et aI., 1997). 
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1.2.2 Life cycle of Lentiviruses 
The lentivirallife cycle is similar to that of all members of the Retroviridae family and 
consists of different steps as depicted in Fig 1.9. 
Attachment and entry 
The interaction of the lentivirus with the target cell occurs via binding of the viral 
envelope glycoprotein to a specific receptor on the cell plasma membrane, which 
defines the cellular target for the virus (viral tropism). Primate lentiviruses infect helper 
T -lymphocytes, macrophages, microglial, dendritic and Langerhans cells by interacting 
with CD4 and one of several chemokine receptors, most frequently CCR5 or CXCR4 
(Bell, 1998; Zaitseva et aI., 1997). Once bound to the cellular receptor, the viral 
membrane undergoes fusion with the cellular membrane. After virion-bound matrix and 
capsid proteins disassemble and the nucleoprotein complex is delivered into the cells, 
reverse transcription begins in the cytoplasm. 
Reverse transcription 
Reverse trans~ription leads to the synthesis of double-stranded, linear DNA from a 
single-stranded RNA template using cellular tRNA. as a primer. The enzyme that 
catalyzes this step in viral replication, reverse transcriptase, has low fidelity due to the 
lack of proofreading ability and therefore, is partly responsible for the high variability of 
the viral genome. Recent studies have shown that during reverse transcription, a central 
DNA flap is created due to the presence of a central polypurine tract (cPPT) and central 
termination sequence (CTS) within the pol coding sequence (Chameau et aI., 1992; 
Chameau et aI., 1994). The creation of this unique triple-stranded DNA region appears 
to be important for the nuclear import of preintegration complex (PIC), in both dividing 
and non-dividing cells (Follenzi et aI., 2000; Zennou. et aI., 2000). Recent vector designs 
have, therefore, incorporated the cis signals (cPPT and CTS) for the creation of this 
_. 
central DNA flap and thereby allow more efficient nuclear import of the vector genome. 
Integration 
Once synthesis of the linear viral DNA is complete, viral integrase performs spe'cific 
cleavages at the 5' and 3' termini and catalyzes integration into the host genome. 
Integra~ion is essential for retroviral gene expression (Sakai et aI., 1993) and allows the 
provirus to become a permanent genetic element in the host. 
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Transcription and viral protein synthesis 
Early transcription from the provirus results in the production of doubly spliced mRNAs 
encoding Rev, Tat and Nef. Translation of mRNA leads to accumulation of Tat and 
Rev. Together, Tat and Rev induce a shift to a "late" transcription mode whereby 
un spliced and singly spliced RNA species are primarily produced. Unspliced and singly 
spliced mRNAs encode structural genes necessary for the production of viral progeny. 
Virion assembly and release 
The viral RNA and structural proteins are packaged into viral particles and released by 
budding at the plasma membrane. After the polyproteins, Gag and GaglPol, are cleaved 
by the viral protease, mature particles become fully infectious. In currently available 
lenti viral vectors, gag/pol are not present in the transfer construct, but are provided in 
trans by a packaging construct (Naldini et aI., 1996). Thus, once the transfer vector is 
integrated in the host cell, its inability to direct production of gag/pol ensures that there 
will be no subsequent viral progeny. 
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Figure 1.9. Lentivirallife cycle. Following binding of the retrovirus to its specific cell 
membrane receptor (CD4 and CK receptors), the viral and cellular membranes fuse, 
and the core virion is internalized into the cell. Reverse-transcriptase directed double-
stranded retroviral genomic DNA is then generated, followed by integrase directed 
integration into host cell DNA. Retroviral transcripts using host transcriptional 
machinery then proceed, with the eventual formation of new retroviral virions that 
bud from the cell surface, allowing a new round of infection to occur. 
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1.2.3 Lentiviral Vectors 
Lentiviral (LV) vectors are replication defective, hybrid viral particles made by the core 
proteins and enzymes of a lentivirus and the envelope of a different virus, most often 
the vesicular stomatitis virus (VSV). 
The applicability of a safe lentiviral vector in human disease is broad because (1) the 
host range of lentiviruses can be virtually unlimited when using vesicular stomatitis G 
glycoprotein (VSV -G) to produce pseudotype envelopes; (2) many relevant targets for 
gene therapy are non-dividing cells (neurons, hepatic cells, hematopoietic stem cells, 
myocytes); and (3) the stability of the transgene is potentially indefinite due to 
chromosomal integration. 
LV vectors offer potential for treatment of a wide variety of syndromes, including 
genetic/metabolic deficiencies, viral infection and cancer. Inherited genetic defects such 
as adenosine deaminase deficiency, familial hypercholesterolemia, cystic fibrosis, 
mucopolysaccharidosis type VII, types I and II diabetes, classical phenylketonuria and 
Gaucher's disease may be overcome by lentiviral vector-mediated gene therapy because 
they constitute single-gene deficiencies for which the involved genes are known. 
Certain types of cancer may benefit from the use of LV vectors. "Hypoxia and lack of 
vascularization lead to the generation of tumor cells" whi~h exhibit limited or no 
proliferation. Partly because of the lack of growth, these cells are highly resistant to 
genotropic agents. A LV vector may prove to be a useful vehicle for delivery of a 
"lethal" gene (such as herpes virus thymidine kinase) to quiescent tumor cells. 
Viral diseases may also constitute appropriate targets for lentiviral gene delivery. In 
particular, a number of gene therapy approaches have been proposed for the treatment 
of HIV infection. For some of these strategies, phase I studies have recently begun in 
humans. Preliminary studies have dealt with defective murine oncoviruses for delivery 
of anti-sense RNAs, RNAi, ribozymes and trans-dominant proteins against HIV 
replication. 
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1.2.3.1 Elements of a prototypical LV vector 
The general strategies employed in the design of a LV vector involve segregation of 
trans-acting sequences that encode for viral proteins from cis-acting sequences involved 
in the transfer of the viral genome to target cells. The vector particles are assembled by 
viral proteins expressed in the producer cell from constructs stripped of the majority of 
viral cis-acting sequences. The viral cis-acting sequences are linked to the transgene and 
are introduced into the same cell. As the vector particle can only transfer the latter 
construct, the infection process is limited to a single round without further spreading. 
The packaging functions for the LV are provided by at least two separate expression 
plasmids that use transcriptional signals different from those of the virus (Fig. 1.10). A 
"core" packaging construct, derived from the HIV-1 proviral DNA, directs expression 
of viral structural proteins, except for the envelope. Proteins expressed by the packaging 
construct (Gag/Pol, predominantly) form the capsid and polymerase components and 
recognize specific cis-acting sequences in the retroviral RNA genome and its reverse-
transcribed DNA products. This recognition leads to reverse transcription and 
integration. A separate construct expresses a heterologous envelope that is incorporated 
into the vector particles (pseudotyping) and allows entry into the target cells. A third 
construct, the transfer vector, contains retroviral cis-acting elements required for 
packaging by the vector particles, reverse transcription, nuclear translocation and 
integration in the target cells. It transfers an expression cassette for the gene(s) of 
interest containing an internal promoter (Fig. 1.10). The three expression constructs are 
maintained in the form of bacterial plasmids and can be transfected into mammalian 
cells to produce replication-defective virus stocks (Naldini et aI., 1996). 
Packaging construct 
Early versions of packaging plasmids encoded most viral structural. and regulatory 
proteins with the exception of the envelope glycoprotein (Naldini et aI., 1996). A 
deletion within the 5' untraslated region upstream of gag and within the encapsidation 
signal was engineered to reduce the" efficiency of incorporation of t.he helper RNA and 
thereby prevent recombination between vector and helper RNA molecules. The viral 
LTR promoter was replaced with a heterologous promoter such as the cytomegalovirus 
immediate early promoter. The 3' LTR was replaced with a heterologous 
polyadenilation signal (e.g., from SV40 or the insulin gene or another gene). A deletion 
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or mutation within Env ensured that no envelope glycoprotein was synthesized. The 
helper plasmid still expressed all other regulatory and accessory proteins of mv -1. 
More recent variants of packaging plasmids have further deletions and modifications to 
eliminate all the accessory genes (Kim et aI., 1998; Zufferey et aI., 1997). The goal of 
creating these minimal constructs is to design helper constructs that express only those 
genes that are essential for gene transfer into a wide variety of cells at high efficiency. 
Early versions of the packaging plasmids contained the RRE and also expressed Rev. In 
order to further enhance safety, packaging systems have been devised in which the mv-
1 gag/pol and rev sequences have been segregated onto separate plasmids (Dull et aI., 
1998). Tat has also been eliminated from this system by using a Tat-independent gene 
transfer vector (see section 1.3.4). Such a packaging system uses four plasmids for the 
creation of vector stocks instead of three. This increases the safety of the system by 
further decreasing the probability of recombination between different helper plasmids 
and gene transfer vectors to recreate a replication-competent virus because mUltiple 
recombination steps need to occur for this to happen. 
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Figure 1.10. Elements of a prototypical Lentiviral Vector. The packaging construct 
expresses the gag and pol genes from the CMV promoter and intervening sequences 
and polyadenylation site of the human B-globin gene. As the transcripts of the gag and 
pol genes contain cis-repressive sequences, they are expressed only if Rev promotes 
their nuclear export by binding to the RRE. The envelope construct, encodes a 
heterologous envelope to pseudotype the vector, here shown coding for VSV-G. The 
transfer construct contains HIV -1 cis-acting sequences and an expression cassette for 
the transgene. It is the only portion transferred to the target cells. Only the relevant 
parts of the constructs are shown. 
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Gene Transfer Vector 
The ideal gene transfer vector will lack all viral protein coding sequences and have a 
capacity for large transgenes. It should posses, in addition to the transgene expression 
cassette, all cis-acting sequences for efficient packaging, nucleocytoplasmic transport, 
reverse transcription and integration of the vector RNA. The first-generation vectors 
carried a deletion between the middle of the gag coding region and extending into the 
env coding region, thereby essentially eliminating all viral coding sequences (N aldini et 
aI., 1996). It may not be possible to eliminate gag sequences completely because the 
sequence at the beginning of this gene has been shown to contain elements that can 
increase packaging efficiency of the vector RNA (Clever et aI., 1995; Luban and Goff, 
1994). A frame shift mutation or stop codon inserted within the gag reading frame can 
ensure premature termination of translation. The vectors also contain the RRE between 
the major 5' splice donor site and the 3' tat/rev splice acceptor site. The transgene 
expression cassette is usually positioned between the second coding exon of rev and the 
nef gene. Polyadenylation of the viral RNA (including that derived from the internal 
promoter) occurs using signals present in the 3' U3 and R sequences within the LTR. 
The most common internal promoter enhancer elements used in mv -1 vectors are those 
derived from the cytomegalovirus immediate eady gene and the cellular 
phosphoglycerokinase promoter from mouse or human. It is believed that one may be 
able to replace these promoters with other tissue-specific or regulatable elements, in 
order to restrict or modulate trangene expression. 
The first generation HIV -1 vectors required Tat to obtain optimal titers, since 
expression from the viral LTR promoter requires co-expression of Tat. To overcome 
this, hybrid promoters that use enhancer elements from other viruses, instead of those 
present in the U3 of the HIV-l, have been created (Dull et aI., 1998; Kim et aI., 1998). 
These vectors appear to be nearly as efficient in terms of vector titer as the original Tat-
dependent vectors t~at contained the wild type HIV -1 L TR. Although there is a report 
showing that Tat, in addition to its effect on transcription from the viral LTR, can also 
affect the efficiency of reverse tran,scription (Harrich et aI., 1997). studies using HIV 
vectors have not revealed this requirement (Dull et aI., 1998; Kim et aI., 199~; 
Srinivasakumar and Schuening, 1999). 
Figure 1.11 shows various modifications of gene transfer vectors to improve safety and 
expression. Considerable progress in biosafety was achieved by the successful 
generation of self-inactivating LVs. It has been shown that most of the U3 region of the 
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3' LTR can be safely deleted without compromising vector titer (lwakuma et aI., 1999; 
Zufferey et aI., 1998). Such a deletion ensures that transcription from the 5' LTR 
promoters is efficiently suppressed following reverse transcription and integration into 
the target cell genome. Another advantage of using vectors with deletion of the U3 
region is enhanced transgene expression from internal promoters (Zufferey et aI., 1998). 
This is probably due to the decrease in promoter competition between the viral LTR and 
the internal promoter. 
Further elements were also incorporated in the expression cassette to improve it 
performance (Fig. 1.11). Hepatitis B virus contain cis-acting elements that can 
substitute for Rev and RRE function in HIV-l subgenomic constructs (Donello et aI., 
1996; Huang and Liang, 1993; Huang and Yen, 1994). Experiments have revealed that 
addition of a regulatory element from woodchuck hepatitis virus (WPRE) in retroviral 
and lentiviral vectors downstream of the transgene can increase expression by five to 
eight fold (Zufferey et aI., 1999). This element acts at the post-transcriptional level, in 
all probability promoting the efficiency of polyadenylation of the nascent transcript, 
increasing the total amount of mRNA in the cells (Donello et aI., 1998). Addition of the 
WPRE to mv -derived vectors improved substantially the level of trangene expression 
from several types of promoter in vitro and in vivo (Deglon et al., 2000; Zufferey et aI, 
1999). 
A recently described modification of the transfer vector backbone restored the 
infectivity of vector particles to the level of wild-type virus (Follenzi et aI., 2000; 
Zennou et aI., 2000). An additional copy of the polypurine tract, which primes 
transcription of the viral plus strand DNA, is present in the middle of the HIV geneome, 
included in the pol coding region (Fig. 1.11). This sequence (cPPT) was shown to be 
required for efficient replication of mv -1 by mutational analysis (Charneau et aI., 1992; 
Ilyinskii and Desrosiers, 1998). Addition of this cPPTin the backbone of the transfer 
vector improved viral. transduction in both dividing and non~ividing cells. 
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5' U3 can be replaced with 
enhancers from other promoters 
to make Tat-independent vectors 
and to prevent reconstitution 
of U3 in SIN vectors 
Extended gag region 
increases packaging 
efficiency; frame-shift 
or stop codon prevents 
Sag protein expression 
Insert cPPT/CTS 
Increases efficiency of 
nuclear import of PIes in 
dividing and non-dividing cells 
Deletion in U3 region 
increases safety and 
improves gene 
expression from 
internal promoters 
3'LTR 
Insert WPRE 
Increases gene 
expression by 5-8 fold 
Figure 1.11. Schematic representation of a gene transfer vector based on HIV-l and 
modifications to improve safety and expression (see text for details): LTR: long 
terminal repeat; SD: splice donor; SA: splice acceptor; SIN: self-inactivating; RRE: 
REV responsive element; WPRE: woodchuck post-transcriptional regulatory element; 
cPPf/CTS: central polypurine tract/central termination sequence. 
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Envelope construct 
The most popular envelope glycoprotein that has been used for pseudotyping lentiviral 
vectors is the VSV-G glycoprotein (Bums et aI., 1993). VSV-G provides two major 
advantages to the development of gene delivery vectors. Firstly, entry of VSV into the 
target cell occurs via binding to ubiquitous phospholipid components of the cell 
membrane: phosphatidylinositol, phosphatidylserine and GM3 ganglioside. This mode 
of entry provides a broad host range which includes non-mammalian cells derived from 
fish, Xenopus, mosquito and Lepidoptera. Secondly, the VSV envelope forms highly 
stable viral particles. Owing to this increased stability, efficient concentration of the 
vectors can be achieved by ultracentrifugation. Concentration of vectors leads to 
increased titers by about 2 orders in magnitude. 
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1.2.3.2 Safety characterisation 
Because lentiviruses are potentially lethal human pathogens, the most urgent issue 
regarding the safety of LV vectors is their potential for recombination leading to 
replication-competent retrovirus (RCR), also referred to as "helper" virus. Generation of 
helper virus in preparations of replication-defective vectors has been documented in 
numerous instances involving oncoviruses (Donahue et aI., 1992; Vanin et aI., 1994). In 
later generations of vecto~s in which viral protein-coding regions were divided in the 
packaging cells, the frequency of recombination leading to helper was decreased, but 
not eliminated (Otto et aI., 1994). Helper virus has the potential for inducing 
pathogenesis as demonstrated by studies in which monkeys were infused with 
transduced bone marrow cells after ablation of endogenous marrow with gamma 
irradiation (Purcell et aI., 1996). In these studies, helper virus gave rise to lymphoma in 
monkeys. 
Contemporary LV vectors were made virtually helper-free by segregating vector 
components into four plasmids (see section 1.2.3.2). 
Another important safety issue involves the activation of cellular proto-oncogenes by 
the inserted provirus (Coffin et aI., 1997). The genetic elements that can cause such 
insertional activation include the promoter, enhancer and the poly(A) site of the virus. 
For example, leukemia viruses (e.g. ALV) have been shown to induce lymphomas via 
the activation of c-myc expression by the promoter of the provirus (Fung et aI., 1981). 
Theoretically, insertion of HIV -1 LTR's might lead to transcriptional activation of 
heterologous genes. However, this has not been yet demonstrated. To address the issue 
of insertional activation, self-inactivating (SIN) vectors were developed (Yu et aI., 
1986). The same principles were applied to recent LV vectors (Miyoshi et aI., 1998; 
Zufferey et aI., 1998). For example, self-inactivating vector described by Miyoshi et aI. 
was constructed by deleting 133 bp in the U3 region of the 3' LTR including the TATA 
box and the binding sites for Spl and NF-kB. This deletion not only minimizes 
expression of vector RNA, but may also be useful in preventing the insertional 
activation of cellular proto-oncogenes by the integrated provirus. 
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1.3 Hemoglobinopathies 
Hemoglobinopathies are a group of inherited disorders characterized by the absence of 
functional a-like or B-like globin chains (Stamatoyannopoulos, 2001). Sickle cell 
disease (SCD) and B-thalassemias are two of the most common categories of 
hematopoietic diseases. SCD include sickle cell anemia, sickle cell-hemoglobin C 
disease and sickle cell-B-thalassemia. Millions worldwide are affected; one of 400 
African Americans, over 70,000 victims, are afflicted. These diseases are major health 
problems, associated with severe morbidity, lower-than-average life expectancy and 
serious, long-term disability. Clearly, it is of interest to combat these deadly diseases. 
In the circulatory system, erythrocytes (red blood cells) transport oxygen to bodily 
tissues and carbon dioxide to the lungs for exhalation. Within erythrocytes, this process 
is mediated by hemoglobin, a molecule that consists of two a-like and two B-like globin 
chains and four iron-coordinated heme moieties. The human a-like and B-like globin 
loci, located on chromosomes 16 and 11 respectively, encode these protein chains. 
During development, different a- and B-globin genes are expressed to produce a 
developmental stage-specific hemoglobin molecule that meets the oxygen demand of 
the developing fetus (Fig. 1.12). Naturally occurring mutations within these loci cause 
the production of abnormal hemoglobins and anemia. Abnormal hemoglobins appear in 
one of three basic circumstances: 
1. Structural defects in the hemoglobin molecule. Often, mutations in the gene 
for one of the two hemoglobin subunit chains, a or B, change a single amino acid 
building block in the subunit. Most commonly the change is innocuous, perturbing 
neither the structure nor function of the hemoglobin molecule. Occasionally, alteration 
of a single amino acid dramatically perturbs the behavior of the hemoglobin molecule 
and produces a disease state. Sickle hemoglobin exemplifies this phenomenon. 
2. Diminished productio~ of one of the two subunits of the hemoglobin 
molecule. Mutations that produce this condition are termed "thalassemias". Equal 
numbers of hemoglobin a and B chains are necessary for normal function. Hemoglobin 
. chain imbalance damages and destroys red cells thereby producing' ~n~mia. Although 
there is a dearth of the affected hemoglobin subunit, with most thalassemias the few 
subunits synthesized are structurally normal.. 
3. Abnormal associations of otherwise normal subunits. A single subunit of the a 
chain (from the a-globin locus) and a single subunit from the B-globin locus combine to 
produce a normal hemoglobin dimer. With severe a-thalassemia, the B-globin subunits 
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begin to associate into groups of four (tetramers) due t6 the paucity of a-chain partners. 
These tetramers of B-globin subunits are functionally inactive and do not transport 
oxygen. No comparable tetramers of a globin subunits form with severe B-thalassemia. 
Alpha subunits are rapidly degraded in the absence of a partner from the B-globin gene 
cluster (y, 8, B globin subunits). 
1.3.1 The Thalassemias 
The thalassemias are defined as a heterogenous group of inherited disorders of 
hemoglobin synthesis, all characterized by the absence or reduced output of one or more 
of the globin chains of hemoglobin. They are most prevalent in the Mediterranean 
region, the Middle East, the Indian subcontinent and South-East Asia, representing a 
serious health problem in certain areas where gene frequencies reach 3-10% of the 
population (Weatherall and Clegg, 1996). They can be classified at several levels. First, 
there is a clinical classification, which simply describes the degree of severity. Second, 
the thalassemias can be defined by the particular globin chain that is synthesized at a 
reduced rate (genetic classification). Finally, it is now often possible to subclassify them 
according to the particular mutation that is responsible for defective globin chain 
synthesis (molecular classification). 
Based on clinical features, the thalassemias are divided into the major forms of the 
illness, which are severe and transfusion-dependent and the symptomless minor forms, 
which usually represent the carrier state, or trait. Thalassemia major results either from 
the homozygous inheritance of a particular mutation or from the compound 
heterozygous state of two different mutations. Thalassemia intermedia describes 
conditions that are associated with a more severe degree of anemia than the trait, 
although they are not as severe as the major forms. Finally, there are some forms of 
thalassemia trait that are clinicapy and hematologic ally completely silent; they are 
designated as a silentcarrier state. 
According to their genetic basis the thalassemias are classified into a, B, y, a and EyaB 
varieties, depending on which chain or chains are synthesized at a reduced rate. 
As their molecular pathology has been ascertained, it is now feasible to develop a more 
accurate approach to the designation of different types of thalassemias. For example, in 
many cases, it is possible to describe the genotype of a patient with the clinical picture 
of B-thalassemia major according to the particular mutations at the homologous pairs of 
B-globin chain loci. 
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1.3.1.1 8-Thalassemia 
The B-thalassemias are the most intensively studied monogenic disorders in man. Over 
180 different mutations that giving rise to the clinical phenotype of B-thalassemia have 
been identified (Olivieri, 1999). These mutations can be classified in two distinct 
categories: BO mutations, in which no B-globin chains are produced and B+ mutations, in 
which some B chains are produced but at a reduced rate. The deficiency or absence of B-
globin chains reflects the action of mutations that affect every level of B-globin gene 
function; that is, transcription, mRNA processing, translation and post-translational 
stability of the B-globin chain product. These mutations are classified according to the 
mechanism by which they affect B-globin gene expression. 
The pathophysiology of B-thalassemia is directly linked to the degree of imbalance in 
the production of a and B-globin chains (Weatherall, 2001). In the most severe form of 
B-thalassemia found in homozygotes and compound heterozygotes, B-thalassemia 
major, the profound anemia requires regular lifelong blood transfusions; without 
treatment, the condition is lethal within the first year of life. In B-thalassemia 
intermedia, the anemia is less profound and may only require occasional transfusions. 
Chronic transfusions aimed to correct the anemia, suppr~ss massive erythropoiesis and 
inhibit increased gastrointestinal absorption of iron. However, transfusion therapy leads 
to iron overload, which primarily affects the liver, heart and endocrine tissues. The iron 
overload is lethal if untreated and its prevention is the major goal of current patient 
management. At present, the only means to cure the disease definitively is through 
allogeneic bone marrow transplantation (Lucarelli et aI., 2001). 
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1.4 The 8-globin gene cluster 
The human B-globin gene locus is the subject of intense study and over the past two 
decades a wealth of information has accumulated on how tissue-specific and stage-
specific expression of its genes is achieved. The five genes of the human B-globin locus 
are arranged in a linear array on chromosome 11 and are expressed in a developmental 
stage-specific manner in erythroid cells (Fig. 1.12; Stamat?yannopoulos & Grosveld, 
2001). 
The complex program of transcriptional regulation leading to the differentiation and 
developmental stage-specific expression in the globin locus is mediated by DNA-
regulatory sequences located both proximal and distal to the gene-coding regions. The 
most prominent distal regulatory element in the human B-globin locus is the locus 
control region (LCR), located from about. 6 to 22 kb upstream of the e-globin gene 
(Forrester et aI., 1987; Grosveld et aI., 1987). The LCR is composed of several domains 
that exhibit extremely high sensitivity to DNase I digestion in erythroid cells (called 
hypersensitive, or HS, sites), and is required for high-level globin gene expression at all 
developmental stages (Higgs, 1998). 
1.4.1 Developmental Stage-specific expression of the 8-globin genes 
Over the last 40 years, an immense body of descriptive and experimental evidence has 
been reported in an effort to understand the biological phenomenon of hemoglobin 
switching. As reported more than 20 years ago by Nienhuis and Stamatoyannopoulos 
(Nienhuis and Stamatoyannopoulos, 1978), the phrase hemoglobin switching represents 
"the gradual replacement, in the blood stream, of red cells containing predominantly one 
hemoglobin with red cells which contain predominantly another". Their definition 
articulates the now classic correlation among changes in red cells, their site of 
production and their globin content during human ontogeny. This switching paradigm is 
illustrated in Figure 1.12 B (Wood, 1976). 
The five genes of the human B-globin gene locus are arranged in the same order as they 
are expressed during development (Fig. 1.12). The e-globin gene is expressed in the 
embryonic yolk sac and located at the 5' end. After the switch in the site of 
hematopoiesis from the yolk sac to the fetal liver, the e-gene is repressed and the two g-
globin genes, located downstream of e, are activated. In a second switch, completed 
shortly after birth, the bone marrow becomes the major site of hematopoiesis, 
coincident with activation of the adult B-globin gene, while the g-globin genes become 
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silenced. The d-globin gene is also activated in erythroid cells derived from bone 
marrow hematopoiesis but is expressed at levels less than 5% of that of the B-globin 
gene. Studies utilizing transgenic mice produced with a variety of constructs containing 
portions or the entire human B-globin locus have provided insight into the cis-control of 
globin gene switching. Knock-out mice bearing null mutations in a number of genes 
have identified several trans-acting proteins necessary for globin expression. The 
individual genes of the human B-globin locus are developmentally regulated through 
their proximal promoters, but expression in transgenic mice is usually low and variable 
due to position of integration effects. Position effects are overcome by linkage to the 
LCR and high-level, position-independent expression is observed for the human g- or B-
globin genes (Enver et aI., 1990; Grosveld et aI., 1987). Genetic information governing 
the stage-specificity for all B-like globin genes is located in gene proximal regions. 
These elements represent transcription factor-binding sites that recruit proteins or 
protein complexes in a stage-specific manner. Examples exist for the presence of both 
positive and negative acting factors that tum genes on or off at a specific developmental 
stage. 
1.4.2 The n-globin locus control region 
The B-globin LCR (locus control region) is composed of five HS sites located upstream 
of the e gene within a 20 kb region (Fig. 1.12). The presence of HS indicates that trans-
acting factors are binding to these regions and displacing or destabilizing nucleosomes. 
Expressed genes are located in an "open" chromatin context more accessible to trans-
acting factors and in general containing nucleosomes with highly acetylated histones. In 
contrast, "closed" chromatin generally has deacetylated histones and is bound by the 
linker histone HI, is less accessible to DNA binding factors and genes in these regions 
are not expressed. Mechanisms by which chromatin structure controls activation and 
repression of transc!iption are not well understood. Proteins that bind and activate 
transcription may access DNA without disruption of the nucleosome or they may 
. require the assistance of protein cofactors that function to make DN~ ~ore accessible 
by modifying the nucleosome (Kingston and Narlikar, 1999; Tyler and Kadonaga-, 
1999). Other less defined parameters such ~s the nature of the inherent DNA sequence 
and the stage of the cell cycle, influence the structure of chromatin (Peterson and Logie, 
2000). 
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The mechanism by which the LCR cont~ols B-globin gene expression has been 
extensi vely studied, primarily using transgenic and Knock-out mice 
(Stamatoyannopoulos & Grosveld, 2001). It is important to realize that these two assays 
manipulate the genes in quite different ways and the results are not always 
complementary or in agreement with each other. Transgenic mice contain the human B-
globin gene transferred into novel or ectopic integration sites; whereas, Knock-out mice 
manipulate the endogen?us native locus in the mouse. In transgenic mice, human B-
globin transgenes are silent at most integration sites or transcribed to about 1% of the 
endogenous mouse B-major level. In contrast, addition of the LCR including all four 
erythroid specific HSs to the B-globin transgene results in expression to about 100% 
levels at all integration sites, and expression is copy number-dependent (Ellis et aI., 
1996; Grosveld et aI., 1987; Talbot et aI., 1989). This copy number-dependent, position-
independent transgene expression is the defining feature of LCR activity. Further 
investigation demonstrated that individual HS2, HS3 and HS4 elements and their 
smaller "cores" of approximately 200-300 bp, also direct copy number-dependent 
transgene expression but to lower levels (10-25%) (Philipsen et aI., 1993; Talbot and 
Grosveld, 1991). 
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Figure 1.12. (A) Genomic organization of human globin genes. 
(B) Haemoglobin synthesis and sites of haematopoiesis during human fetal 
development. 
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The LCR is often referred to as an enhancer, but does' not have classic enhancer activity 
because it does not function equally well in either orientation (Tanimoto et aI., 1999). 
Rather, it appears that complete LCR activity requires all HS, and these have some 
distinct roles (Fraser et aI., 1993). For example, HS3 can activate B-globin transgenes at 
all single copy integration sites where it establishes open chromatin and remodels 
chromatin on the promoter to permit expression (Ellis et aI., 1996). In contrast, although 
HS2 has strong enhancer activity in transient transfection studies (Tuan et aI., 1989), it 
is unable to direct expression in single copy transgenic mice (Ellis et aI., 1993). These 
data suggest that at ectopic sites, the HS function together as a unit, making the LCR 
sufficient to open chromatin and enhance full expression of B-globin trans genes. 
Open chromatin is likely to be established by the binding of erythroid trans-acting 
factors that recruit chromatin remodelling complexes (Blobel et aI., 1998; Armstrong et 
aI., 1998; Gong et aI., 1996), as has been described for histone acetylation changes on 
active human B-globin genes (Schubeler et aI., 2000). This open chromatin may not 
extend throughout transgenes containing the entire human LCR B-globin cluster, as 
different domains that correlate with the presence of low level intergenic transcription 
have been described during globin switching in mice (G~bnau et aI., 2000). 
1.4.2.1 Looping versus linking: two models of LCR activity 
The looping model was first proposed to explain the interaction between the LCR and 
individual genes in the B-globin locus. In this model, the B-globin LCR acts as an 
integral unit (a "holocomplex") to stimulate the transcription of individual globin genes 
by looping through the nucleoplasm (Bungert et aI., 1995; Choi and Engel, 1988; 
Wijgerde et aI., 1995). The transgenic mouse data have largely been interpreted as 
supporting a holocomplex model of LCR action at ectopic sites (Grosveld, 1999). Once 
open chromatin has been establis.hed, it is proposed that each of the HS then interacts 
with each other by _DNA looping mediated via the bound factors to form an LCR 
holocomplex (Fig. 1.13 A). The holocomplex would then interact with a single globin 
'. gene in the cluster, and switching during development would be accomplished by stage-
specific silencer elements associated with the e- and g-globin gene promoters. A key 
question in the looping model is whether there is a direct interaction between LCR and 
promoters. Previous support for this model has come from several types of studies. The 
ability of an enhancer to activate a promoter located on a physically separate DNA 
molecule, is most easily explained by direct contact between the enhancer and the gene. 
70 
This has been observed in transvection in Drosophil~ (Bickel and Pirrotta, 1990) and in 
a number of in vitro experiments with artificial DNA constructs (Dunaway and Droge, 
1989; Mahmoudi et aI., 2002). Competition between genes for a single regulator 
(Hanscombe et aI., 1991; Wasylyk et aI., 1983), leading to alternate transcription is also 
most easily explained by looping, particularly because the competitive advantage of the 
enhancer-proximal gene is lost when the genes are closely spaced at distances further 
from the enhancer (Heuchel et aI., 1989). However, all this evidence is indirect, and 
each can also be explained by other mechanisms. Nevertheless, very recent data from 
Grosveld lab demonstrated that the distal regulatory elements and the active genes, 
which are linked in cis in the murine B-globin locus, interact in vivo while the 
intervening DNA loops out. This looping is only seen in expressing cells and provides 
direct in vivo evidence for the looping model (Tolhuis et aI., 2002). In particular, the 
observation that two hypersensitive sites at the far ends of the region cluster with the 
LCR and the active genes (i.e., all hypersensitive sites) provides new insights into long-
range interactions. On the basis of these data they propose that direct interactions 
between distal DNase I hypersensitive sites and looping out of chromatin is crucial in 
establishing an open chromatin domain and activatin,g transcription. Furthermore, 
evidences suggesting long-range chromatin regulatory interactions has been provide in 
vivo. In fact, Fraser lab shows that the HS2 enhancer element of the B-globin LCR is in 
close physical proximity to an actively transcribed B-globin gene located over 50 kb 
away (Carter et aI., 2002). 
Quite different conclusions have been arrived at using knock-out technology on the 
mouse B-globin locus (Higgs, 1998). Deletions of individual or all the HS in the 
endogenous locus do not alter chromatin structure and have relatively minor effects on 
expression of the globin genes (Epner et aI., 1998; Reik et aI., 1998). These data suggest 
that the LCR is not required for chromatin opening at the endogenous mouse B-globin 
locus and suggest that more distant elements control chromatin structure (Bulger and 
Groudine, 1999). A linking model that does not invoke DNA looping has been proposed 
. to explain the knockout results (Fig. 13 B). In this model, the function of the LCR is to 
enhance B-globin expression by ensuring that factors are bound at intervals across the 
cluster and that the gene is localized to the right nuclear compartment. The linking 
model is not consistent with the ability of the LCR to open chromatin at ectopic 
transgene sites, but the holocomplex model cannot easily explain the effect of LCR 
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deletions in the mouse B-globin locus. However, the two models are not necessarily 
mutually exclusive and may be strengthened by being merged. 
Several recent chromatin immunoprecipitation (ChIP) analyses of factor binding in the 
B-globin locus of cultured erythroid cell lines have provided news clues to 
understanding the regulation of B-globin gene expression (Bulger et aI., 2002; Johnson 
et aI., 2001). It was suggested that hyperacetylation at th~ B-globin gene promoter is 
partially NF-E2 dependent and the association of RNA polymerase II is wholly NF-E2 
dependent. The hyperacetylation of LCR is NF-E2 independent and RNA polymerase II 
is associated with the B-globin LCR prior to NF-E2 binding. Based on this data, a three-
step model for B-globin gene activation was proposed (Johnson et aI., 2001; Sawado et 
aI., 2003). 
For the purpose of gene therapy where globin expression cassettes delivered by viral 
vectors must express at ectopic sites, it will be important to design the cassettes based 
on transgene constructs that express to high levels as single copy integration events. 
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A) Looping 
B) Linking 
Figure 1.13. Proposed models for LCR-globin gene interaction. A globin gene is denoted 
as a green rectangular box with the promoter region indicated in a lighter green. 
Transcription factors are shown as colored ovals and circles. The four erythroid-specific 
hypersensitive site cores (HSs) are indicated by small colored boxes. The flanking DNA 
sequences of the HSs are depicted as loops between the HS cores. Transcripts are denoted 
by wavy arrows. (A) Looping model. Transcription factors bind to the LCR HSs and the 
gene promoter. The LCR directly interacts with the gene promoter by looping out the 
intervening DNA, thus forming an active transcription complex at the gene promoter. (BY 
Linking model. Sequential binding of transcription factors along the DNA directs changes 
in chromatin conformation and defines the transcriptional domain. The transcription 
factors are linked to one another from the LCR to the gene promoter by non-DNA-
binding proteins and chromatin modifiers (shown as colored ovals and circles). 
Adapted from Harju S et al., 2002. 
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1.4.3 Regulation of the B-glohin genes 
The B-globin gene is a relatively small gene comprising three coding exons and two 
introns. The exons code for 146 amino acids and correspond to functional domains in 
the protein. For example, exon 2 codes for the part of the globin chains involved in 
heme binding and tetramer formation, and exon 3 codes for many of the amino acids 
required for cooperative binding of heme and interactions between tetramer subunits. 
The second intron, in addition to the normal splicing function appears to be important 
for polyadenylation and release of the transcript from the template to allow the transport 
from the nucleus to the cytoplasm (Antoniou et aI., 1998; Custodio et aI., 1999). 
Each globin gene has a number of regulatory elements (promoter, enhancer, or 
silencers) that are important for its precise developmental regulation. These elements 
are thought to interact with the more distant 8 globin LCR to achieve high levels of 
gene expression. Each regulatory element is composed of binding motifs for multiple 
erythroid restricted and ubiquitously expressed transcriptional activators or suppressor. 
These factors interact and synergize with each other and other cofactors resulting in the 
formation of multimeric complexes that change chromatin structure to allow complex 
interactions giving rise to the action of the basic transcription, machinery and the 
formation of an initiation complex. 
The proximal part of the 8-globin gene contains an initiator sequence, a TAT A box at 
-30, a G-rich sequence at -50, a CAAT box at -75, and two CACCC boxes at -90 to 
-110. The initiator element was discovered through in vitro analysis of promoter 
mutations at the +1 site of the gene (Antoniou et aI., 1995; Lewis and Orkin, 1995). A 
G-rich sequence called "8 DRE repeats" at -50 is highly conserved during evolution 
(Stuve and Myers, 1990). Mutations of the repeats affect promoter function in 
transfection assays in erythroid cells and a DNA binding activity has been associated 
with the element (Myers et aI., 1989). 
The CAAT box region is important for promoter function in erythroid cells (Antoniou 
and Grosveld, 1990), and has been shown to bind several different factors: the 
" erythroid-specific' protein GAT A-I, the ubiquitous CAAT -binding protein CP1 (also 
" . 
called NF-Y) and a DNA binding activity that was denoted DSFr (Delvoye et aI., 1993). 
CP1 is thought to be a positive regulator of the CAAT box, but this has not been 
confirmed in vivo. GAT A-I binds fairly weakly at the CAAT box and probably is not 
functionally important at this position. DSFr is involved in the up-regulation of 
74 
transcription and in MEL cells was identified as CIEBP-g through expression cloning 
and antibody studies (Wall et aI., 1996). 
Of the two CACCC boxes, the proximal appears to be more important for their function. 
The CACCC box binds several factors in vitro (Hartzog and Myers, 1993), but the 
functional protein in vivo is the transcription factor EKLF. The B-globin CACCC box 
has a higher binding affinity for EKLF than the e or g-globin CACCC boxes and 
mutations that substantially decrease the binding affinity of the CACCC box for EKLF 
produce a thalassemic phenotype (Donze et aI., 1995). 
The upstream part of the promoter contains additional sites for GATA-l (at -120 and 
-200) and CPl (at -160), and these appear to be important for inducible B-globin 
promoter activity in erythroleukemia cells (Antoniou and Grosveld, 1990; deBoer et aI., 
1988). 
The B-globin gene has been reported to contain two enhancer elements, one located near 
the junction of the second intron and the third exon and another a 6 hundred base pairs 
downstream from the poly-A site of the gene (Antoniou et aI., 1988; Behringer et aI., 
1987; deBoer et aI., 1988; Wall et aI., 1996). 
1.4.3.1 Transcriptional regulation of n-globin genes during erythropoiesis 
The tissue- and developmental-specific expression pattern of the individual globin 
genes is achieved through the action of transcription factors on regulatory sequences 
that are immediately flank the individual genes and on more distant sequences that are 
important for the regulation of all the genes of the locus. The factors that regulate globin 
genes are either tissue restricted or ubiquitous with respect to their expression pattern. 
Only a few factors have been studied in detail for their direct role in the transcription of 
the globin genes, many of them affect globin gene transcription through their 
importance in hematopoietic or erythroid differentiation in general (see Section 1.1.3.2). 
On the other hand, several factors, important for globin gene transcription are ubiquitous 
and influence the expression of many genes, most of which are not erythroid specific. 
GATA-l 
GAT A-I, a zinc finger transcription factor, plays a central role in erythroid 
development. It was first identified by its ability to bind functionally important DNA 
regulatory sequences found in globin genes (deBoer et aI., 1988; Evans and Felsenfeld, 
1989). Since then, GATA-binding motifs «T/A)GATA(A/G)) have been identified in 
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the promoters and/or enhancers of virtually all erythroid and megakaryocytic-specific 
genes studied (Orkin, 1992; Weiss and Orkin, 1995). GATA-l contains two zinc 
fingers, both of the Cys-X2-Cys-XI7-Cys-X2-Cys configuration. 
Expression of GAT A-I is restricted to erythroid, megakaryocytic, eosinophilic, mast 
and multi potential precursor cells within the hematopoietic system (Evans and 
Felsenfeld, 1989; Tsai et aI., 1989). The sole non-hematopoietic site of expression is the 
Sertoli cells of the testis (Ito et aI., 1993). Gene targeting studies in mice have shown 
that GATA-l is essential for normal erythropoiesis (Pevny et aI., 1991). GATA-l 
hemizygous male knock-out mice (GATA-l is located on the X-chromosome) die at 
mid-embryonic gestation (E10.5) from severe anemia with arrest in erythroid 
maturation at a proerythroblast-like stage (Fujiwara et aI., 1996). Differentiated in vitro 
GAT A-l- ES cells likewise fail to mature past the proerythroblast stage and undergo 
rapid apoptosis, indicating a role for GAT A-I in cell survival as well as maturation 
(Weiss and Orkin, 1995). Loss of GATA-l expression in megakaryocytes also leads to 
defects in maturation characterized by impaired endoreduplication and granule 
formation, disorganized platelet demarcation membrane synthesis and 
hyperproliferative growth (Shivdasani et aI., 1997). In primitive erythroid cells, GATA-
1 expression is regulated by a 5' enhancer, whereas its expression in definitive erythroid 
cells requires an additional element located in the first intron. Together, these two 
elements form the GAT A-I locus hematopoietic regulatory domain (HRD) (Shimizu et 
aI., 2001). 
The C-terminal and the N-terminal zinc-fingers (CF and NF, respectively) in GATA-l 
are required for recognition of the GAT A motif and DNA binding as well as for 
physical interaction with other transcription factors. The highly conserved NF is 
essential for interaction with the GAT A-I coactivator FOG (Friend Of GATA) as well 
as with EKLF, LM02 and CREB binding protein (CBP), and enhances the specificity 
and stability of binding of the twq-finger DNA binding domains to palindromic GAT A 
recognition sequences (Fig. 1. 14) (Blobel et aI., 1998; Crispino et aI., 1999). CF is 
necessary for GAT A-I function, while NF is required for definitive but not for primitive 
erythropoiesis. This suggests that different GAT A-I functional domai!ls ~re required for 
target gene activation in primitive and definitive erythropoiesis (Shimizu et aI., 2001): 
Thus, both transcriptional regulatory elements and protein functional domains may 
ensure proper lineage specification in primitive and definitive erythropoiesis. 
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Binding of erythroid-specific transcription factors, such as GATA-l, to enhancers of 
erythroid-specific genes early in development or differentiation could be a key factor in 
initiation and maintenance of active chromatin structures (Martin et aI., 1996). GATA-1 
orchestrates multiple programs of erythroid development, including control of the cell 
cycle and apoptosis, as well as differentiation (see Section 1.4.3.1). At the biochemical 
level, GATA-l is thought to recruit critical proteins to target sites. The interaction of 
GATA-l with CBP/p300 suggests at least one mechanism by which histone acetylases 
might be brought to specific site (Blobel, 2000; Blobel et aI., 1998). By modifying 
chromatin-bound histones or perhaps by modification of GATA-1 itself, acetylases 
could enhance transcriptional activity of erythroid-specific loci (Boyes et aI., 1998). 
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Figure 1.14. Hypothetical model of NF-E2, GATA-l and EKLF cooperative interaction 
to recruit CBP and p300 to the 13- lobin CR. Thi ould lead to acetylation of nearby 
histones and transcription factors. Acetylation of histones leads to changes -in chromatin 
structure, and acetylation of transcription factors might stabilize their interaction with 
DNA or alter their transcriptional activity. It is conceivable that this high molecular 
weight complex also connects to the promoters of the globin genes through a looping 
mechanism (from Blobel G, Blood, 2(00). 
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Friend of GAT A (FOG) 
The FOG (Friend of GAT A) family of proteins comprises a novel class of multi-type 
zinc finger nuclear polypeptides that interact physically with GAT A factors and 
likewise serve essential functions in development. FOG-I, the founding member of this 
family, was identified through a yeast two-hybrid screening in which the amino zinc 
finger of GAT A-I was employed as bait (Tsang et aI., 1997). The gene for FOG-1 
encodes a 998-amino-acid polypeptide with nine predicted ~inc fingers. Four of these 
zinc fingers (fingers 1, 5,6, and 9) individually are able to mediate an interaction with 
GATA-1 (Fox et aI., 1999). FOG-1 is expressed abundantly in erythroid and 
megakaryocytic cells and co-expressed with GAT A-I during embryonic development 
(Tsang et aI., 1997). FOG-1-'- mice die in mid-embryonic gestation (10.5 to 11.5 days 
postcoitum) from severe anemia with an arrest in erythroid maturation at a stage similar 
to that observed with the GATA-1-null mice (Tsang et aI., 1998). This has provided 
genetic evidence that FOG-1 and GAT A-I function through a common pathway in 
erythroid development. However, unlike the GATA-l" mice, FOG-1 null mice failed to 
produce any megakaryocytes, suggesting that FOG-1 also has a GAT A-I-independent 
role in early megakaryopoiesis. 
Point mutations of GATA-1 resulting in markedly red~ced affinity for FOG-1 (but 
normal DNA binding activity), fails to rescue erythropoiesis in a GATA-1-deficient cell 
line (Crispino et aI., 1999). A similar point mutation in humans leads to severe 
congenital dyserythropoietic anemia and thrombocytopenia (Nichols et aI., 2000). Such 
patients have an overabundance of abnormal megakaryocytes resembling GATA-1-
megakaryocytes. Taken together, these findings demonstrate that a direct physical 
interaction between GAT A-I and FOG-1 is critical for normal erythropoiesis as well as 
late stages of megakaryopoiesis. 
A second mammalian member of the FOG family (FOG-2) is expressed predominantly 
in heart, brain, lung, and gonadal tissues (Tevosian et aI., 1999). FOG-2-'- mice die 
during embryogenesis from cardiac defects characterized by thin ventricular 
myocardium, Tetralogy of Fallot malformation, common atrioventricular valve and 
defective coronary vasculature (Tevosian et aI., 2000). All GAT A family members are 
capable of interacting with either FOG-lor FOG-2 through conserved residues in their 
amino zinc fingers. Knock-in of a FOG non-interacting point mutation into the GAT A-4 
gene, one of the cardiac expressed GAT A factors, results in embryonic death and a 
constellation of heart defects similar to that observed in the FOG-2-'- mice (Crispino et 
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aI., 2001). This indicates that interactions between GATA and FOG proteins are critical 
for mUltiple developmental processes. 
Efforts have now been focused on understanding the mechanism by which FOG 
proteins influence GATA-mediated processes. Virtually all erythrocyte- and 
megakaryocyte-expressed genes contain GAT A DNA-binding sites in both their 
promoters and enhancer elements (Orkin, 1992). Since a single FOG-l molecule can 
potentially bind more than one GATA-l molecule, FOG-l might function as a 
molecular bridge between distant GATA-I-DNA complexes (Fox et aI., 1999). This 
could bring distal enhancer elements into proximity of the promoter through DNA 
looping, a mechanism invoked in models of enhancer-promoter interactions and also in 
the activity of the B-globin LCR (Bulger and Groudine, 1999). However, mutants of 
FOG-l that are capable of binding only a single molecule of GAT A-I rescue erythroid 
maturation from a FOG-l deficient cell line as well as the wildtype molecule, providing 
evidence against such a model in its simplest form (Cantor et aI., 2002). Another 
possibility is that FOG provides a transcriptional activation domai~ either by itself or 
via interaction with another transcriptional coactivator. This predicts that protein 
domains outside of the GATA-binding zinc fingers would be required for its activity. 
However, FOG-l molecules containing extensive and overlapping deletions spanning 
the entire molecule (but retaining at least one GATA-binding zinc finger) are also able 
to rescue erythroid maturation of a FOG-l-
'
- cell line (Cantor et aI., 2002). This suggests 
that a simple interaction between FOG-l and GATA-l is by itself sufficient to activate 
GAT A-I. This could occur through an allosteric change in GAT A-I or perhaps by the 
displacement of a repressor protein bound to GAT A-I. Indirect support for the latter 
model is suggested by the earlier work of Evans and Felsenfeld, who reported that 
GATA-l has reduced transcriptional activity in hematopoietic cells compared to non-
hematopoietic cells, suggesting that the hematopoietic environment somehow dampens 
GATA-mediated response (Evans and Felsenfeld, 1991). 
Nuclear Factor-erythroid 2 (NF-E2) 
Nuclear Factor-erythroid 2 (NF-E2) was the second erythroid specifIC protein that was 
identified through DNA-binding studies in vitro. It was discovered through its binding 
to an AP-l motif in the promoter of the porphobilinogen deaminase gene (Mignotte et 
aI., 1989), and was somewhat ignored until it was shown that this factor could bind to 
the HS2 region of the B-globin LCR (Ney et aI., 1990). NF-E2 is expressed in several 
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hematopoietic lineages, including erythroid, mast, and megakaryocytic cells. It is also 
expressed in the intestine of anemic mice and may be involved in iron metabolism 
(Andrews et aI., 1993). NF-E2 is a 45 kDa protein with a basic DNA-binding domain, 
an adjacent leucin zipper domain, an N-terminal proline-rich domain, and a cap'n collar 
(CNC) domain necessary for transcriptional activation (Bean and Ney, 1997). 
NF-E2 heterodimerizes with members of the family of small, ubiquitously expressed 18 
kDa Maf proteins, which themselves have no transcriptional activation domain but 
which are essential for binding site recognition (Motohashi et aI., 1997). 
The overall stimulatory activity of the LCR (at least of HS2) in the chromatin 
environment of transgenic mice or in stably integrated constructs in cells appears to 
depend on NF-E2 motifs (Caterina et aI., 1994; Caterina et aI., 1994; Ellis et aI., 1993; 
Talbot and Grosveld, 1991). A series of studies using transgenic mice with a B-globin 
yeast artificial chromosome (Y AC), suggested that the deletion of HS elements 
markedly reduced the expression of all of the globin genes at all developmental stages 
accompanying the malformation of DNase I hypersensitivity in the LCR (Li et aI., 1998; 
Milot et aI., 1996). In addition, it was also shown that the protein Bach1, which 
heterodimerizes with the p18 NF-E2 subunit and interacts with MARE (Maf responsive 
element or NF-E2 binding site) sequences at HS2, HS3 and HS4, is able to cross-link 
HS sites, thereby looping out intervening DNA regions (Yoshida et aI., 1999). These 
results suggest that a series of protein-protein and protein-DNA interactions establish 
the formation of a larger LCR complex (Wijgerde et aI., 1995). Furthermore, NF-E2 is 
critically involved in remodeling the nucleosome structure over the HS2 region, where 
it interacts with the tandem MARE sites (Armstrong and Emerson, 1996; Gong et aI., 
1996). In contrast with the study supporting a role for NF-E2 in B-globin gene 
expression, p45 NF-E2-null mice had nearly normal levels of B-globin protein, and 
deletion of HS2 had no significant effect on the timing or extent of expression -of the 
gene (Fiering et aI., 1995). Disruption of one of the genes coding for one of the Maf 
subunits shows no phenotype, most likely because of compensation by one of the other 
Maf proteins (Kotkow and Orkin, 1996). 
Erythroid Kruppel-like factor (EKLF) 
Tissue- and stage-specific expression of the' various globin genes is determined by the 
interactions between the LCR and the specific globin gene promoters, interactions 
mediated by" recruiting chromatin modifying, coactiva~ors and transcription complexes 
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(Levings and Bungert, 2002). The most extensively s.tudied stage-specific activator is 
EKLF, which is crucial for human B-globin gene expression. The EKLF-DNA binding 
site consensus sequence 5'-NCNCNCCCN-3' corresponds to a functionally important 
motif within the adult B-globin gene promoter. Mutation of this sequence in humans is 
found in some patients with B-thalassemia. Targeted disruption of the EKLF gene in 
mice also results in lethal B-thalassemia. EKLF knock-out mice die from severe anemia 
at the fetal stage due to failure of adult B-globin gene. activation. EKLF-
'
- mice 
containing a complete human B-globin locus transgene have reduced levels of B-globin, 
but elevated levels of g-globin expression, compared to wildtype mice containing the 
same transgene (Perkins et al., 1996; Wijgerde et al., 1996). Taken together, these 
experiments suggest that EKLF participates in the switch from embryonic/fetal globin 
to adult B-globin expression in humans. 
New insight into EKLF function has come from experiments showing that EKLF 
requires the presence of a SWIISNF-related chromatin remodeling complex (E-RCl, 
EKLF coactivator remodeling complex-I) for its tissue-specific regulation, indicating 
that it may affect transcription by altering chromatin configuration (Armstrong et aI., 
1998). Reintroducing EKLF into an EKLF-null erythroid cell line, which harbors a copy 
of the human B-globin locus, resulted in enhanced differentiation and 
hemoglobinization, as well as reduced proliferation. This may point to a role for EKLF 
in cell cycle regulation and hemoglobinization, in addition to regulation of B-globin 
gene expression (Coghill et aI., 2001). 
The Fli-J oncogene 
A member of the Ets family of transcription factors, Fli-l, was identified in Friend 
virus-induced erythroleukemia and affects the self-renewal of erythroid progenitor cells 
(Howard et aI., 1993). In pluripotent human hematopoietic cells, di.fferentiation is 
followed by reduced Fli-l expression and over expressing Fli-l inhibits erythroid 
differentiation, impairs the cells' ability to respond to specific erythroid inducers such 
as hemin, and reduces the levels of GAT A-I (Athanasiou et aI., 2000). In the 
erythroblastic cell line HB60, Fli-l expression is downregulated by' erythropoietil! 
(Epo), which induces terminal erythroid differentiation. Constitutive expression of Fli-l 
blocks Epo-induced differentiation and enhances cell proliferation in HB60 cells, 
suggesting that Fli-l targets erythroid cells to either proliferation or differentiation, in 
" 
response to Epo (Tamir et aI., 1999). Fli-l binds a cryptic Ets consensus site within the 
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retinoblastoma (Rb) gene promoter, repressing Rb expression, which results in impaired 
terminal erythroid maturation and continuous presence of nucleated erythrocytes in 
peripheral blood (Lee et aI., 1992). Negative regulation of Rb by Fli-l could destine 
erythroid progenitors to self-renewal, while Epo-induced repression of Fli-l expression 
will enable differentiation (Tamir et aI., 1999). 
PU.l 
The putative oncogene Spi-l (PD.l) protein product is a hematopoietic-specific Ets 
factor, promoting differentiation of lymphoid and myeloid lineages (Scott et aI., 1994). 
PD. 1 expression in erythroid progenitors can induce erythroleukemia in mice. Like Fli-
1, PD. 1 blocks erythroid differentiation and restoration of terminal erythroid 
differentiation in murine erythroleukemia (MEL) cells requires PD.l suppression 
(Rekhtman et aI., 1999). 
PD.l can interact directly with GATA-l and repress GATA-l mediated transcriptional 
activation (see Section 1.1.3.2.3). Both the PD.l DNA binding domain and 
transactivation domain are required for GATA-l suppression and for blocking terminal 
differentiation in MEL cells. PU.l does not seem to affect binding of other factors, such 
as FOG, to GATA-l, nor does it prevent GAT A-I DNA binding (Rekhtman et aI., 
1999). It is likely that PD.l binds to assembled, DNA-bound GATA-l complexes and 
represses their activity. Ectopic expression of PD.l in Xenopus embryos blocks 
erythropoiesis. Exogenous GAT A-I is able to relieve this blockage of erythroid 
differentiation in MEL cells as well as in Xenopus embryos and explants, suggesting 
that lineage commitment decisions are regulated by their relati ve levels. 
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1.4.3.2 Putting the puzzle together: a model for 8-gl~bin gene regulation 
A four-step model for human B-globin gene regulation has been suggested (Levings and 
Bungert, 2002) the first step involves partial unfolding of globin chromatin structure 
and generation of a highly accessible LCR. It is mediated by erythroid-specific proteins, 
which bind to sequences throughout the globin locus. GAT A-I , which is known to 
associate with histone acetyl-transferases, may be involved in this step. The disruption 
of the LCR chromatin structure allows binding of transcription factors such as EKLF, 
GATA family members and the HLH proteins to the LCR HS sites, and the recruitment 
of chromatin-remodeling complexes and coactivators. In the third step, chromatin 
domains permissive for transcription are being established. Intergenic transcription was 
suggested to modify chromatin structure of an active gene domain, distinguishing it 
from an accessible but inactive one, that way separating the globin genes into 
developmental stage-specific chomatin domains. Finally, transcription complexes are 
being transferred from the LCR to individual globin gene promoters within 
transcriptionally permissive domains, allowing the developmental stage-specific pattern 
of globin gene expression. 
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1.5 Specific Aims 
For most clinical applications, restricting the expression of a retrovirally delivered 
therapeutic transgene to a specific subset of cells within a tissue, or to specific progeny 
of a multi potent stem cell, is a mandatory requirement. This need can be achieved either 
by targeting vector entry into a specific cell subset (transductional targeting) and/or by 
targeting the expression of the transgene by appropriately regulating its transcription 
(transcriptional targeting). Redirecting retroviral particle entry can be achieved by either 
pseudotyping, genetically modifying the envelope glycoprotein or by inserting soluble 
adaptors between the viral particle and the desired target cell. Proof of principle for this 
type of technology has been provided in the past for both oncoretroviral and lentiviral 
vectors. However, increasing specificity, while maintaining infectivity of a retroviral 
particle, turned out to be difficult and the entire technology is still far from meeting the 
safety and efficacy requirements for real clinical application (reviewed in Larochelle et 
aI., 2002). On the other hand, redirecting transcriptional properties has proven a 
relatively easier task, although the RNA nature and the limited size of a retroviral 
genome impose significant constrains on the complexity of the regulation that can be 
achieved in both oncoretroviral and lentiviral vectors. 
The goal of this project is the development and the exploitation of transcriptionally-
targeted lentiviral vectors, based on the use of cellular transcription control elements 
conferring tissue- and/or lineage-specific expression upon integration into the target 
cells. This approach will be validated in the context of gene transfer and therapy models 
requiring stem cells transduction and restriction of gene expression to specific progeny 
differentiating from transduced cells. The project implies: 1) the design of new vectors 
and the development of suitable, high-titer packaging systems; 2) the transduction of 
cell lines and stem cells of different origin and the analysis of specifi~ally restricted 
transgene expression in vitro; 3) the development of in vivo models to test the efficacy 
of the newly designed vectors in restricting the expression of a given transgene in a 
tissue- and cell-specific fashion and, finally, 4) the development of transcriptionally-
" . 
targeted lentiviral vector for B-globin expression. 
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1.6 Specific Background 
Retroviral vectors are widely used to integrate and express exogenous genes into a 
variety of animal cells and provide a safe and relatively efficient gene transfer tool for 
human gene therapy (Verma and Somia, 1997). To date, they represent the only gene 
transfer system allowing active integration of foreign DNA at high efficiency into the 
target cell genome and are the vectors of choice in most of the clinical trials for gene 
therapy. However, a significant limitation of retroviralvectors derived from the 
Moloney murine leukemia virus (MoML V) backbone is their inability to integrate into 
the genome of non-dividing cells, which essentially limits their use to ex vivo 
applications and to cells which can be induced to replicate in culture without losing a 
specific, therapeutically relevant phenotype. As an example, hematopoietic stem cells 
(HSCs) are very difficult to maintain in culture in an active mitotic state without 
compromising their self-renewing and bone marrow (BM) repopulating capacity and are 
therefore difficult to transduce with retroviral vectors at an efficiency compatible with 
clinical applications. A number of groups have recently reported that mV-l-derived LV 
vectors can integrate into the genome of non-dividing cells in vivo and ex vivo and are 
much more efficient than MoML V -deri ved vectors in transducing HSCs without 
compromising their repopulation capacity upon transplantation (Miyoshi et aI., 1999; 
Woods et aI., 2000). Several years of research have drastically improved both design 
and packaging of LV vectors, and virtually abolished the safety concerns originally 
raised by the idea of transducing human cells with a vector derived from HIV. 
For correction of genetic disorders affecting a specific progeny of pluripotent stem cells, 
the ultimate goal of gene therapy would be to integrate a therapeutic gene in long-
lasting and self-renewing stem cells and regulate its expression in specific, 
differentiated lineages. In these applications, controlling the expression of a transferred, 
therapeutic gene at quantitative and qualitative (tissue- or cell-specific) levels is a 
critical and often limiting, factor. Appropriate transgene regulation in the framework of 
a retroviral vector is a difficult task, due to a number of technical factors such as limited 
vector capacity, transcriptional int~rference between the viral ~ TR and internal 
enhancers/promoters and genetic instability of complex regulatory sequences in this. 
context (Coffin et aI., 1997). Transcriptional targeting of LV vectors meets essentially 
the same type of technical difficulties encountered with oncoretroviral vectors. 
However, transcriptional interference is usually not a problem in a lentiviral context, 
since the "self-inactivating" (SIN) design is mandatory to ~inimize the regions of 
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potential overlapping, and therefore recombination, between the transfer vector and the 
packaging construct (see Section 1.2.3.4). This allows the use of internal promoters 
combined with tissue- or cell-specific enhancers to regulate transgene expression. With 
this simple design, expression of a reporter or a therapeutic transgene has been 
effectively restricted to erythroblasts and to antigen-presenting cells derived from 
murine or human HSCs, by the use of erythroid-specific enhancers driving the ankyrin-
1 promoter or the human HLA-DRa promoter respectively (Cui et aI., 2002; Moreau-
Gaudry et aI., 2001; Richard et aI., 2001). Attempts have also been made to introduce 
into LV vectors exogenously regulated transcriptional elements, such as a tetracycline-
responsive element linked to a minimal promoter to drive the gene of interest and 
different variants of tetracycline-regulated, chimeric transcriptional activators (Kafri et 
aI., 2000; Vigna and Naldini, 2000). The major limitation of using internal transcription 
units within LV vectors is the absence of introns in the sub genomic transcript used to 
express the gene of interest, which significantly affects its post-transcriptional fate 
(polyadenylation, nuclear export, stability) and ultimately reduces its efficacy in terms 
of protein output. For some gene therapy applications, for example, the correction of 
globin chain imbalance in B-thalassemia, a high protein output is just as important as its 
restricted expression, which makes practically inadequate the use of intronless B-globin 
cDNAs expressed by internal promoters. This problem has been partially resolved by 
placing the entire human B-globin gene under the control of its own promoter and a 
reduced version of the B-globin LCR in reverse orientation within a first-generation LV 
vector. With this design, potentially therapeutic levels of human B-globin have been 
obtained for the first time in a murine model of B-thalassemia (May et aI., 2000; May et 
aI., 2002; May and Sadelain, 2001; Rivella et aI., 2003). 
As in the case of oncoretroviral vectors, transcriptional targeting of LV vectors can be 
conveniently achieved by LTR enhancer replacement (Lotti et aI., 2002). A critical 
advantage of this targeting strategy is the use of the spliced, major viral transcript to 
express the gene of Interest, which partially overcomes the major limitation of the 
internal promoter design. The interna~, less efficient transcription uni.t c~n nevertheless 
be used to independently express a second gene providing an additional function, such. 
as an in vivo selectable marker. An additional advantage of LTR enhancer replacement 
as a targeting strategy is that the integrated provirus carries two copies of a genomic 
enhancer within the two LTRs. The presence of two active enhancers flanking the 
transgene transcriptional unit could reduce the chances Of chromatin-mediated 
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inactivation of transcription, which is known to affect the long-term maintenance of 
retroviral trans gene expression in vivo, particularly in stem cells (Challita and Kohn, 
1994). Double copies of at least some cell-specific enhancers could indeed act as 
transcriptional insulators, thus replacing LCRs, matrix-attachment or other elements 
influencing chromatin configuration to shield randomly integrated transgenes from 
chromatin-mediated silencing. Indeed, reduced LCR sequences do not appear to confer 
position-independent expression to the viral-encoded transgene [May, 2000 #285], and 
their role in maintaining open chromatin conformation to transcribed loci has been 
challenged by several authors (Epner et aI., 1998; Reik et aI., 1998). Matrix- or scaffold-
attachment elements have also been introduced in retroviral vectors to reduce position 
effect variegation, with only partial success (Dang et aI., 2000; Park et a!., 2000). 
Binding of tissue- or lineage-specific transcription factors to specific regulatory regions 
(e.g., those defined by DNase hypersensitive sites) could be a key factor in initiating 
and maintaining active chromatin structures around genes regulated in development or 
differentiation (Martin et a!., 1996; Orkin, 1995) providing a rationale for' using 
transcriptionally targeted vectors based on specific enhan,cers to restrict transgene 
expression to a specific progeny of the HSC. 
Gene therapy of hemoglobinopathies or thalassemias would require restricted 
expression of a globin transgene only to the erythroid progeny of hematopoietic stem 
cells and represents one of the most challanging models to test the efficiency of 
transcriptional targeting of viral vectors. The B-thalassemias are a group of inherited 
anemias characterized by reduced or absent production of hemoglobin B-chains (see 
Section 1.3.2~1). Conventional treatment is based on lifelong blood transfusion and 
continuous iron chelation. The only available cure is allogeneic bone marrow 
transplantation (BMT), which is however available for less than 30% of the thalassemic 
patients. Gene therapy could be a potential alternative to BMT. The clinical history of 
the disease and over 15 years of BMT experience indicate that even a mild correction 
(> 15%) of the globIn imbalance in a fraction (>25%) of maturing erythroblasts is 
.. sufficient to reduce the morbidity caused by ineffective erythropoie~is, to improve the 
clinical management of the disease and to increase the patients' life expectancy. For. 
therapeutic purposes, reproducing the full complex regulation of the B-globin gene 
might therefore be unnecessary. During the years, a number of scientists have tried to 
obtain lineage-restricted, high-level transcription of the B-globin gene in the framework 
of a MoMLV-derived vector, with limited success (Sadelain et,aI., 1995). Recently, the 
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synthesis of potentially therapeutic levels of human B-globin was achieved in the 
erythrocytes of bone marrow chimeras tran"splanted with B-thalassemic bone marrow 
cells, transduced with the 1st generation LV vector TNS9 (May et aI., 2000). TNS9 
lentiviral vector contains the human B-globin gene, including extended promoter 
sequences and the B-globin 3' proximal enhancer, and LCR elements (3.2kb), cloned in 
a reverse orientation in respect to the mv LTR transcriptional direction. Although these 
results showed that appropriate regulation of a globin gene can be technically achieved, 
intrinsic limitations to this system are the lacking of position-independent expression of 
virally encoded B-globin, demonstrated by clonal analysis of transduced MEL cells 
(May et aI., 2000), and the size of the vector, which is unlikely to allow the insertion of 
a second transgene for selection of transduced stem cells. Moreover, the TNS9 vector 
has been done in the backbone of a first-generation lentiviral vector, and it contains two 
intact HIV-1 LTRs. A SIN version of the TNS9 lentiviral vector must be developed 
using the third-generation packaging system to prevent recombination events generating 
replication-competent mv -1 virus. 
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Chapter 2 
MATERIAL AND METHODS 
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2.1 Reagents-suppliers 
2.1.1 Chemicals 
All chemicals were obtained from FLUKA, Sigma Chemical Co. or Roche. 
Other chemicals used during the study were obtained from the following sources: 
Agarose for gel electrophoresis 
DNA markers 
Protein markers 
X-Ray film 
Hydrolysed milk powder 
Nitrocellulose for western blot 
Nylon membrane for SouthernlNorthern blot 
ELISA p24 
FICOLL 
2.1.2 Radiochemicals 
a 32p dCTP 
2.1.3 Enzymes 
FMC 
Gibco Brl 
Gibco Brl 
KODAK 
Nestle 
Schleicher and Schuell 
Hybond 
NUNC 
Nycomed 
All DNA modification enzymes and buffers were received from Roche. 
2.1.4 Restriction enzymes and buffers 
All restriction enzymes and buffers were obtained from either Roche or New England 
Biolabs . 
. 2.1.5 Bacterial strains and growth 
The DH5a bacterial strain (F', hsdR17, rk"m/, recA1, endA1) was used for all 
transformations, and grown in Luria Broth JI?edia prepared within the Institute. 
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2.1.6 Plasmids 
Creation of other plasmids are described below (Section 2.5.1). The following were 
provided by Prof. Luigi Naldini (University of Turin Medical School): 
• the pCMV ~R8.91 packaging vector. 
• pRRL.sin-18.CMV.GFP, pHR II 
• the pMD.G plasmid encoding VSV.G protein. 
Unless otherwise stated, all the plasmids contained the' ampicillin resistance gene 
allowing selective growth in LB media. 
2.1.7 Solutions and buffers 
Hematopoietic cell buffer for flow PBS containing 0.1 % (weight for volume) 
cytometric analysis (HC FACS): ratio (w/v) Sodium azide, 0.3 % w/v BSA 
Standard Cell lines buffer for flow PBS containing 5 % w/v FCS 
cytometric analysis: 
50x TAE for agarose gel (for 1 Iitre) 242g Tris Base 
57.1 ml Glacial acetic acid 
100ml 0.5M EDTA, ph8.0 
Water to 1 Ii tre 
2.2 Tissue culture reagents 
2.2.1 Plastic ware 
All standard tissue culture plastic ware, (tissue culture flasks, roller bottles, collagen 
coated transwell apparatus, tissue culture plates) was obtained form Coming Costar. 
2.2.2 Media 
IMDM Biowhittaker 
X-VIVO 10 Biowhittaker 
RPMI1640 Euroclone 
BIT 9500 Stem Cell technology 
DMEM .. Euroclone 
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2.2.3 Sera, Supplements and antibiotics 
Fetal Calf Serum Mascia Brunelli, Italy 
Fetal Bovine Serum Euroclone 
Trypsin Gibco Brl 
L-Glutamine Gibco Brl 
Peni cillinlS treptom ycin Gibco Brl 
HEPES Gibco Brl 
Polybrene Sigma 
2.2.4 Growth factors 
Recombinant human Stem cell factor (SCF) R&D Systems, and Pepro Tech, England 
Recombinant human Flt-3 Ligand (Flt3-L) Pepro Tech, England 
Recombinant human Thrombopoietin (TPO) PeproTech, England 
Recombinant human interleukin-3 (rhIL-3) R&D Systems 
Recombinant human interleukin-6 (rhIL-6) R&D Systems 
Erythropoietin (EPO) R&D Systems 
2.2.5 Other 
Phosphate buffered Saline (PBS) was obtained from Euroclone. 
2.3 Antibodies and antisera 
Anti human NGF antibody: 
Hybridoma supernatant produced at DIBIT HSR. 
Anti human NGF biotin conjugated: 
Antibody purified from hybridoma and conjugated with Biotin, by facility in DIBIT 
. HSR. 
Antimouse IgG (FITC. R-PE conjugated): , 
Obtained from Southern Biotechnology Associates, U.S.A. 
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Mouse IgO (used for block in Hematopoietic gene transfer analysis): 
Obtained form Sigma Chemical co. U.S.A. 
Streptavidin comjugated with R-PE. FITC. or Tricolor: 
Obtained form Caltag Laboratories, U.S.A. 
Anti-human CD38. R-PE. FITC. or Tricolor conjugated: 
Obtained from Caltag laboratories, U.S.A. 
Anti-human CDl3 antibodies. R-PE conjugated: 
Obtained from Caltag laboratories, U.S.A. 
Antihuman CD45 antibodies. R-PE conjugated: 
Obtained from Caltag laboratories, U.S.A. 
Antihuman OpA antibodies. R-PE conjugated: 
Obtained from Caltag laboratories, U.S.A. 
Anti human CD34 antibodies (anti HPCA-2). R-PE or FITC conjugated: 
Obtained from Becton Dickinson Immunocytometry systems, U.S.A. 
Anti human CD45. R-PE. FITC. or Tricolor conjugated: 
Obtained from Caltag laboratories, U.S.A. 
Isotype control antibodies. Mouse IgO conjugated with R-PE. FITC. or Tricolor: _ 
Obtained from Caltag laboratories, U.S.A. 
Anti-mouse Ter 119-PE: 
Obtained from Pharmigen 
Anti-mouse Or-I-PE: 
Obtained from Pharmigen 
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Anti-mouse CD.45.1-FITC/-TC: 
Obtained from Pharmigen 
Anti-mouse CD.45.1-PE: 
Obtained from Pharmigen 
Anti human gIobins: 
Obtained from ICN Biotechnology, U.S.A. 
Anti human-FLAG: 
Obtained from Sigma. 
2.4 Cells 
2.4.1 Stable cell lines 
~ Des~ril1tion Sour~g 
293T Endothelial, Human Naldini L, University of 
embryonic kidney Turin Medical School 
NIH3T3 Fibroblast, murine bone Ferrari G., TIGET 
marrow 
He La Human carcinoma FromATCC 
HEL Human erythroleukemic FromATCC 
K562 Human myeloblastic FromATCC 
U937 Human monocytes FromATCC 
MEL Murine erythroleukemic From Antoniou M. 
KASUMI-l 
-. 
Human lymphoblastic FromATCC 
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2.4.2 Primary cells 
Human hematopoietic cells: 
All primary human cells were received from Ospedale San Raffaele, Milan, Italy, with 
informed consent, following the legal and ethical regulations instated by both the above 
mentioned hospital and by the Italian Fisica Sanitaria (Rome, Italy). 
Human CD34+ cells: 
Were most kindly purified and prepared from UCB, BM or MPB sources by either 
Claudia Rossi, by FICOLL density separation followed by magnetic selection based on 
the Miltenyi MACS kit for cell separation, following the manufacturers recommended 
protocol. Samples were frozen in FCS containing 10 % DMSO, and stored in liquid 
Nitrogen until required for use. 
2.5 Methods 
Methods are divided into 4 sections: 
2.5.1 Molecular methods 
2.5.2 Tissue culture methods 
2.5.3 Gene transfer methods 
2.5.4 Animal study methods 
2.5.1 Molecular methods· 
2.5.1.1 Generation of erythroid specific LV vectors: 
An EcoRIISacI fragment containing part of the 3' LTR of the HIV-1 derived lentiviral 
vector pHR2 was sub-cloned into the Pvull site of the pUC-19 plasmid. The plasmid 
was digested with EcoRV and BanII, self-ligated to'generat~ a -418- to -40 deletion 
(where +1 is the transcription start site) in the U3 region of the LTR, or ligated with a 
200-bp BamHI fragment containing the GATA-1 HS2 human genomic fragment (-856 
to -655) to obtain a chimerical LTR. The two LTRs were then .. in~roduced in the 
pRRL.SIN vector backbone to obtain the pRRL.sin-40.GFP (-40) and the 
pRRL.GATA.GFP (G) vectors, respectiv~ly. A second, independent transcriptional 
cassette (PGK.L\.LNGFR) was introduced into the HindII/SacII sites to generate the 
vectors pR~L.sin-40.GFP.PGK.L\.N (-401P) and pRRL.GATA.GFP.PGK.L\.N (GIP). 
The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was 
96 
cloned in the filled EcoRI or HindU sites of the G/P vector to generate the 
pRRL.GATA.GFP.W.PGK.~N. (G.W/P) or pRRL.GATA.GFP.PGK. ~N.W (G/P.W) 
vectors, respectively. To generate the pRRL.sin-18.GATA.GFP (-18/G) vector, a 
fragment of 370 bp containing the GAT A-I HS2 and a portion of the HIV-l LTR (-40 
to +75) was inserted in the filled BamHI site of the pRRL.GFP.sin-18 vector. For some 
experiments, the G.W/P vector was further modified by the insertion of a 118-bp, 
HpaU/ClaI fragment containing the HIV-l central polypurine tract (cPPT), as 
previously described (Follenzi et aI., 2000). 
B-globin vectors: 
The FLAG sequence was inserted at the 5' end of the human B-globin coding sequence 
byPCR. 
We used as template the pT7T3D plasmid containing the human beta globin cDNA and 
the two primers: 
primer forward: 5' ccccatggactacaaggacgacgacgacaaggtgcacctgactcctgaggag 3' 
primer reverse: 5'gggcggccgcaaggaagcgagcuagtgatacugtgggcc 3'. 
The PCR product was digested NcoIlNotI, blunted and cloned into pBS.lI.SK digested 
" 
with EcoRV. The vector containing the insert in opposite 'orientation was digested 
XmaIlSalI, and the insert was cloned in the two lentiviral vectors pRRL. sin-
40. GATA1.ppt. G FP. wpre and pRRL.sin-40.GATA1.ppt.GFP.wpre.PGK.L1LNGFR 
digested AgeIlSa11. In this way the GFP sequence was replaced by FLAG-B-globin and 
we obtained the two final vectors: pRRL.GATA1.j3glo andpRRL.GATA1.j3g1oPGK.L1N. 
2.5.1.2 Transformation of competent bacteria and small scale bacteria 
preparations 
DNA to be transformed was mixed with 200J,11 of competent DH5a cells prepared 
specifically for the heat shock mediated transformation method (Maniatis, Fritsch et ai, 
1982). The mix was incubated on ice for 20 minutes, then 1 minute and 45 seconds in a 
, waterbath at 42°C, and then returned to ice for a further 10 minutes: "Th.e mix was then 
added to 1 ml of LB media and incubated at 37°C with agitation for one hour. The mix 
was then plated onto LB agar plates, conta,ining the required antibiotic resistance and 
placed overnight in a 37°C bacterial incubator. The following day, colonies were picked 
and placed into 1.5 ml of LB media containing antibiotics, and grown overnight with 
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agitation at 37°C. The small bacteria preparations were subjected to small or large scale 
DNA preparation as required. 
2.5.1.3 Small scale (miniprep) preparation of plasmid DNA from bacteria 
Small amounts of plasmid DNA were purified from bacteria, for restriction analysis, 
following the alkaline lysis method for DNA isolation (Maniatis, Fritsch et ai, 1982). 
2.5.1.4 Large scale preparation of plasmid DNA 
This method is a scaled up method of the alkaline lysis method, using identical solutions 
unless stated. Typically 500 ml of an overnight growth of DH5a bacteria in antibiotic 
containing LB media was used per preparation. The bacteria were pelleted at 6000 rpm 
for 10 minutes in a Sorvall centrifuge. The residual media was discarded and the 
centrifuge tube inverted to drain as much media as possible away from the pellet. 4 ml 
of alkaline lysis solution 1, containing Lysozyme at a final concentration of 12.5 Ilg/ml, 
was added to the pellet, and the bacteria resuspended by gentle mixing. The bacterial 
mix was then placed on ice for 10 minutes. 8 ml of alkaline lysis solution 2, was then 
added, the sample mixed and returned to ice for a further 10 minutes. 7 ml of ice cold 
alkaline lysis solution 3 was added, the sample again thoroughly mixed, and returned to 
ice for a further 20-30 minutes. 
The tube was centrifuged at 11000 rpm in a Sorvall centrifuge, the lysate filtered 
through medical gauze into pyrex tube (the residual pellet was discarded) and 11ml of 
isopropanol added to precipitate the nucleic acid. 10 minutes later the samples were 
centrifuged at 11000 rpm, the liquid discarded, the pellet properly drained, and then 
resuspended in 2.5 ml of DNase free water. RNase was added to a final concentration of 
21lg/ml and the sample incubated at 37°C for 15 minutes. 
Beckman quick seal tubes (BQS) were prepared as follows. 11g of Caesium Chloride 
(CsCI) were measured into 50 ml Falcon tubes to which was added 400 J.d of Ethidium 
Bromide (10mg/ml stock). 7.5 ml of water was then added to the RNase treated pellet, 
" and this was added to the CsCl. After the CsCI had dissolved, the sol~ti9n was taken up 
using a 10 ml syringe and injected into the BQS, the tubes balanced, and then sealea 
using the Beckman heat sealing device. 
Samples were centrifuged in a Beckman NVT 65 rotor at 55,000 rpm, for at least 20 
hours. The tubes were gently removed from the rotor, a hole punched in the top of the 
tube using a large gauged needle, and a _syringe with needle attached was inserted just 
98 
below the DNA band which was clearly distinguished from the rest of the gradient due 
to the intense red colour following the ethidium bromide intercalation. The DNA band 
was gently removed and injected into a 15 ml Falcon tube. 1 ml of butanol saturated 
with water was added to the tubes, the tubes shaken, left to settle and the upper phase 
discarded (clearly pink coloured). This process was repeated several times until no pink 
colour was visible. The process was then repeated one more time after this to be sure of 
ethidium bromide removal. 
An equal volume of isopropanol saturated with CsCI was added, the tubes again mixed 
left to settle and the upper phase discarded. This process was repeated twice. Water was 
then added to the tubes, up to 5 ml, 250 ml of 3M sodium acetate added, and a further 
10 ml of absolute ethanol added on top. Tubes were mixed and placed at -20°C for 30 
minutes and then washed by repeated 70% ethanol mixing and centrifugation. Purified 
DNA was resuspended in DNase free water and quantified using the standard 
260/280nm absorbance method on a spectrophotometer. DNA was stored at 4°C if 
required immediately, or stored at -20°C for longer use. 
2.5.1.5 Southern blot analysis 
Extraction of genomic DNA from cells: 
1-5xl06 cells were lysed in 800 1-11 the following buffer: 
Soutern Lysis buffer: 
50 mM Tris pHS.O 
100mMEDTA 
400mMNaCI 
1% w/v SDS 
25JlI of proteinase K (10mg/ml stock) was added and the mix incubated overnight at 
55°C. 
100Jlg of RNase was added ant the mix incubated for a further 2 hours at 37°C. An 
" equal volume of phenol/chloroform was added and the samples mixed for 15 minutes, 
followed by centrifugation for 30 minutes at 15,000 rpm. The aqueous phase was 
removed and an equal volume of phenol/chloroform added. The above step was 
performed, the aqueous phase taken and an equal volume of chloroform added, the 
samples mixed and centrifuged as above, the aqueous phase taken and nucleic acid 
precipitated by the addition of an equal volume of isopropanol.' 
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A glass pasteur pipette was blunted by inserting into °a bunsen flame and the precipitated 
DNA extracted by dipping the pasteur and gently pulling. The genomic DNA was 
clearly visible, it was allowed to air dry briefly, and then the inserted into 100 J,11 of 
DNAse free water, and the DNA allowed to dissolve overnight at 4°C. Nucleic acid 
concentration was determined using the 260/280nm absorbance measurements on a 
spectrophotometer. 
Isolation of probe: 
20J,1g of the pEOFP-C3C (ClonTech), DNA were digested with the enzymes, Eeo47111 
and Seal, to release a 790bp sequence of OFP gene. After running on a 0.8% w/v 
agarose gel, in T AE buffer, the band corresponding to the required DNA was excised 
using a scalpel, and the DNA fragment purified using the QiaexII DNA extraction kit 
from Qiagen following the manufacturers instructions. Concentration was measured and 
the probe labelled as described below. 
Digestion of genomic DNA and gel electrophoresis: 
10 J,1g of genomic DNA was digested with EeoRI, AflII or Xbal enzyme by repeated 
addition of enzyme and buffer, (2 separate additions of concentrated enzyme and buffer 
over 16-18 hours). The digested DNA was run on a 3% agarose gel in TAE buffer, 
containing ethidium bromide, overnight at 35 volts. The gel was photographed. 
Southern blotting: 
The DNA was denatured by incubating the gel in O.2M NaOH, O.6M NaCI for 1 hour 
with one exchange of buffer. The gel was then neutralised by incubating the gel for 1 
hour in 1.0M Tris HCI, pH7.5, 1.5M NaCl. Southern blot assembly performed as 
described (Maniatis, Fritsch et aI, 1982) using Hybond Nylon filters (presoaked in 
distilled water and l.9X SSC. Southern blot was performed overnight in lOX SSC. After 
blotting the filter was rinsed in 6X SSC and crosslinked using a Stratalinker. 
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Hybridisation: 
The filter was washed with O.lX SSC, 0.5% w/v SDS at 65°C for 1 hour, exchanging 
the buffer, twice, followed by an overnight incubation in prehybridisation solution at 
42°C. 
Pre-hybridisation solution: 
5X Denhardt's 
5XSSCP 
50% deionised formamide 
The prehybridisation solution was removed and replaced with hybridisation solution 
containing the radioactive labeled probe. The filter was incubated overnight at 50°C, 
followed by a 30 minute wash in 2X SSC, 0.1 % SDS (with one change) and a 2 hour 
wash at 60°C with O.lX SSC, 0.1 % w/v SDS (with 3 changes). The filter was blot dried 
and exposed to KODAK autoradiograph film, for various times and the films 
developed. 
Radioactive labelling of probe: 
Radioactive labeling was performed using the Roche Random primed DNA labeling kit 
and the quick spin columns, following the manufacturers instructions. 
Southern blot solutions: 
100X Denhardts: 19 FICOLL 400 
19 Polyvinylpropylene(PVP) 
19 BSA (fraction V) 
-. 
Up to 50 ml with water 
20XSSC 350.6g NaCI 
176.5g Citric acid, trisodium salt 
DNase free distilled water up to 2 litres 
20XSSCP 88.2g Sodium citrate (trisodium salt) 
140.3g NaCI 
.. 43.7g Na2HP04 
~ 12.7g Na2HP04.H2O 
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DNase free distilled water up to 1 litre 
Hybridisation solution (for 20 ml): 6 ml20X SSC 
0.2 ml 100X Denhardts 
10 ml deionised formamide 
1 ml 10% w/v SDS 
2g Dextran Sulphate 
2.8 ml of B.S256+probe 
B .S256( lOX) 16 mg polyA 
16 mg polyC 
400 mg yeast t-RNA 
100 mg Salmon Sperm DNA 
9 mg E. coli DNA 
Note: The radioactive probe is mixed with B.S256, boiled for 10 minutes and quenched 
on ice, prior to adding to hybridisation solution. This is to ensure that the probe is 
denatured. 
2.5.1.6 Northern blot analysis 
Total cellular RNA was extracted by guanidine-isothiocyanate, poly(At selected by 
oligo(dT)-cellulose chromatography, size-fractionated on 1 % agarose-formaldehyde gel, 
blotted onto nylon membranes, hybridized to 107 dpm of 32P-Iabeled NGFR, GFP, 8-
globin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes, and exposed 
to X-ray film. 
Pre-hybridization solution per NO.rthern 20x SSCP 
Denhardts 100x _. 
SDS 10 % 
Salmon sperm 
.' 
FormamideD 
Water 
Hybridization solution per Northern 20x SSCP 
Denhards 
~ SDS10% 
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I Fonnarnide D 
Dextran solphate 50 % 
2.5.1.7 Poliacrylamide gel electrop~oresis (PAGE) and western blotting 
PAGE: 
12% denaturating PAGE gels were made following the published instructions (Maniatis, 
Fritsch et ai, 19S2), and assembled on the Biorad mini protean II gel apparatus following 
the manufacturers recommended instructions. 
1-5xl06 cell samples, were first lysed in 200 III of protein lysis buffer. 
Protein lysis buffer: 150mMNaCI 
1 % v/v Nonidet P-40 
0.5% w/vDOC 
0.1% w/v SDS 
50 mM Tris (pHS.O) 
25 III of lysate was mixed with 25 III of 2 fold concentration cracking buffer containing 
B-Mercaptoethanol, and loaded into the well of the PAGE using a Hamilton syringe. 
2 fold cracking buffer (for 10 ml): 1.5 ml of 0.S3 M Tris Hcl pH 6,S 
3 ml of 20% SDS 
2 ml of glycerol 
Iml of B-Mercaptoethanol 
2.5 ml of water 
250 mg of Bromo Phenol Blue 
The gel was run in Tris-GIycine buffer (27.9 g glycine, 6 g Tris, dissolved in l1itre of 
water), containing 0.1 % v/v SDS, at 55 rnA, until the Bromo Phenol Blue dye had run 
out of the gel. As a molecular weight marker, 4 JlI of Rainbow marker (Biorad) was 
used. 
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Blotting: 
Nitrocellulose membranes (Scleicher and Schuell) cut to the same size as the PAGE gel 
were pre-soaked in transfer buffer: 
Transfer buffer (for 1 litre): 3g Tris 
14.4 g Glycine 
200 ml Methanol 
800 ml Water 
Blotting was performed using the Biorad western blotting apparatus and assembled 
following the manufacturers instructions. Upon assembly, the inside of the apparatus 
was filled with transfer buffer, and run overnight at 200 volts at 4°C. 
Antibody staining: 
After transfer of the proteins had been performed, the membrane was blocked in PBS 
containing hydrolysed milk (2,5% w/v) for 30 minutes. The m~use anti-FLAG or the 
rabbit anti-human globin antibody (lCN Biotechnology, U.S.A) was added to the 
blocking reaction at a final concentration of 10 Jlglml and incubated with agitation for 2 
hours at room temperature. The membrane was washed three times with PBS/0.05% v/v 
Tween 20, and fresh blocking solution containing the anti-mouse or anti-Rabbit IgG 
Peroxidase-conjugated antibody at a 1 in 10,000 dilution was added to the membrane. 
Incubation was performed for two hours at room temperature or 16 h at 4°C with 
agitation. The membrane was washed as before and peroxidase activity was measured 
using the commercially available ECL kit (Amersham) following the recommended 
instructions. The membrane was exposed to KODAK autoradiograph film and 
developed. 
2.5.1.8 Polymerase chain reaction specific for GFP: 
Primers specific for the GFP were obtained from PRIMM, Italy and had the following 
sequences: 
GFP (sense): 5' -atg gtg agc aag ggc gag-3'. 
GFP (antisense): 5' -gtt act tgt aca gct cgt c-3' 
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Both primers had melting temperatures of 55°C.PCR with these primers enables 
distintion from endogenous NGFr sequences, as these have been designed against the 
eDNA. 
dNTP's were obtained from Roche, water was in house prepared DNase free, while the 
Taq polymerase enzyme and buffer were obtained from Dynazyme. 
Celllysates to serve as templates for the PCR reaction were prepared by lysing 100,000 
cells in 25 J-ll of lysis buffer (1: 1 mix of lysis buffer A and B, containing Proteinsase K 
at a final concentration of 50J-lg/ml): 
Lysis buffer A lOOmMKCI 
10 mM Tris pH8.3 
2.5mMMgC12 
Lysis buffer B 10 mM Tris pH8.3 
2.5 mMMgCl2 
1 % v/v Tween 20 
1 % v/v Nonidet P-40 
Lysed cells were incubated overnight at 37°C, heat-inactivated for 15 minutes at 94°C 
and then stored at -20°C until required. 
The PCR mix was prepared as follows: 
GFP-F (25pmollml) 1 J-ll 
GFP-R (25pmollml) 1 J-ll 
lOx Taq buffer 5 J-ll -
Taq polymerase 1 JlI 
dNTP(lOmM) _. 1 JlI 
Lysate 25 J-ll 
Water Up to final volume of 50 ~l 
The mix was placed in a Perkin Elmer PCR'tube, 25 JlI of mineral oil placed on top, and 
peR performed in a Cellbio Hibaid Touchdown PCR machine following the 
programme below: 
A first denaturation of 5 minutes at 95°C then a cycle platform composed of: 
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-Denaturation step, of 45 seconds, 95°C 
-Annealing step, of 2 minutes at 60°C 
-Extension step, of 3 minutes at 72°C 
The samples were subjected to 50 cycles, followed by a final 10 minutes extension at 
72°C. 
PCR samples were mixed with DNA loading dye and run on a 0.8% w/v agarose gel in 
T AE buffer, containing Ethidium Bromide, and visualised on a UV lamp. 
Negative controls for the PCR reaction were water alone. The positive control dilution 
series was performed by diluting the positive control cell lysate in lysis buffer. 
2.5.2 Tissue culture methods 
2.5.2.1 Maintenance of cell lines 
HeLa, MEL and NIH-3T3 were maintained in DMEM media supplemented with 10% 
PCS IMDM media containing 10% PBS. HEL, K562, U937 and KASUMI were 
maintained in RPMI-1640 with 10% PCS. 293T cell lines were maintained in IMDM 
media and 10% PBS. All these media were supplemented with penicillin/streptomycin 
at 100 units/ml, and L-glutamine at 2 mM (complete media). Cells were typically 
passaged twice a week by washing once in PBS, adding trypsin solution to the adherent 
cells, incubating for 5 minutes and then resuspending in fresh media. Non-adherent cells 
were passaged by simple dilution of the cells in fresh media. Typical passage levels are 
described below. 
All adherent cell lines were passaged at 115 to 1120 dilutions twice per week depending 
on experimental requirements. 
K562, HEL, MEL, KASUMI-1 and U937 were passaged at 1110 dilutions twice a week 
All cells were maintained at 37°C in a humidified incubator with atmospheric 5% CO2. 
2.5.3 Gene transfer methods. 
2.5.3.1 Generation of Lentiviral vectors: 
Viral stocks pseudotyped with the vesicular stomatitis G protein (VSV -G) were 
prepared by transient co-transfection of 293T cells using a three-plasmid system (the 
transfer vector, the pCMV ~R8.74 encoding Gag, Pol, Tat and Rev, and the pMD.G 
plasmid encoding VSV -G). 
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Transfection of DNA using Calcium phosphate precipitation: 
l.Seed and incubate 5x106 293T cells in a 10 cm dish, appoximately 24 hours before 
transfection in IMDM, 10%FBS, Penicillin (25U/ml), Streptomycin (25U/ml). 
2.Change medium 2 hours before transfection. 
3.The plasmid DNA mix is prepared by adding 3,5 J.tg ENV plasmid (pMD2-VSV -G), 
6,5 J.tg of Core Packaging plasmid (pRRLsin18.PPT.CMV.GF.Wpre) together per dish. 
The plasmid solution is. made up to a final volume of 450 J.tl with 0.lXTE/dpH20 (2:1) 
in a 50 ml polypropilene tube. Finally add 50 J.tl of 2.5M CaCI2• 
4.The precipitate is formed by dropwise addition of 500 J.tl DNA-TE-CaCI2 mixture 
from step while vortexing at full speed. The precipitate should be added to the 293T 
cells immediately following addition the 2X HBS. High magnification microscopy of 
cells should reveal a very small granular precipitate of the CaPi-precipitate plasmid 
DNA, initially above the cell monolayer, and after incubation in the 37 °C incubator 
overnight, on the bottom of the plate in the spaces between the cells. 
5. The CaPi-precipitated plasmid DNA should be allowed to stay on the cells for 14-16 
hours, after which the media should be replaced with fresh media for virus collection to 
begin. Discard medium as infectious waste. 
6.Collect the cell supernatans at 25 and 48 hours after changing the media. 
7. Centrifuge a 1000 rpm, for 5 min at and filter through 0.22 J.tm pore nitrocellulose 
filter. 
8. Use the conditioned supernatant as it is or proceed to concentration. 
2.5.3.2 Viral harvest and concentration 
1. Collect the supernatant from calcium phosphate-transfected 293T packaging cells. 
2. Centrifuge at 1500 rpm for 5 min at RT and filter through 0.22 J.tm filter. 
3. Use the conditioned supernatant as it is or proceed to concentration by 
ultracentrifugation. 
4. Concentrate the conditioning medium by ultracentrifugation at 50,000 x g (19,500 
rpm in SW28 rotor) 2 h at RT. " 
5. Discard the supernatant by decanting and re-suspend the pellets in 0.5 ml of sterile 
PBS containing 1 % BSA. 
6. Store at 4°C the concentrated vector from the first collection until the end of the 
second collection. 
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7. Fill the tubes used for the first collection with· the supernatants from the second 
collection. 
S. Repeat points 1-2-3 for the second collection. 
9. Re-suspend the final pellets in a very small volume (11500 of the starting volume of 
medium) of sterile PBS-1 % BSA. 
10. Pool in a small tube and rotate on a wheel at RT for 1 h. 
11. Split into small aliquots (20-50 Jll), store at -SO°C and titer after freezing. 
2.5.3.3 Titration of Lentiviral vectors: 
1. Plate 5x104 HeLa cells per well a day before in a 6-well COSTAR (the day after you 
will have approximately 105 cells/well). 
2. The following day, prepare serial ten-fold dilutions of viral stocks. Take a 24-well 
plate and add in each well I.S ml of medium (lMDM 10% FBS). Then add to the first 
well of the first row 200 JlI of viral stock (10-1 dilution). After pi petting several times, 
change tip and take 200 JlI of 10-1 dilution and put in the second well. Take 200 JlI of 
10-2 dilution and put in the third well and continue until you have 10-6 dilution. 
3. If you are titrating concentrated vector stock, you should add 2ml of IMDM in the 
first well of the dilution plate and 2JlI of the concentrated vector preparation and 
continue with the serial dilutions as described above (in this case you have dilutions 
from 10-3 to 10-8). 
4. Take HeLa cells from the incubator and aspirate the media. Add 1ml of medium 
(IMDM 10% FBS)with 2X polybrene (1000X-Smg/ml). 
5. Add to wells 1 ml of serial dilutions changing tips each time or starting from the most 
diluted sample. 
6. Incubate for 4S-72 hours at 37°C in a 5% CO2 incubator. 
7. Wash wells with 2 ml of PBS. 
S. Add 200Jll of trypsin in PBS to each well. Wait until cells are detached from plates 
(5' at 37°C). 
9. Add 2 ml of PBS to each well and harvest cells in FACS tubes. 
10. Centrifuge at 100 rpm for 5 min at RT. 
11. Aspirate the supernatant and add 1 ml of FIXING SOLUTION to the pellet, vortex 
the tubes (samples are stable at 4° for few days). 
12. FACS samples and calculate the titer. 
lOS 
Notes: 
The MOl (multiplicity of infection): TU/mlln. of cells to be infected for the following 
ranges: infection efficiency is primarily controlled by vector concentration (TU/ml). 
MOl should be considered only for certain ranges of concentration of cells (>104 
cells/ml) and vector (> 106 TU/ml). 
2.5.3.4 Stable cell lines. 
1. HeLa and NIH-3T3 cells were maintained in DMEM supplemented with 
10% FCS, and transduced in six-well plates in the presence of 8 jlg/ml of 
polybrene. 
2. Human erythroleukemic (HEL, MEL), myeloblastic (K562) and monocytic 
(U937, Kasumi-l) cell lines were grown in RPMI 1640 supplemented with 
10% FeS, and transduced with viral supernatant at different MOl in the 
presence of 4 jlg/ml of polybrene. 
3. On day 4 after transduction, cells were harvested and analyzed by flow 
cytometry for transgene expression. 
2.5.3.5 CD34+ stem/progenitor cells. 
1. Human CD34+ stem/progenitor cells were purified from the Ficoll 
mononuclear cell fraction of umbilical cord blood by positive selection using 
the CD34 magnetic cell isolation kit. 
2. CD34+ cells were infected with viral stocks at a MOl of 50-200 in serum-free 
IMDM containing 20% BIT serum substitute, 20 ng/ml rhIL-6, 20 ng/ml 
rhTPO, 100 ng/ml stem cell factor and Flt3-L, for 24 hours. 
3. Transduced CD34+ cells were washed in IMDM with 10% fetal bovine 
serum, plated at a density of 1,000 cells/ml in methylcellulose medium 
containin_g 4U/ml rhEpo, 10 ng/ml GM-CSF, 10 ng/ml rhIL-3, 50 ng/ml 
rhSCF, and scored by light and fluorescent microscopy 10 to 14 days after 
plating. 
4. Transduced CD34+ cells were grown in liquid culture in three differen"t 
conditions: 
a) in the same medium used for transduction to maintain an undifferentiated 
phenotype; 
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b) in X-VIVO-I0 serum-free ~edium supplemented with 20 nglml rhSCF 
and 4U/ml rhEpo to induce erythroid differentiation; 
c) in IMDM supplemented with 20% FBS, 20 nglml rhIL-3 and rhIL-6 to 
induce myeloid differentiation. 
S. Cell phenotypes and transduction levels were determined by flow cytometry. 
2.5.3.6 Infection by ce~trifugation (Spinoculation protocol). 
1. Resuspend target cells in viral sup. +8J.1g1ml polybrene (I,S-3xl05 cells/ml) 
2. Plate in 24 wells/plate (lml) or 6 wells/plate (3ml). 
3. Centrifuge at 1800 rpm 4S min at 30°C. 
4. Harvest the cells, centrifuge in tube, resuspended in medium and incubate at 37dC 2h. 
S. Repeat from step no. 1 
2.5.4 Animal study methods. 
All animals were maintained at the BL-2 level animal facility at DIBIT HSR, by the 
Carles Rivers staff appointed to manage it. NON-SCID mice were received from 
Charles Rivers, Italy. 
2.5.4.1 Preparation of cells and injection of mice. 
Cells were passaged as described. The experimental cells were washed twice in PBS, 
ensured to be a single cell suspension, and resuspended in SOO J.11 of PBS at numbers 
stated in the text. The cells were taken up into a 1 ml syringe with low gauge needle 
(26Gx 112") and transported to the mice. 
Mice were prepared as described in the text. Tail vein injection was performed by 
holding a high intensity lamp to the tail of the mouse, and waiting for the veins to 
become clearly visible. The need,le was then gently inserted into the vis"ible vein and the 
plunger very slowly_ depressed to inject the cells into the mouse. 
After succesful completion of injection the mice were returned to their cages and 
maintained as described above. Gentalyn antibiotic was include in the. water supply to 
prevent bacterial infections. 
2.5.4.2 Termination of mice and extraction of the bone marrow. 
Mice were· terminated by carbon monoxide inhalation. The femurs and tibias were 
removed by surgical procedure, the bones cleaned of muscle and cartilage fibre, the 
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epiphyses cut and the femurs flushed with c,omplete media. The bone marrow tissue was 
disaggregated bu physical methods, the cells suspended in IMDM media containing 
20% FCS, penicillin/streptomycin at 100 units per ml, and L-Glutamine (2mM). 
Cells were returned into culture and assayed as described in the text. 
2.5.4.3 Transplantation in NOD/SCID mice 
A breeding colony of NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME) was 
housed in a positive airflow ventilated rack, bred and maintained in micro isolators 
under specific pathogen-free condition. Mice to be transplanted were sub-lethally 
irradiated at 6 to 8 weeks of age with 3S0 cGy of total body irradiation from a Cesium 
source. Transduced human CD34+ cells (1.S to 3 x 105) were administered within 24 
hours after irradiation in a single intravenous (tail vein) injection. Mouse BM was 
analyzed by flow cytometry 5 to 11 weeks post-transplant. BM cells were plated at a 
density of 0.S-2 x 105 cells/ml in methylcellulose preparation preferentially supporting 
the growth of human colonies. 
2.5.4.4 Transduction of murine bone marrow (BM), and BM transplantation 
Murine BM cells were harvested from CS7BL/6 mice (Charles River) by flushing 
femurs and tibiae, and infected for 24 hrs with viral stocks at a MOl of 200 in serum-
free IMDM containing BIT serum substitute, and SO ng/ml muSCF, 10 ng/ml muIL-3, 
10 ng/ml huFlt-3L, and 20 ng/ml huIL-6. Transduced cells were injected (S x 106 
cells/mouse) into the tail vein of recipient 8-12-wk-old male CS7Bl/6-Ly-S.l mice 
(B/6.SJL-CD4Sa-Pep3b from Jackson Laboratories), irradiated with two split doses of 
400 cGy 4 hrs apart. Nine to eleven weeks after BMT, animals were sacrificed and 
hematopoietic tissues were collected for FACS analysis and clonogenic assay. 
2.5.4.2 Flow cytomctry analysis 
L\LNGFR expression in transduced cells was monitored by flow cytometry or 
epifluorescence microscopy using an indirect staining with the anti~hu1nan p7S-NGFR 
monoclonal antibody (MoAb) 20.4 (ATCC) and the R-phycoerythrin (PE)-conjugated 
goat anti-mouse serum (Southern Biotechnology Associates, Birmingham, AL). Human 
cell surface phenotype and human cell engraftment in transplanted NOD/SCID mice 
were determined by flow cytometry using RPE-conjugated anti-human CD4S (DAKO, 
Glostrup, Denmark) to detect total human leukocytes, CD34 (Becton Dickinson, San 
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Jose, CA) for stem/progenitor cells, CD19 (DAKO) for B lymphocytes, CD14 (DAKO) 
for monocytes, CD13 (Caltag Laboratories, Burlingame, CA) for myeloid cells, GpA 
(DAKO) for erythrocytes. Indirect staining with biotinylated anti-p75-NGFR MoAb and 
Tricolor (TC)-conjugated Streptavidin (SA V Caltag Laboratories) was used to monitor 
transduction efficiency in each BM cell subpopulation. Mouse cell phenotyping was 
carried out using PE-conjugated anti-mouse TER-119 and Gr-1 (PharMingen) 
antibodies. The FITC-c~njugated, anti-mouse CD4S.2 MoAb (PharMingen) was used to 
evaluate donor-host chimerism in BM-transplanted mice. Isotype-matched non-specific 
antibodies were used as controls (Becton Dickinson). For cytofluorimetry analysis of 
non-erythroblastic cell populations, BM cells were lysed with 8.3% ammonium chloride 
to remove erythroid cells, and washed with PBS containing 0.1 % bovine serum albumin 
and 0.01 % sodium azide. Cells were then re-suspended at 1-2 x 106 cells/ml and 
incubated with mouse IgG (Sigma, Saint Louis, MS) and 5% human serum (HS), to 
block nonspecific binding to Fe receptor. 
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Chapter 3 
Generation of high titer lentiviral vectors for HSC gene transfer. 
3.1 Viral supernatant production by co-transfection of 293T cells. 
The development of gene therapy strategies to correct hemetopoietic and genetic 
disorders has been hampered by the low level of gene transfer into human HSCs using 
vectors derived from. oncoretroviruses such as Moloney murin leukemia virus 
(MoML V) virus (Kohn, 1997; Richter, 1997). Oncoretroviruses require cell division for 
integration and as repopulating HSCs are largely quiescent, oncoretroviral vectors are 
largely inefficient in these targets. Thus, much interest has recently been focused on 
vectors derived from lentiviruses, such as lIIV-I, which have been shown to transduce a 
variety of non-dividing cells (Lewis and Emerman, 1994; Naldini et aI., 1996). 
Furthermore, lentiviral (LV) vector viral particles pseudotyped with a glycoprotein G of 
VSV (VSV -G) envelope can enter a large variety of target cells as a result of the 
ubiquity of the VSV -0 phospholipidic receptor, and can be easily concentrated by 
ultracentrifugation (Naldini et aI., 1996). 
To test the efficiency of HIV-l-derived, LV vectors as a gene transfer system into 
HSCs, we decided to produce a viral supernatant starting' from a second-generation 
packaging system, kindly provided by Prof. Luigi Naldini (University of Turin). This 
system consists of three different plasmids (see Section 1.2.3) that are illustrated in Fig. 
3.1. The multiple deleted pCMV.~R.8.91, which encodes Gag, Pol, Tat and Rev 
proteins, was us'ed as a packaging construct (Fig. 3.1 A), while the pMD.G vector was 
used to express the heterologous VSV.O envelope (Fig. 3.1 B) (Zufferey et aI., 1997). 
Finally, the pRRL.CMV.OFP.sin-18 (-18/C) vector, originally described by Dull et al., 
was used as transfer vector (Dull et aI., 1998). This HIV -1 vector contains a 400-
nucleotide deletion in the U3 region of the 3' LTR (Fig. 3.1 C) (Zufferey et aI., 1998). 
This deletion encqmpasses a region in which has been mapped all of the major 
determinants responsible for regulating lIIV-l LTR promoter activity, including the so-
called negative responsive element (NRE) , the two NFkB and the NF-ATc binding 
sites, the three SPI binding sites, and also the TATA box (see Fig. 3.1 C). Since in the 
life cycle of all retroviruses, during the process of reverse transcription, the U3 region of 
the 3'LTR is duplicated to form the corresponding region of the 5'LTR (Coffin et aI., 
1997) this .deletion will be transferred to the 5'LTR after infection of a target cell. 
Consequently, the transcriptional units from the LTRs in a provirus are eliminated. This 
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Figure 3.1. Schematic map of the three constructs used to generate second-generation LV 
particles. (A) pCMV.AR8.91 vector in its plasmid (upper) and proviral forms (bottom). This 
construct expresses Gag, Pol, Tat and Rev viral proteins under transcriptional control of the 
CMV promoter and is used as a packaging vector. (B) pMD.G vector in its plasmid form. 
The pMD.G vector, expressing the VSV.G protein under transcriptional control of the CMV 
promoter, is used as the envelope construct. (C) pRRL.sin-18.CMV.GFP (-l81C) V t in 
its proviral form. The 3 ' JR carri s -418 to - 18 deletion removing the U3 
nhancer/promoter region of mV- I. This vector contains GFP under transcriptional control 
of the CMV promoter and is used as a transfer vector. SD: splice donor; SA: splice acceptor; 
RRE: REV responsive element; (A)n: polyadenylation site; 'P: packaging signal. 
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type of vector is called a self-inactivating (SIN) vector (Yu et aI., 1986). Another 
characteristic of this SIN vector originates from work that showed that the function of 
the tat gene can be provided by strong constitutive promoters upstream of the vector 
transcriptional start site (Kim et aI., 1998). For this reason, the U3 region of the 5'LTR 
of the pRRL.SIN vectors was deleted and replaced by the enhancer/promoter region of 
Rous Sarcoma Virus (RSV), to generate a chimerical, tat,-independent 5'LTR (Dull et 
aI., 1998). 
VSV -G-pseudotyped viral particles were generated by transient cotransfection of 
appropriate amounts of the -18/C transfer vector with the pMD.G and the 
pCMV.~R.8.91 vectors into 293T cells, as illustrated in Fig. 3.2. To obtain a good 
preparation of viral supernatant, a very high efficiency (>90%) of 293T transfection is 
required. Due to the presence of the GFP gene in the transfer vector, efficiency of 
transfection is easily monitored by fluorescence microscopy. Fig. 3.3 shows brightfield 
and UV -light views of the same field of transfected 293T cells, 24h after transfection. 
Transfection efficiency of 293T cells was determined by FACS analysis of GFP 
expression 2 days after transfection. A representative analysis of 3 independent transient 
transfection of 293T is shown in Fig. 3.4. The viral sup~rnatant was harvested 36 h after 
transfection and stored in small aliquots at -80°C. 
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SYSTEM TO MAKE LENTIVIRAL VECTORS 
-Transient co-transfection of three constructs into 293T cells: 
PACKAGING CONSTRUCT 
POL ~  
' REV 
o 
293T 
TRANSFER VECTOR 
LTR 
SO SA 
ENVELOPE CONSTRUCT 
Il~:1:~l~ ::::"':::: 
I I 
I I 
SO SA 
-collection of conditioning medium (c.m.) after 36 h 
-End point titer on HeLa cells: 
-transduction of lxl05 HeLa cells with serial diluition of c. m. 
-FACS analysis after 48 h (transduction efficiency: TU/ml) 
-TU/ml= n° of infected cells/diluition 
Figure 3.2. Illustration of the different steps of lentiviral supernatant production. 
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Figure 3.3. Expression of GFP in transient transfected 293T cells. 293T cells were 
transfected with the three plasmids described in Fig. 3.1 and scored for GFP 
expression after 2 days by fluorescence microscopy. A,C, bright-field view of 
transfected 293T cells; B,D, green fluorescence view of the same fields (GFP-
specific filters). Magnification: 10 X 
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File: 293T 28/11/99.002 Acquisition Date: 28-Nov-99 
Gate: G1 Gated Events: 4186 
Total Events: 10000 X Parameter: FL1-H GFP (Log) 
Marker Left, Right Events % Gated % Total Mean 
All 1, 9910 4186 ~ 41.86 1169.23 
M1 8, 9910 4055 ~ 40.55 1206.83 
File: 293T 28/11/99.007 Acquisition Date: 28-Nov-99 
Gate: G1 Gated Events: 4469 
Total Events: 10000 X Parameter: FL 1-H GFP (Log) 
Marker Left, Right Events % Gated % Total Mean 
All 1, 9910 4469 @ 44.69 1912.20 
M1 8, 9910 4459 99.78 44.59 1916.48 
File: 293T 28/11/99.008 Acquisition Date: 28-Nov-99 
Gate: G1 Gated Events: 4322 
Total Events: 10000 X Parameter: FL 1-H GFP (Log) 
Marker Left, Right Events % Gated % Total Mean 
All 1, 9910 4322 100.00 43.22 1278.10 
M1 8, 9910 4242 @ 42.42 1302.08 
Figure 3.4. FACS analysis of GFP expression in 3 different plates of transient transfected 
293T cells. 293T cells were transfected with the three plasmids described in Fig. 3.1 and 
monitored for GFP expression by single-channel cytofluorimetry (X axis). Expression 
profiles are indicated by a red (mock) or a green (-18/C vector) line respectively. 
Percentages of GFP expressing cells are indicated within each panel and by a red oval in the 
statisical analysis. 
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3.2 Viral supernatant titration. 
Titration to determine the number of transducing units (TU)/ml in the viral vector stock 
consists of testing serial dilutions on appropriate target cells. The method and time it 
takes to determine the titer depends on the particular marker gene encoded in the 
transfer vector and, of course, on the type of transcriptional regulation of the marker 
gene. For example, vectors with GFP or luciferase ma.rkers, under transcriptional 
control of a constitutive promoter, can be harvested about 2-3 days post-infection, while 
for vectors with drug resistant markers it takes approximately two weeks for drug-
resistant colony formation. For vectors in which the marker gene is regulated in a cell-
lineage specific fashion, the use of the appropriate cell target is needed. For example, 
viral titers of vectors with erythroid-specific expression of the marker gene should be 
calculated by transduction of an erythroblastic cell line. However, under normal 
conditions, the most common target cells used to determine viral titers are HeLa and 
293T cells. 
In our case, viral supernatant titers were determined by transduction of He La cells. A 
fixed number, usually 1x105, of HeLa cells were infected with serial dilutions of the 
-18/C viral supernatant. Dilutions of viral supernatant started from 10-1 up to 10-3• HeLa 
cells were transduced with diluted viral supernatant in the presence of 8J.tg/ml of 
polybrene (see Materials and Methods). Transduction efficiency was determined by 
FACS analysis of GFP expression (Fig. 3.5). Viral titers are usually calculated at that 
dilution where there is a linear regression of GFP expression and are expressed as 
transducing units per ml (TU/ml) of viral supernatant. This is a conventional unit 
calculated by dividing the number of GFP-expressing cells to the dilution of viral 
supernatant used to transduce cells. Fig. 3.5 shows a representative titration of the viral 
supernatant on HeLa cells. Viral titer of the -18/C vector was calculated at a dilution of 
10-2 and yielded a titer of 3x106 TU/ml. 
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Figure 3.5. End-point titration of the -18/C vector viral supernatant in HeLa cells. 
HeLa cells transduced with serial dilutions of the viral supernatant (10-1-10-3) were 
grown as bulk cultures and analyzed for GFP expression by single-channel 
cytofluorimetry (X axis). Expression profiles are indicated by a red (mock) or a green 
(-18/C vector) line respectively. Percentages of GFP expressing cells are indicated 
within each panel. Viral titer was calculated at a dilution of 10-2 as indicated in the 
bottom quadrant. 
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3.3 Transduction of CD34+ cells with lentiviral vectors. 
Human HSCs are an attractive target for gene therapy of inherited disorders as well as 
other acquired disorders because these cells have the ability to regenerate the entire 
hematopoietic system (see Section 1.1.2). Although retroviral transduction is efficient 
for human hematopoietic progenitor cells that have been stimulated to divide by 
cytokines, exposure to cytokines can lead to differentiati~n of HSCs, possible loss of 
homing abilities and probable reductions in long-term repopulating capability. Since 
HIV vectors may facilitate the transduction of quiescent HSCs, we decided to test the 
activity of the -18/C LV vector by transduction of human CD34+ cells maintained under 
conditions that minimize cycling and preserve the in vivo repopulating capability of 
these cells. 
Before starting with transduction experiments, VSV -0 pseudotyped viral particles were 
concentrated by ultracentrifugation to reach viral titers that ranged between 5x108 and 
5x109. Human CD34+ stem/progenitor cells were isolated from umbilical cord blood-
derived mononuclear cell by immunomagnetic selection of positive cells, using a 
magnetic beads-conjugated anti-human CD34 (see Materials and Methods). Cord blood-
derived CD34+ cells were cultured for 24 hours in serum-free medium containing 20% 
of BIT 9500 serum-substitute in the presence of cytokines and transduced with the 
pRRL.CMV.OFP.sin-18 vector at a multiplicity of infection (MOl) of 100, determined 
on HeLa cells. This means that, theoretically, 100 TU were used to infect one CD34+ 
cell. After three days post infection, cells were analyzed by flow cytometry for CD34, 
CD38 and OFP expression (Fig. 3.6). Under these conditions, more than 70% of the 
cells retained a CD34+ phenotype (Fig. 3.6, upper panel), while about 50% of CD34+ 
cells were also CD38-, the more immature phenotype of the human HSCs (Fig. 3.6, 
middle panel). OFP expression was evaluated in the CP38- and CD38+ subpopulation of 
CD34+ cells (Fig. 3.6, bottom panels). More than 54% of total CD34+ cells were 
transduced as measured by the expression of OFP driven by the internal CMV promoter. 
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Figure 3.6. Expression of CD34, CD38 (upper panels) and GFP (lower panels) in liquid 
culture of human CD34+ hematopoietic stem/progenitor cells transduced with the -I8/C 
vector and analyzed 4 days after infection. Cells were analyzed by triple-
immunofluorescence flow cytometry after staining with a TC-conjugated anti-CD38 
antibody and PE-conjugated anti-CD34 antibody. % values are indicated in the gated areas 
(upper and middle panels). % values in each quadrants indicate cells double positive for 
CD34 and GFP expression (lower panels). . 
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A comparison of the transduction efficiency between CD34+/CD38- and CD34+/CD38+ 
cells, also shows that the more immature CD38- subpopulation had a higher transduction 
efficiency with respect to the double positive subpopulation (73% vs 34%, Fig. 3.6, 
bottom panels). This observation suggests that LV vectors are able to transduce 
quiescent human HSCs at a very high efficiency, even more than cycling progenitor 
cells. 
To analyze transgene expression at the level of single colonies, CD34+ cells, transduced 
with the -18/C vector, were plated in methy1cellulose to perform the colony forming cell 
in vitro (CFC or CFU) assay. Between 10 and 14 days after plating, methy1cellulose 
clonal cultures were scored for GFP expression by fluorescence microscopy (Fig. 3.7). 
Colonies were morphologically scored as BFU-E, CFU-GM or CFU-GEMM. In the 
representative experiment shown in Fig. 3.7, BFU-E and CFU-GM colonies showed a 
strong positive GFP signal by fluorescence microscopy. No difference in colony-
forming efficiency was found in control, mock-transduced cells versus -18/C-
transduced cells, indicating that lentiviral infection did not interfere with human HSC 
differentiation. 
In summary, these results show that high titer lentiviral supernatants were generated 
using the second-generation packaging system and that the VSV-G pseudotyped -18/C 
vector is able to transduce quiescent human HSCs at a very high efficiency. 
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Figure 3.7. Expression of GFP in methylcellulose colonies derived from CD34+ human 
hematopoietic progenitors transduced with the -18/C lentiviral vector (see Fig. 1.3 C). A,C, 
bright-field view of fully mature BFU-E colonies 14 days after plating; B,D, green 
fluorescence view of the same fields (GFP-specific filters). Magnification: 10 X 
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Chapter 4 
Development of erythroid specific Lentiviral vectors. 
4.1 Transcriptional targeting of Lentiviral vectors by L TR enhancer replacement. 
Correction of genetic disorders affecting specific progeny of HSCs (for example, 
hemoglobinopathies) requires restricting expression of the therapeutic gene in a cell 
lineage-specific fashion. In these cases, transcriptional targeting of the transferred gene 
is mandatory. Transcriptional targeting of LV vectors has been attempted by placing the 
gene of interest under the control of restricted internal promoters (Cui et aI., 2002; 
Marodon et aI., 2003; Moreau-Gaudry et aI., 2001) in the framework of a self-
inactivating (SIN) vector. 
In order to obtain a high-expressing, erythroid-specific LV vectors, we developed a 
transcriptional targeting strategy based on replacing the U3 enhancer of the mv LTR 
with cell-specific, genomic transcriptional control elements. Restriction of LV transgene 
expression to an erythroid cell context has been attempted by replacing the viral U3 
enhancer elements in the 3'LTR with the DNase hypersensitive site region (HS2) from 
upstream of the GAT A-I erythroid-specific promoter (-856 to -655). GAT A-I HS2 
contains an autoregulatory element (ARE) able to restrict transcription of a heterologous 
promoter to human or murine erythroblastic cell lines (Nicolis et aI., 1991; Tsai et aI., 
1991). This same element has been used recently in our laboratory in the context a 
MoMLV -derived retroviral vector and it has been shown to confer erythroid lineage 
specificity upon transduction of human and murine HSCs (Grande et aI., 1999). 
The 3' LTR of the first generation pHR2 LV vector (Dull et aI., 1998) has been used to 
generate self-inactivating LV vectors (SIN) carrying an almost comlpete deletion of the 
U3 region, from position -418 to -40 with respect to the transcription st~ site (Fig. 4.1). 
The same deletion in the U3 region has also been replaced by a 200-bp human genomic 
fragment containing the autoregulatory element of GAT A-I (ARE or HS2) described 
before (Fig 4.1). The -40 deleted LTR and the GATA-IIHIV-l chimeric LTR (GATA-
LTR), were used to replace the 3' LTR of the pRRL.SIN lentiviral vector, carrying GF.P 
as a reporter gene (Zufferey et aI., 1998). The resulting vectors, pRRL.sin-40.GFP (-40 
in Fig. 4.1) and pRRL.GATA.GFP (G in Fig. 4.1), were used as transfer vectors and 
were pseudotyped with the VSV -G envelope by the second-generation of lentiviral 
packaging system described in Section 3.1. 
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SA 
RRL.sin-40.GFP (-40) 
RRL.GATA.GFP (G) 
Figure 4.1. Schematic map of the RRL.sin-4O.GFP (-40) and the 
RRL.GATA.GFP (G) LV vectors. In the -40 vector, the LTR carries a -418 to -
40 deletion removing the U3 enhancer, while in the G vector the same region is 
replaced by the GAT A-I HS2 auto regulatory enhancer. An arrow indicates the 
transcription start site of the chimeric LTR promoter. A crossed arrow indicates 
the disabled LTR promoter in the -40 vector. SD: splice donor; SA: splice 
acceptor; RRE: REV responsive element; (A)n: polyadenylation site. 
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4.2 Viral titration ofGATA-LTR vectors. 
Viral titers are usually determined by transducing HeLa cells with serial dilutions of 
viral supernatant (see section). But, in this case, due to the expected erythroid specificity 
of the vector cassette, determination of titers by quantifying the proportion of GFP-
expressing HeLa cells was not possible. To overcome this problem viral titers of the G 
vector were evaluated by transducing an erythroblastic cell line where the GAT A-I 
gene is normally expressed. Among GATA-1-expressing erythroblastic cell lines it was 
decided to use HEL (human erythroleukemia cells) as a model system to determine viral 
titers of our erythroid specific vectors. This cell line was derived from the peripheral 
blood of a patient with Hodgkin's disease who later developed erythroleukemia (Martin 
and Papayannopoulou, 1982). HEL cells have a morphology of erythroblasts and are 
maintained in culture indefinitely under suspension conditions. HEL (5x105) cells were 
transduced with a serial dilution of the G vector viral supernatant in the presence of 
4p.g/ml of polybrene (see Materials and Methods). Dilutions of G vector viral 
supernatant started from 10-1 up to 10-3• Transduction efficiency was determined by 
FACS analysis of GFP expression (Fig. 4.2). Viral titer was calculated at a dilution of 
10-3 and yielded a titer of 1.5x107 TU/ml. Usually, vector titers ranged from 2 x 106 to 5 
X 107 TU/ml, with a mean of 4.5 x 106• 
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File: 24/1/01.012 Gate: G1 
Gated Events: 7292 Total Events: 10000 
X Parameter: FL 1-H GFP (Log) Y Parameter: FL3-H (Log) 
Region Events % Gated % Total X Mean 
R1 7292 ~ 72.92 182.96 
R2 6315 ~ 63.15 210.70 
File: 24/1/01.013 
Gated Events: 7612 
X Parameter: FL 1-H GFP (Log) 
Gate: G1 
Total Events: 10000 
Y Parameter: FL3-H (Log) 
Region Events % Gated % Total X Mean 
R1 7612 ~ 76.12 23.01 
R2 1893 ~ 18.93 84.03 
File: 24/1/01.014 Gate: G1 
Gated Events: 7708 Total Events: 10000 
X Parameter: FL 1-H GFP (Log) Y Parameter: FL3-H (Log) 
Region Events % Gated % Total X Mean 
R1 7708 100.00 77.08 4.77 
R2 256 @ 2.56 66.02 
I TU/ml (10-3)= 5x1()5 X 10-3 X 0.03 = 1.5Xl07 1 
Figure 4.2. End-point titration of G vector viral supernatant on HEL cells. HEL cells 
transduced with serial dilutions of the viral supernatant (10-1-10-3) were grown as bulk 
cultures and analysed for GFP expression by single-channel cytofluorimetry (X axis). 
Percentages of GFP expressing cells are -indicated in the gated area and by a red oval 
in the statistic panel. Viral titer was calculated at a dilution of 10-2 as indicated. 
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4.3 Erythroid specific expression of chimeric GATA·LTR in stable cell lines. 
To test the presence, and eventually, the level of residual transcriptional activity of the 
deleted, enhancer-less, -40 LTR and the erythroid lineage specificity of the chimerical 
GATA-LTR, -40 and G viral supernatants were used to transduce bulk cultures of 
erythroid and non-erythroid stable cell lines. Transduction of K562 and HEL, as 
erythroblastic cell lines, and HeLa and NIH3T3, as non-erythroblastic cell lines, was 
done by addition of 2 ml of undiluted -40 or G viral supernatant in the presence of 4 
J.1g/ml of polybrene (see Materials and Methods). Five days after transduction, the 
transcriptional activity of the two vectors was assessed by FACS analysis of GFP 
expression in transduced cells (Fig 4.3). As expected, the -40 vector showed no GFP 
expression from the -418/-40 deleted LTR (thin lines in Fig. 4.3), while the G vector 
showed strong GFP expression from the chimeric GATA-LTR, but only in the HEL and 
K562 erythroblastic cell lines (bold lines in Fig. 4.3). The erythroid specific expression 
of the G vector and the absence of transcriptional activity in -40 vector were confirmed 
by Northern blot analysis of poly-A+ RNA extracted from G- and -40-transduced HEL, 
K562, HeLa and 3T3 cells (Fig. 4.4). As expected, accumulation of LTR-driven 
transcripts was never detected in cells transduced with the -40 vector (Fig. 4.4). In cells 
transduced with the G vector, transcripts derived from the GATA-LTR were only 
detected in GATA-1-expressing HEL and K562 cells and not in U937 and HeLa cells 
(Fig. 4.4). 
In summary, these data showed that the enhancer-less HIV-1 LTR is virtually inactive 
in the absence of TAT, as previously reported for two similar U3 deletions (-45 and -36) 
in the context of lentiviral SIN vectors (Zufferey et aI., 1998). However, the 
transcriptional activity of the -40 LTR is restored by the insertion of the GATA-1 HS2 
enhancer, but its expression is restricted only to GATA-1-expressing K562 and HEL 
cells. 
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Figure 4.3. Analysis of GFP expression in cell lines transduced with the G LV vector, 
carrying a GFP gene under the control of the GATA-l HS2-modified LTR (see Fig. lA), 
and with a control -40 vector, carrying a GFP gene under the control of an enhancer-less 
LTR. Human erythroblastic HEL and K562 and non-hematopoietic HeLa, and murine 
fibroblast NIH-3T3 cells, were infected with the two vectors at an MOl of 10, grown as bulk 
cultures, and analyzed for GFP expression by single-channel cytofluorimetry (X axis). 
Expression profiles are indicated by a thin (-40 vector) or a bold (G vector) line respectively. 
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HEL K562 HeLa 3T3 
-40 (; -40 (; -40 (; -40 (; 
GFP 
GATA-l 
GAPDH 
Figure 4.4. Northern blot analysis of poly-A+ RNA extracted from HEL, K562, HeLa 
and NIH-3T3 cell lines transduced with the G or the -40 LV vectors and hybridized with 
GFP (upper panels), GATA-1 (middle panels) and GAPDH (lower panels) probes. 
Molecular weight markers (in kilobases) are indicated on the left. 
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4.3 Genomic stability of L TR-modified lentiviral vectors. 
Several reports have shown that LTR modification, expecially in oncoretroviral vectors, 
caused frequent rearrangements of the vector genome (Kaptein et aI., 1998). To 
determine whether a similar event occurrs in the context of an HIV -1 backbone, we 
decided to perform genomic Southern blot analysis of HEL cells transduced with G and 
-40 vectors. Genomic DNA extracted from HEL, three weeks after transduction, was 
restricted with AflII. This restriction enzyme cuts once in each LTR and gives a proviral 
fragment of 2.6 kb and 2.4 kb for G and -40 vectors respectively (Fig. 4.5 A). Southern 
blotting and hybridization with a GFP probe, showed that transduced HEL cells 
harbored stably integrated vectors with intact recombinant LTRs and with the expected 
proviral size (Fig. 4.5 B), confirming the genomic stability of vectors containing LTR 
modifications in the context of an mY-derived backbone. 
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Aflll AflII 
RRL.GATA.GFP (G): 
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Figure 4.5. (A) Schematic map of the RRL.sin-4O.GFP (-40) and the RRL.GAT A.GFP 
(G) LV vectors in their proviral form, previously described in Fig. 3.1. Restriction sites 
used for the Southern blot analysis are indicated. B) Southern blot analysis of genomic 
DNA extracted from HEL cell lines transduced with the -40 or the G vectors, digested 
with AflII, and hybridized to a GFP probe. Molecular weight markers (in kilobases) are 
indicated on the left. 
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Chapter 5 
Chimeric L TR vs internal promoter: two alternative ways to overcome the same 
problem. 
5.1. Chimeric LTR vs internal promoter: vector design. 
Since the "self-inactivating" design is mandatory to minimize the regions of potential 
overlapping and therefore recombination potential between the transfer vector and the 
packaging construct, transcriptional interference from the viral LTR is usually not a 
problem in a lentiviral context (see Section 1.2.3.4). This allows the use of internal 
promoters combined to tissue- or cell-specific enhancers to regulate transgene 
expression. With this simple design, expression of a reporter or a therapeutic transgene 
has been effectively restricted to erythroblasts (Moreau-Gaudry et aI., 2001), to antigen-
presenting cells (Cui et aI., 2002) and, very recently, to CD4+ cells (Marodon et aI., 
. 2003) derived from murine or human HSCs. The major limitation of using internal 
transcription units within LV vectors is the absence of introns in the sub- genomic 
transcript used to express the gene of interest, which significantly affects its post-
transcriptional fate (polyadenylation, nuclear export, stability) and ultimately reduces its 
efficacy in terms of protein output. For some gene therapy applications, for example, the 
correction of globin chain imbalance in human B-thalassemia, a high protein output is 
just as important as its restricted expression. This makes the use of intronless B-globin 
cDNAs expressed by internal promoters inadequate. We developed the LTR enhancer-
replacement as an alterantive startegy of transcriptional targeting. A critical advantage 
of this transcriptional targeting strategy is the use of the spliced, major viral transcript to 
express the gene of interest, which partially overcomes the major limitation of the 
internal promoter design. The internal, less efficient transcription unit.can nevertheless 
be used to independently express a second gene providing an additional function, e.g., 
an in vivo selectable marker, to the transduced cells. An additional advantage of 
enhancer replacement as a targeting strategy is that the integrated provirus carries two 
copies of a genomic enhancer within the two L TRs. The prese'nce of two act~ ye 
enhancers flanking the transgene transcription unit could reduce the chances of 
chromatin-mediated inactivation of transcription, which is known to affect the long-
term maintenance of retroviral transgene expression in vivo, particularly in stem cells 
(Challita and Kohn, 1994). 
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In order to test the advantages of our vector design as a transcriptional targeting 
approach, we compared the activity of the G vector with that of a RRL.sin-
18.GATA.GFP (-18/G) vector containing the same combination of enhancer/promoter 
in the conventional internal position in the context of a SIN LV vector (Fig. 5.1 A). In 
these two vectors the GFP is under control of the same transcriptional unit, the only 
difference is that in the G vector transcription starts from the LTR, while in the -18/G 
vector transcription starts from the internal position, downstream of the splice donor and 
acceptor sites (Fig. 5.1 A). 
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5.2 Chimeric L TR vs internal promoter: "transgene expression efficiency 
In the first instance, we decided to test the performance of the G and -18/G vectors 
under the best conditions of transduction in order to compare populations of cells that 
are fully infected. For this reason, HEL cells were transduced with the G and -18/G 
vectors at a relatively high MOl (around 10), using the spinoculation protocol described 
in Materials and Methods. To study the stability of GFP expression over time, the 
transduced HEL cells were maintained in culture as bulk populations for two months 
and were monitored for GFP expression by FACS analysis every two weeks. 
Transduction efficiency was determined five days after transduction by FACS analysis 
of GFP expression and it was very similar for both vectors (virtually 100%, Fig. 5.1 B). 
However, when we compare the mean fluorescence intensity (MFI) of GFP expression 
of both vectors, a four-fold higher GFP expression is present in cells transduced with 
the G vector with respect to those transduced with the -18/G vector (MFI: 2300 vs 560, 
Fig. 5.1 B). GFP expression of the integrated proviruses in the two bulk populations 
monitored by FACS analysis showed no substantial difference in terms of long-term 
stability of transgene expression between the G and -18/G vectors. 
The higher efficiency in transgene expression of the GATA-LTR was confirmed at a 
molecular level by Northern blot analysis. The Poly-A + mRNAs were isolated from G 
and -18/G transduced HEL bulk populations of cells four weeks after transduction and 
were hybridized to a GFP or a GAPDH probes (Fig. 5.2 A). Northern blot analysis 
showed that genomic transcripts from the G vector were accumulated in HEL cells at a 
level five-fold higher than that of the sub-genomic transcript from the -18/G vector, as 
quantified by phosphorimaging after normalization for GAPDH mRNA content (Fig. 
5.2 A). 
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Figure S.l. (A) Schematic map of the RRL.GAT A.GFP (G) and the RRL.sin-
18.GATA.GFP (-18/G) vectors in their proviral form. HS2 indicates the GATA-1 HS2 
auto regulatory enhancer replacing the HIV LTR U3 region in the G vector. An arrow 
indicates the transcription start site of the chimeric LTR promoter. A crossed arrow 
indicates the disabled LTR promoter in the -18/G vector. Restriction sites used for the 
Southern blot analysis shown in Fig. 3.4 B are indicated. (B) Analysis of GFP expression 
in HEL cells transduced with the -18/G and G LV vector. HEL cells were infected with 
the two vectors at an MOl of 10, grown as bulk cultures and analyzed for GFP expression 
by single-channel cytofluorimetry (X axis). Expression profiles are indicated by a red 
(mock infected cells) or a green (infected. cells) peaks respectively. Mean fluorescence 
intensity (MFI) of GFP expression is in arbitrary units. 
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5.3 Chimeric L TR vs internal promoter: 'vector DNA stability 
Since the presence of repeated sequences in the vector DNA enhances the chances of 
rearrangements of the vector genome, we decided to performe genomic Southern blot 
analysis to exclude any bias in the stability of the integrated proviruses. The same type 
of analysis allows the comparison of vector copy number between G and -18/G 
transduced bulk cultures (Fig. 5.2 B).Genomic DNA was extracted from the two bulk 
populations of cells arid restricted with AflII. This restriction enzyme cuts in the R 
region and, for this reason, cuts twice in the G and three times in the -18/G vector (Fig. 
5.1 A). Hybridization with a GFP probe showed that both vectors transmitted an intact 
provirus with the expected size (2.7 kb for G vector and 0.9 kb for -18/G vector) and 
with comparable vector copy number between G and -18/G transduced bulk cultures 
(Fig. 5.2 B). 
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Figure 5.2. (A) Northern blot analysis of poly-A+ RNA extracted from HEL cells 
transduced with the G or the -18/G LV vectors and hybridized with GFP (upper panel) 
and GAPDH (lower panel) probes. (B) Southern blot analysis of genomic DNA extracted 
from HEL cell lines transduced with the G or the -18/G vector, digested with AflII and 
hybridized with a GFP probe. 
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5.4 Chimeric L TR vs internal promoter: clonal analysis 
To compare the efficiency of transgene expression between G and -18/G vectors at the 
level of a single cell, the transduced bulk cultures were subcloned by limiting dilution, 
two months after transduction following the experimental design depicted in Fig. 5.3. 
We chose a cloning strategy that avoids selection based on transgene expression to 
ensure that all integration sites could be examinated,' including those where viral 
expression is silenced or very weak. Conventional drug selection or cell sorting by 
FACS would indeed eliminate the latter cells and bias any analysis toward the subset of 
integration sites that are permessive for a threshold expression level compatible with 
drug resistance or fluorescence emission. Transduced HEL cell bulk cultures were 
subcloned at 0.2-0.3 cellslwell by limiting dilution (Fig. 5.3 C). Single clones were 
isolated after two weeks of culture and grown for up to two months for further analysis. 
More than 50 clones for each vector were scored for GFP expression by FACS analysis 
(Fig. 5.3 D). Since the bulk cultures were virtually 100% transduced, the vast majority 
of clones analyzed expressed GFP. All positive clones were further expanded and 
genomic Southern blot analysis was performed to determine the-'integrity of the provirus 
and vector copy number for each clone. The integrity of the provirus was determined by 
digestion of genomic DNA with AflII, while the vector copy in each clone was 
determined by digestion of genomic DNA with EcoRI. EcoRI cuts only once in the 
vector (see Fig. 5.1 A) and if GFP is used as a probe, it hybridizes with DNA fragments 
greater than 2 kb, including the vector sequence and the flanking host chromosomal 
DNA (end-fragment analysis). In both groups of clones, end-fragment analysis with 
EcoRI showed no evidence of common or preferential sites of proviral integration (Fig. 
5.3 E). In all clones tested, the proviral integrations ranged between 2 and ~ for the 
-18/G vector-derived clones, with a mean of 5.6, and from 4 to 17 for the G vector-
derived clones, with a mean of 10.4. Since all selected clones of both groups carried 
more than one copy of integrated vector per cell, the single copy level of GFP 
expression was obtained by dividin~ all the integrations of each group by the number of 
clones analysed. The results showed a 2.6-fold increase in GFP expression level per 
integration in the clones derived from the G vector with respect to those derived from 
the -18/G vector (average of MFliaverage of integration: 98.2 vs 37.9, respectively). A 
higher efficiency of GFP expression in G vector-derived clones was confirmed when we 
compared single clones for each group with the same,. or a similar, number of 
integrations per cell (Fig. 5.4 B). GFP expression levels were consistenlty higher in 
141 
o Infection of HEL cells with 
-18/G and G vectors 
® F ACS: bulk culture 
level of GFP expression 
o8.0((J;> ~ 
og8g 1@Jii&D?l 
(MOl: 10) 
every. 
2 wks 
!i!---------. 
@ t2 months 
~IOning by limiting dilution 
® 
Copy number analysis 
-0 
MFI of GFP /integration 
• .. 
u • 
• .. . . • 
.. 
• 
• 
. .. . 
• • • I •• 
Vector Copy Number 
IWWWWWWWWWI t 2 wks 
@ Screening of infected 
clones by F ACS 
2 months 
-III 
~-r-------' ~....---------, 
Figure 5.3. Experimental design. A large panel of HEL cell clones bearing -18/G and G 
vectors were generated and analyzed. HEL cells were infected with -18/G and G recombinant 
virions (A) and analyzed by FACS every week for two months (B). HEL cells were then 
subc10ned (C) and scored for GFP expression by FACS (D). Vector copy number was 
determined by Southern blot analysis (E). Mean fluorescence intensity (MFI) of positive 
clones was determined by FACS analysis (F). 
142 
clones transduced with the G vector than in those transduced with the -18/G vector 
(1275 vs 168, 980 vs 397; 778 vs 252, Fig. 5.4 A).Interestingly, GFP expression levels 
varied considerably among clones transduced with the -18/G vector (MFI: 56 to 547) 
and correlate quite well with the number of integrated proviruses (2 to 9, Fig. 5.5). On 
the contrary, in clones transduced with the G vector GFP levels were uniformly higher 
(MFI: 815 to 1,275) and essentially independent from the vector copy number (4 to 17, 
Fig. 5.5). This strange behavior of the G vector-derived clones is probably due to the 
concomitant presence of multiple copies of integrated proviruses per cell (>4). 
Probably, 4 copies of vector DNA are sufficient to reach the maximum level of GFP 
expression from an erythroid specific promoter under these conditions and the typical 
correlation of expression with number of integrations was abolished. Furthermore, 2 out 
of 19 HEL clones transduced with the :"18/G vector lost transgene expression during 
prolonged culture, while all 21 clones transduced with the G vector showed sustained 
transgene expression throughout the two months of culture (not shown).Overall, these 
results seem to indicate that an LV vector carrying a GATA-modified LTR directs 
higher levels of targeted gene expression at low vector copy number than a vector 
containing the same enhancer/promoter combination in an internal position. 
Furthermore, the presence of GAT A-I HS2 in the LTR seems to protect its expression 
from position effect variegation in the target cell genome. 
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Figure 5.4. (A) Single-channel flow cytometry of GFP expression in HEL cell clones 
transduced with the G (left panel) or the -18/G (right panel) vectors and analyzed 2 
months after transduction. Distribution of transduced cells are indicated by red peaks. 
Mean fluorescence intensity (MFI) of GFP expression is in arbitrary units. (B) 
Southern blot analysis of genomic DNA extracted from HEL clones transduced with 
the G or the -18/G vector, digested with EcoRl, and hybridized to a GFP probe. The 
number of proviral integrations is reported for each clone. 
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G 
25 
Transduction of HEL cells with a relatevely high MOl allowed us to compare transgene 
expression efficiency of -18/G and G vectors starting from fully transduced, highly 
expressing bulk cultures. But, with this experimental design, due to the concomitant 
presence of multiple copies of the vector in all clones analyzed, we lost all information 
regarding chromatin position effects on transgene expression of a single vector clone. 
Position effects reflect the long-range influence of chromatin structure and may silence 
transcription or alter Its efficiency. The result of this chromatin influence can lead to 
highly variable expression among clones, with complete silencing of provirus 
expression in a significant fraction of clones either immediatly after insertion or 
following cell expansion. This phenomenon is known as position effect variegation 
(PEV) (Karpen, 1994). Position-dependent silencing and PEV are particularly 
troublesome for retroviral vectors containing the human B-globin gene [Rivella, 1998 
#25]. To better investigate the influence of chromatin on transgene expression of a 
randomly integrated provirus, we decided to transduce the target cells with a low MOl 
(between 0.1 to 0.5) to favor single integration events and to clone the cell immediatly 
after transduction, following the experimental design depicted in Fig. 5.6. HEL cells 
were transduced with the -18/G, the G and the -18/e vectors (Fig. 5.6 A). In the last 
vector, GFP is under transcriptional control of an internal eMV promoter between two 
SIN-18 deleted LTRs (see Section 3.1 and Fig. 3.1). The -18/e vector is one of the most 
common LV vector used in gene transfer protocols and was used here as a standard 
control for both transgene expression efficiency and integration position effects on 
transgene expression. Transduced HEL cells were mantained as bulk cultures and 
transduction efficiency was determined by FAes analysis of GFP expression four days 
after transduction (Fig. 5.7). Transduction efficiency was very similar between the three 
different bulk populations: 48%, 53% and 44% for G, -18/G and -18/C vectors, 
respectively (Fig. 5.7). HEL cells were therefore subcloned at 0.3 celllwell by limiting 
--
dilution a few days after transduction (Fig. 5.6 e). Single clones were isolated after two 
weeks of culture and grown for up to two weeks for further analysi~. For each vector 
more than 50 clones were scored by FAeS analysis for GFP expression (Fig. 5.6 D). 
Among them, all those clones that were negative for GFPexpression, determined by 
FACS analysis, were further expanded and scored for vector integration by peR 
analysis (Fig. 5.6 E). Vector DNA positive clones were further analyzed by Southern 
blotting to determine the integrity of the provirus and vector copy number, as previously 
described (Fig. 5.6 F). Results obtained by peR and confirmed by Southern blot 
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Figure 5.6. Experimental design. A large panel of HEL cell clones bearing -18/G, G and -
18/e vectors were generated and analyzed. HEL cells were infected at low MOl (0.1-0.5) 
with -18/G, G and -18/e recombinant virions (A) and analyzed by FAeS (B). HEL cells were 
then subcloned 5 days after transduction (e) and scored for GFP expression by FAeS (D). 
GFP negative clones were analyzed by peR (E) and copy number in peR positive clones was 
determined by Southern blot analysis (F). 
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Figure 5.7. Analysis of GFP expression in HEL cells transduced with the G, -18/G and -18/e 
LV vectors. HEL cells were infected with vectors at an MOl of 0.1-0.5, grown as bulk cultures. 
and analyzed for GFP expression by single-channel cytofluorimetry (X axis). Expression 
profiles are indicated by a red (mock infected cells) or a green (infected cells) line 
respectively. Percentages of GFP expressing cells are indicated within each panel. 
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analysis are shown in Fig. 5.8. Analysis of those G, -18/G and -18/C cell clones that 
were negative for GFP expression as determined by FACS analysis are illustrated. Most 
clones derived from G vector bulk population were negative for vector DNA, and only 3 
out of 24 (12.5%) of them contain transcriptionally inactive proviruses. On the other 
hand, 10 out of 19 (52%) of the -18/G and 9 out of 20 (45%) of the -18/C cell clones 
contain inactive proviruses (Fig. 5.8). 
The insertion of the HS2 element in the LTR of our lentiviral vector enhances the 
expression of transgenes over a threshold level determined by the expression profile of 
the negative control making silent transgenes more likely to become active and active 
trangenes less likely to become silent. 
Overall, these results strongly suggest that a double copy of the GATA-HS2 erythroid-
specific enhancer could act as a transcriptional insulator, thus replacing LCRs, matrix-
attachment or other elements influencing chromatin configuration to shield randomly 
integrated transgenes from chromatin-mediated silencing. These results are in partial 
with a recent study from Groudine group (Sutter et a!., 2003). In this paper they tested 
the ability of a transcriptional activator to function as a chromatin insulator in cultured 
cells. They showed that position effect variability can be suppressed by a 
metallothionein transcription factor MTF. 
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Figure 5.8. G, -18/G and -18/C cell clones negative for GFP expression by FACS analysis 
were scored for vector DNA integration by PCR and Southern blot analysis 5 weeks after 
transduction. 3 out of 24 (13%) of G, 10 out of 19 (52%) of -18/G and 9 out of 20 (45%) 
-18/C GFP- clones were positive for vector DNA. 
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Chapter 6 
Optimising transfer vector design. 
6.1 Expression of two independently regulated transcriptional units. 
One of the possible advantages of our targeting strategy is that the internal transcription 
unit can be used to express a second gene providing an additional function, for example 
an in vivo selectable marker, generating a bi-functional LV vector. However, the 
presence of two different transcriptional units in the same vector could generate 
transcriptional interference one with the other.To test the influence that a second 
transcriptional cassette could have on expression starting from GATA-LTR, the 
&NGFR cDNA was cloned downstream from the GFP gene in both G and -40 vectors 
as a second reporter gene, under the control of a constitutive PGK promoter (Fig. 6.1 
A). If the insertion of this second PGK-~LNGFR transcriptional cassette is functional, it 
allows monitoring of cell transduction and immunoselection of transduced cells 
independently from the transcriptional activity of the targeted LTR. The resulting 
vectors, RRL.sin-40.GFP.PGK.~N (-401P in Fig. 6.1 A) and RRL.GATA.GFP.PGK.~N 
(GIP in Fig. 6.1 A), were pseudotyped with the VSV.G envelope and packaged at titers 
ranging from 5 x 106 to 5 X 107 TU/ml, as determined by infection of HeLa cells with 
serial dilutions of viral supernatants and FACS analysis of ~LNGFR expression (Fig. 
6.1 B). Dilutions of G vector viral supernatant started from 10-2 up to 10-3• Transduction 
efficiency was determined by FACS analysis of GFP expression (Fig. 6.1 B). Viral titer 
was calculated at a dilution of 10-3 and yielded a titer of 2x107 TU/ml. To study the 
expression characteristics of the two transcriptional units, human myeloblastic (Kasumi-
1), myelomonocytic (U937), erythroblastic (K562 and HEL) and non-hematopoietic 
(HeLa) cell lines as well as murine erythroblastic (MEL) and fibroblastic (NIH-3T3) 
cell lines were infected with -401P and G/P vectors (MOl: 5-10) and grown as bulk 
cultures. Transduction efficiency ranged between 67 and 96%, depending on the cell 
line, as determined by FACS analysis of LNGFR expression. 
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Figure 6.1. (A) Schematic map of the RRL.sin-40.GFP.PGK.AN (-40/P) and the RRL.GA T A. 
GFP.PGK.AN (G/P) LV vectors. In the -40/P vector, the LTR carries a -418 to -40 deletion 
removing the U3 enhancer, while in the GIP vector the same region is replaced by the GATA-
1 HS2 auto regulatory enhancer. The arrows indicate the transcription start sites of the LTR 
or the internal phosphoglycerokinase (PGK) promoter. (B) End-point titration of the G/P 
vector viral supernatant in HeLa cells. HeLa cells transduced with serial dilutions of the viral 
supernatant (10-2-10-3) were grown as bulk cultures and analyzed for GFP expression (X axis) 
and LNGFR expression (Y-axis) by FACS. Percentages of LNGFR expressing cells are 
indicated within each qudrant. Viral titar aws calculated at a dilution of 10-3 as indicated. 
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Southern blot analysis of genomic DNA showed stable integration of intact proviruses 
and the polyclonal nature of all tested cell populations (Fig. 6.2). Expression of vector-
derived transcripts was analyzed by Northern blotting of poly(A)+ RNA and 
hybridization to a ~LNGFR-specific probe. As expected, accumulation of LTR-driven 
transcripts was never detected in cells transduced with the -40/P vector (Fig. 6.3). In 
cells transduced with the G/P vector, transcripts derived from the GATA-LTR were 
detected in K562, HEL and MEL cells (Fig. 6.3), but not in U937, HeLa, Kasumi-1 and 
NIH-3T3 cells (Fig. 6.3). Sub-genomic transcripts derived from the internal PGK 
promoter were present in all cell lines transduced with both vectors (Fig. 
6.3).Expression of both GFP and ~LNGFR proteins was quantitatively analyzed by 
double-fluorescence flow cytometry after staining with aPE-conjugated anti-LNGFR 
antibody (Fig. 6.4). Expression of ~LNGFR from the internal PGK promoter was 
observed in all transduced cell lines, while expression of GFP from the GATA-LTR 
was detected only in erythroblastic cells (HEL and K562, Fig. 6.4). The two reporter 
genes were co-expressed in >90% transduced erythroblastic cells. These data indicate 
that the use of a modified LTR and an internal promoter allows the expression of two 
independently regulated genes in the context of a LV vector. 
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Figure 6.2. Southern blot analysis of genomic DNA extracted from K.562 (1), HEL 
(2), HeLa (3) and U937 (4) cell lines transduced with the G/P (upper panels) or the -
40/P (lower panels) vectors, digested with AflII or EcoRI and hybridised with a GFP 
probe. Molecular size markers are indicated in kilobases on the left. 
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Fig 6.3. Northern blot analysis of poly(A)+ RNA extracted from K562, HEL, MEL 
(erythroblastic) , U937 and Kasumi-l (myeloblstic), HeLa and NIH-3T3 (non-
hematopoietic) cell lines transduced with, the -40/P or the G/P vector and hybridized 
with NGFR (upper panels) and GAPDH (lower panels) probes. Molecular weight 
markers (in kilabases) are indicated on the left. 
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Figure 6.4. Double-immunofluorescence FACS analysis of GFP (X axis) and ALNGFR . 
expression (Y axis) in K562, HEL, U937 and HeLa cells transduced with the G/P vector 
(see Fig. 3.11) at a MOl of 10. Cells were grown as bulk culture and analyzed 3 days 
after infection after staining with aPE-conjugated anti-LNGFR antibody. 
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6.2 Selective enhancement of transgene expression by specific positioning of 
WPRE. 
Northern blot analysis showed that transcripts from the modified LTR, although 
restricted, were accumulated at low levels in K562 and HEL cells transduced with the 
double-expression cassette G/P vector when compared to cells transduced with the 
single-cassette vector G (compare Figs. 5.2 A and 6.3). This suggests a negative 
interference of the internal promoter upon transcription of the GATA-LTR, or more 
probably, a diminished stability of the GATA-LTR transcripts. In order to improve the 
level of LTR-driven transcript accumulation in a selective fashion, we cloned a 500-bp 
DNA fragment encompassing the WPRE at alternative positions in the G/P vector, 
downstream of the GFP (G.WIP vector in Fig. 6.5 A) or the ~LNGFR (GIP.W vector in 
Fig. 6.5 A) gene respectively. As a result, the WPRE was contained exclusively in the 
LTR-driven, viral genomic transcript in the G.WIP vector or in both the genomic and 
the sub-genomic, PGK-driven transcripts in the G/P.W vector. Viral stocks derived 
from these vectors were used to transduce HEL, K562 and U937 cell lines (MOl: 10). In 
K562 and HEL cells transduced with the GIP.W vector the level of both the LTR- and 
PGK-driven transcripts was approximately two-fold higher than in cells transduced with 
the GIP vector, as quantitated by phosphorimaging of Northern blots of poly(A)+ RNA 
extracted from bulk cultures (Fig. 6.5 B, lanes GIP.W vs G/P). Conversely, in cells 
transduced with the G.WIP vector the level of the LTR-driven, genomic transcripts was 
selectively increased (about four fold) with respect to cells transduced with the GIP 
vector, while the level of the PGK-driven, sub-genomic transcripts remained essentially 
unchanged (Fig. 6.5 B, lanes G.WIP vs G/P). Interestingly, addition of the WPRE in 
either configuration did not rescue accumulation of genomic transcripts in non-:erythroid 
cells (U937 in Fig 6.5 B) and had therefore no effect on the transcriptional targeting of 
the GATA-LTR. Protein expression data paralleled the results obtained at the level of 
RNA accumulation (Fig. 6.6). PGK-driven, ~LNGFR expression increased slightly in 
both HEL and K562 cells tran~duced with the G/P.W vecto~ c?mpared to cells 
transduced with the G/P and the G.W/P vectors (MFI: 1,336 vs 759 and 1,051 
respectively in HEL cells, and 1345 vs 1,010 and 1,116 respectively in K562 cells, in a 
representative experiment, see Fig. 6.6). Conversely, GFP expression increased three- to 
five-fold in HEL and K562 cells transduced with the GIP.W vector compared to cells 
transduced with GIP and the G.WIP (MFI: 345 vs 78 and 72 respectively in HEL cells, 
and 260 vs 68 and 107 respectively in K562 cells, see Fig. 6.6). Transduced U937 cells 
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Figure 6.5. (A) Schematic map of the RRL.GATA.GFP.PGK.L\N.W (G/P.W) and 
RRL.GATA.GFP.W.PGK.L\N (G.W/P) vectors in their proviral forms. The woodchuck 
hepatitis virus post-transcriptional regulatory element (W) is inserted at alternative 
positions in the vectors, both derived from the G/P vector described in Fig 311A. (B) 
Northern blot analysis of poly(A)+ RNA extracted from K562, HEL, and U937 cells 
transduced with the G/P, G/P.W, or G.W/P vectors and hybridized with LNGFR (upper 
panel) or GAPDH (lower panel) probes. Transcripts originating from the viral LTR or the 
internal PGK promoter are indicated on the left. 
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never showed expression of GFP, while ~LNGFR levels increased slightly in cells 
transduced with GIP.W (MFI: 422) with respect to cells transduced with GIP or G.WIP 
(MFI: 318 and 303 respectively, see Fig. 6.6). These results demonstrate that the 
presence of WPRE within a transcript selectively enhances its accumulation in 
transduced cells, thus allowing differential modulation of the expression levels of two 
different genes carried by the same lentiviral vector. The G.WIP vector was therefore 
chosen to evaluate transcriptional targeting of the GATA-LTR in human primary HSCs. 
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Figure 6.6. Double-immunofluore,scence FACS analysis of GFP (X axis) and 
ALNGFR expression (Y axis) in K562, HEL, U937 cells transduced with the G/P, 
G/P.W and G.W/P vectors (see Fig. 6.1A and 6.3A). Cells were grown as bulk culture 
and analyzed 4 days after infection after staining with aPE-conjugated anti-LNGFR 
antibody. Mean fluorescence intensity of GFP (X MFI) and of NGFR expression (Y 
MFI) are in arbitrary units. 
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Chapter 7 
Activity of GATA-LTR vector in HSCs. 
7.1 Expression of the GATA-LTR is restricted to the erythroblastic progeny of 
transduced human HSCs. 
Human cord blood-derived CD34+ stern/progenitor cells were cultured for 24 hours in 
serum-free medium" supplemented with cytokines (SCF, Flt-3L, lL-6, lL-3) and 
transduced with the G.W/P vector at a MOl of 50-100. Three days after infection, cells 
were analyzed by flow cytometry for CD34, LNGFR and GFP expression. More than 
60% CD34+ cells were transduced, as measured by the expression of LNGFR driven by 
the internal PGK promoter, while only 23% of them expressed GFP from the GATA-
LTR (Fig. 7.1, left panels). To test the activity of the GATA-LTR in differentiated cells, 
transduced CD34+ progenitors were induced to differentiate in liquid culture into either 
myeloid or erythroid lineages. Ten days after induction, expression of GFP and LNGFR 
was evaluated by triple-immunofluorescence FACS analysis of cells stained with 
antibodies against either erythroid (GpA) or myeloid (CD13>" lineage-specific surface 
markers. The proportion of GpA+ cells expressing LNGFR and GFP was comparable 
(69% and 73% respectively), indicating that the GATA-LTR was active in virtually all 
transduced erythroid cells (Fig. 7.1, right panels). Conversely, GFP expression was 
barely detectable in a small fraction (9%) of the CDI3+ myeloid cells, transduced at a 
level of 74% (Fig. 7.1, middle panels). In both differentiation conditions, a fraction of 
GFP+ cells stained negative for both GpA and CD13, indicating the presence of a 
residual, immature subpopulation derived from CD34+ cells and maintaining GAT A-
LTR activity. At a quantitative level, LNGFR expression was higher in undiff~rentiated 
(CD34+) progenitors than in differentiated (GpA+ and CD 13+) progeny (MFl: 174, 58 
and 68 respectively), whereas GFP increased five-fold in the GpA+ progeny of CD34+ 
cells (MFI: from 52 to 255), showing that expression from the GATA-LTR increases 
with erythroid cell differentiation, and suggesting that in an appropriate cell context the 
,\ .. . 
activity of a targeted LTR is higher than that of a constitutive internal promoter. 
To analyze transgene expression at the level of single colonies, CD34+ cells were 
transduced with G.W/P vector, immunoselected for ~LNGFR expression by 
immunomagnetic cell sorting and directly scored for GFP expression by fluorescence 
microscopy in clonal methy1cellulose cultures. The introduction of the immunoselection 
step allowed us to analyze GATA-LTR-driven gene expression only in cells 
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Figure 7.1. Expression of GFP (upper panels) and &NGFR (lower panels) in 
liquid culture of human CD34 + hematopoietic stem/progenitor cells transduced 
with the G. W IP vector and analyzed 3 days after infection (left panels) or 10 
days after induction of myelomonocytic or erythroblastic differentiation (center 
and right panels). Cells were analyzed by triple-immunofluorescence flow 
cytometry after staining with a TC-conjugated anti-LNGFR antibody and PE-
conjugated antibodies against specific cell surface markers for undifferentiated 
progenitors (CD34 right panels), or myeloid (CDI3, center panels) and erythroid 
(GpA, right panels) progeny. % values in the gated areas indicate cells double 
positive for each surface marker and either GFP (upper panels) or &NGFR 
(lower panels) expression. 
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differentiating from transduced progenitors. Colonies were morphologically scored as 
BFU-E, CFU-GM or CFU-GEMM between 10 and 14 days after plating. No difference 
in colony-forming efficiency was found in control, mock-transduced vs G.W/P-
transduced and immunoselected cells. In the representative experiment shown in Fig. 
7.2, most BFU-E colonies (54 out of 57) scored strongly positive for GFP by 
fluorescence microscopy, while only rare CFU-GM colonies (2 out of 49) appeared 
weakly positive by the same assay. 
Overall, these results show that transcription from the GATA-LTR is active at low level 
in a fraction of the CD34+ hematopoietic progenitors, strongly down-regulated during 
myelo-monocytic differentiation and activated and maintained at high levels in cells 
undergoing erythroid differentiation. 
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Figure 7.2. Erythroid-specific expressio~ of GFP in methylcellulose colonies derived from 
CD34+ human hematopoietic progenitors transduced with the G.W/P lentiviral vector (se~ 
Fig. 5), and immunoselected for &NGFR expression before plating. A,C, bright-field view 
of fully mature BFU-E and CFU-GM colonies 14 days after plating; B,D, green 
fluorescence view of the same fields (GFP-specific filters). Magnification: 10 X 
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7.2 Expression of the GATA-LTR in human SCID-repopulating cells. 
The lineage-specific expression of the GAT A-LTR was tested in human hematopoietic 
stem/progenitor cells in vivo in the NOD/SCID mouse model as represented in the 
experimental design illustrated in Fig. 7.3. Briefly, cord blood CD34+ cells were 
transduced with the G.WIP vector, further modified by the addition of the HIV-1 cPPT 
sequence which was recently reported as essential for high efficiency of gene transfer 
into SCID-repopulating cells (SRCs) [Follenzi, 2000 #157]). A total of 10 mice in three 
different experiments were sub-lethally irradiated, inoculated with 1.5-3 x 105 CD34+ 
cells transduced at a different MOl (100 or 200) and sacrificed 5-11 weeks after 
transplantation (Fig. 7.3). Transduction efficiency of CD34+ cells ranged from 49 to 
76% as assayed by ~LNGFR expression 4 days after infection (Table 7.1). Engraftment 
of human cells ranged from 1.5 to 58% as indicated by the proportion of human CD45+ 
cells in mouse BM. Gene transfer efficiency in engrafted human cells ranged from 35 to 
72% as assayed by ~LNOFR expression (Table 7.1). A representative analysis of the 
BM of a NOD/SCID mouse that received a transplantation dose of 3 x 105 CD34+ cells 
transduced at a proportion of 76% is shown in Fig. 7.4. Here, 58% of the BM cells were 
of human origin (CD45+) and 72% of human CD45+ cells expressed ~LNGFR. Further 
staining with antibodies against the lineage markers CD19, CD13 and CD34 showed the 
presence of human lymphoid, myeloid and undifferentiated progenitor cells. LNGFR+ 
cells were found in a similar percentage in all tested lineages (Fig. 7.4). OFP expression 
was detectable in < 1 % of human cells recovered from BM of all but one of the ten 
analyzed mice. In a single mouse (#1.3 in Table 7.1) GFP expression was detected in 
33%, 40% and 36% of transduced CD45+, CD34+ and CD19+ cells respectively, 
suggesting the presence in this animal of a high proportion of immature GAT A-1-
expressing multilineage and lymphoid progenitors. Since. human erythroid 
differentiation occurs at a very low level in vivo in the NOD/SCID model, expression of 
the OATA-LTR -in the erythroblastic progeny of transduced SRCs was analyzed by 
plating BM cells from transplanted and control NOD/SCID mice in clonal 
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Figure 7.3. Transplantation of transduced CD34+ CBCs in NOD/SCID mice. 
166 
Table 7.1. Transduction of SRCs with G.W/P vector 
Weeks after TE FACS Cell dose human cell LNGFRi"human GFP+BFU-E GFP+CFU-GM 
Group Mouse transplantation MOl (%) (1OS) engraftmen(% C045+) cells(%) colonies (%) colonies (%) 
1.1 5 200 76 3 2.5 62 NO NO 
1.2 5 200 76 3 3 63 61 (8/13) o (0/21) 
1.3 9 200 76 3 58 72 73 (29/40) o (0/91) 
II 2.1 9 200 68 2 50.5 44 52 (16/31) 0(0/63) 
2.2 9 200 68 2 6.5 64 NO NO 
2.3 9 200 68 2 9.4 54 NO NO 
2.4 9 200 68 2 23.7 43 46 (11/24) 0(0/43) 
III 3.1 11 100 49 1.5 5.7 47 54 (6/11) 0(0/24) 
3.2 11 100 49 1.5 4 35 NO NO 
3.3 11 100 49 1.5 1.5 45 NO NO 
G.WIP lentiviral vector confers erythroid-specific expression in BFU-E oolonies differentiating from tranoouced SRCs. The result from three 
different experiments are shown. MOl indicates Mu~iplicny of infection for COO4+ cells. TE indicates transduction efficiency assessed by 
FACS 4 days after transduction. NO, not done. 
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Figure 7.4. Multilineage reconstitution of the bone marrow of a NOD/SCID mouse 
transplanted with cord blood-derived human CD34+ hematopoietic stem/progenitor cells 
transduced with the G.W/P lentiviral vector (see Fig. 5) at a MOl of 200. Transduction 
efficiency in the transplanted cells was measured by FACS analysis of &NGFR expression 
4 days after infection (upper left panel). Cells were transplanted in 10 different NOD-SCID 
mice (see Table 1 for complete data). Engraftment was analyzed by FACS analysis of the 
human-specific CD45 marker in bone marrow cells 9 weeks after transplantation (lower left 
panel). Transduction efficiency in the total engrafted cell population (CD45+, lower left 
panel), and in the progenitor (CD34+), B lymphoid (CD19+) and myeloid (CD13+) sub-
populations (right panels) were analyzed by &NGFR expression. The percentage of 
LNGFR-positive and -negative cells withi~ each cell SUb-population is indicated in the 
appropriate quadrants. 
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cultures under conditions that preferentially support outgrowth of human progenitors 
(Cashman and Eaves, 1999). Following 11-14 days after plating, single colonies were 
counted and scored for OFP expression under an inverted fluorescence microscope. 
Overall, 70 out of 119 BFU-E colonies were OFP+ (average: 59%), while none out of a 
total of 232 CFU-OM colonies showed detectable OFP expression (Table 7.1). Figure 
7.5 (A-D) shows OFP expression in fully differentiated human erythroid colonies grown 
from the BM of a "transplanted NOD/SCID mouse. Murine colonies derived from 
control, mock-transplanted NOD/SCID mice were few, OFP- and morphologically 
distinguishable from human colonies obtained from transplanted animals. 
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Figure 7.5. Erythroid-specific expression of GFP in methyl cellulose colonies derived 
from human NOD-SCID mouse-repopulating cells (SRCs) transduced with the G.WIP 
lentiviral vector (see Fig. 13) and analyzed ex vivo 9 weeks after transplantation. A,C, 
bright-field view of fully mature BFU-E and CFU-GM colonies 14 days after plating; 
B,D, green fluorescence view of the same fields (GFP-specific filters). Magnification: 
4X in A, B, 10 X in C, D. 
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7.3 Long-term erytroid-specific expression of the GATA-LTR in murine 
repopulating HSCs. 
To test the lineage-specific expression of the GATA-LTR in a transplantation model 
supporting the terminal differentiation of all progeny derived from transduced HSCs, 
we performed bone marrow transplantation of transduced cells in congenic mice using 
inbred strains that differed only at the CD45 molecule by two known alleles, CD45.1 
and CD45.2. We followed the experimental plan illustrated in Fig. 7.6. BM cells (5 x 
106) from C57B1I6 (CD45.2+) donor mice were transduced with the G vector, further 
modified by the addition of the HIV-1 cPPT and WPRE sequences (MOl: 200), and 
transplanted into lethally-irradiated CS7Bl/6-Ly-S.1 (CD4S.1 +) recipient mice (Fig. 7.6). 
Transduction efficiency of murine progenitors, expressed as a percentage of GFP+ BFU-
E colonies in methy1cellulose assays, averaged 75%. After 9 to 11 weeks following 
transplantation, BM cells from recipient animals were analyzed for expression of GFP, 
and erythroid (TER-119) and myeloid (Gr-1) lineage-specific markers. Engraftment of 
donor cells in the BM, indicated by the proportion of CD45.2+/total CD45+ cells, ranged 
from 26 to 94% (Fig. 7.7). GFP+ cells were detected at a significant level (3.0 to 39%), 
only in the erythroblastic, TERl19+ sub-population of BM cells (Fig. 7.8, upper right 
panel). Conversely, in myeloblastic Gr-1 + cells GFP expression was virtually 
undetectable (0.6 to 1.3%) (Fig. 7.8, lower right panel). After normalization for the 
proportion of engrafted donor cells in BM, TERI19+/GFP+ cells ranged from 3.2 to 
96%. These results indicate that expression of the GATA-LTR is restricted to the fully 
differentiated erythroblastic progeny of transduced mouse-repopulating stem cells in 
vivo. 
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Figure 7.6. Transplantation of murine BM-transduced cells. 
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Figure 7.7. Level of chimerism expressed as the proportion of CD45.2+/total CD4S.1 + 
cells in the BM from 5 mice transplanted with co-isogenic BM cells transduced with 
the G vector. Mter 9 to 36 weeks following transplantation BM cells were stained 
with PE-conjugated anti-CD4S.1 (Y axis) and with FITC-conjugated anti-CD45.2 (X 
axis) antibodies. The percentage of CD45.1+ and CD45.2+ cells is indicated in the 
appropriate quadrants. In the first panel is reported the isotype control for the PE and 
ATC expression of the BM cells of one representative mouse (#2). 
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Figure 7.8. Erythroid-specific expression of GFP (X axis) in the BM from a 
representative mouse transplanted with co-isogenic BM cells transduced with the G 
vector. Nine weeks after transplantation BM cells were stained with PE-conjugated 
anti-Ter-119 (erythroid specific) and Gr-1 (myeloid specific) (Y axis) antibodies. 
Positivity to Ter-119 was analyzed in the blast/lymphocyte-gated cells (R1 in the right 
upper panel), and positivity to Gr-1 was analyzed in the granulo/monocyte-gated cells' 
(R2 in the right lower panel). The percentage of GFP-positive and -negative cells 
within each cell sub-population is indicated in the appropriate quadrants (left panels). 
The degree of chimerism in this representative animal, expressed as the proportion of 
CD45.2+/total CD45+ cells, was 67.5%. SSC: side scatter; FCS: forward scatter. 
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One major limitation to a genetic approach of therapy is the possibility of transcriptional 
silencing of the integrated vectors over time (Challita, 1994). Therefore, we studied the 
stability of GFP expression in long-term bone marrow chimeras. After 20 to 36 weeks 
following transplantation, BM cells from recipient animals were analyzed for 
expression of GFP, and erythroid (TER-119) and myeloid (Gr-l) lineage-specific 
markers (Fig. 7.9, lower panels). Engraftment of donor cells in the BM was indicated by 
the proportion of ·CD45.2+/total CD45+ cells (Fig. 7.9, upper left panel). Primary 
transplant recipients maintained stable levels of the viral-encoded GFP gene over a 36-
week period, suggesting that it contains a powerful enhancer and that it resists transgene 
silencing. Furtermore, the erythroid lineage-specific expression of the GATA-LTR is 
maintained at very high level in almost all transduced erythroid cells even following 9 
monts after transplantation (Fig.7.9). 
These results confirm that GATA-LTR expression potential is maintained throughout 
differentiation, from transduced hematopoietic stem cell to erythroid cell, and that 
vector-encoded GFP expression is not markedly silenced over time. 
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Figure 7.9. Level of chimerism and long-term erythroid-specific expression of GFP 
(X axis) in the BM from a representative mouse transplanted with co-isogenic BM 
cells transduced with the G vector. Nine months (36 weeks) after transplantation BM 
cells were stained with PE-conjugated anti-Ter-119 (erythroid specific), Gr-1 
(myeloid specific), CD4S.1 (Y axis) and TC-cnjugated CD4S.1 antibodies. Positivity 
to Ter-119 was analyzed in the blast/lymphocyte-gated cells (R1 in the right upper' 
panel), and positivity to Gr-1 and CD4S was analyzed in the granulo/monocyte-gated 
cells (R2 in the right lower panel). The percentage of GFP-positive and -negative cells 
within each cell sUb-popUlation is indicated in the appropriate quadrants (left panels). 
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Chapter 8 
Expression of human B-gJobin by GATA-LTR vectors. 
8.1 Expression of human B-gJobin in the HEL cell line. 
On the basis of the results obtained by using transcriptionally targeted LV vectors 
expressing OFP under the control of OATA-LTR, we replaced the marker gene with the 
B-globin cDNA. Transcriptionally regulated LV vectors carrying the human B-globin 
gene were developed in the backbone of the O.W/P vector (Fig. 6.3 A). The OFP 
protein in this construct was replaced by a 440-bp human B-globin cDNA. The resulting 
vector, O.B.WIP.LlN in Fig. 8.1 A, was packaged, as usual, with the VSV.O envelope. 
Viral titers were determined by infection of HeLa cells with serial dilutions of viral 
supernatants and FACS analysis o(LlLNOFR expression. In the first instance, we 
decided to test the activity of the O.B.W/P.LlN vector in the context of erythroid cells 
with a normal content of globin genes, in order to compare the level of the viral B-
globin expression with the equivalent y endogenous gene. HEL cells, which are capable 
of spontaneous and induced globin expression, were used as model system (Martin and 
Papayannopoulou, 1982). This cell line was deriv'ed from the peripheral blood of a 
patient with Hodgkin's disease who later developed erythroleukemia. HEL cells have a 
lymphoblast morphology and cytogenetic studies in vivo disclosed a modal 
chromosome number of 66 and the presence of two Y chromosomes in 86% of the cells 
(Martin and Papayannopoulou, 1982). HEL cells produce mainly hemoglobin Bart's 
(see Section 1.3.1) and infact the major species of globin chains synthesized by the 
these cells were y chains (Oy, Ay, and their acetylated forms). The same pattern of 
globin chain synthesis was also observed in hemin-induced HEL cells. Quantitative 
studies indicated a ten-fold increase in globin synthesis after hemin induction. This 
induction of HEL cells by hemin is associated with quantitative rather than qualitative 
changes in globin genes, though the same group, more recently, reported that hemin 
induction cosinstantly increases, the proportion of a-chains (Papayannopoulou et al., 
1987). Recenlty, the mechanism of action of hemin has been elucidated. It has been 
reported that hemin overcomes the inib~tion of translation due to the phosporylation of 
the a subunit of eIF-2 operated by HRI kinase. HRI kinase has two binding sites for 
heme aTld hemin binding to these sites inhibits HRI function, enhancing the level of 
globin mRNA translation. 
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In order to test the biological activity of the G.B.WIP.~N vector, HEL cells were 
transduced at an MOl of 5 using the spinoculation protocol described in Materials and 
Methods. Transduced cells were mantained as bulk culture and three days after 
infection, transduction efficiency was evaluated by FACS analysis of ~LNGFR 
expression (Fig. 8.1 B). Southern blot analysis of genomic DNA, digested with AflII and 
hybridized to a WPRE probe, showed stable integnition of intact provirus with the 
expected size of 4.5 kb (Fig. 8.2 A). End-fragment analysis of genomic DNA with XbaI, 
which cuts once inside the vector, showed the polyclonal nature of the HEL bulk culture 
(Fig. 8.2 A). 
The transcriptional activity of the G.B.WIP.~N vector was characterized by Northern 
blot analysis of transduced HEL cells, with or without induction of differentiation in the 
presence of 50 J-tM hemin (Fig. 8.2 B). Four days after induction of differentiation, 
poly-A + RNA was extracted from differentiated and non-differentiated HEL cells and 
analyzed by Northern blotting after hybridization with a B-globin probe (Fig. 8.2 B, 
upper panel). Since the nucleotide sequences of U-, y- and B-globins are very similar, 
using B-globin as a probe is possible to detect the signal relative to the viral B-globin 
(around 3.6 kb, Fig. 8.2 B) and the band relative to the endogenous cellular u- and y-
globins (around 0.7 kb, Fig. 8.2 B). This allows a comparison in the level of viral B-
globin expression with that of endogenous globins by phosphorimaging of Northern 
blots after normalization to GAPDH mRNA content (Fig. 8.2 B, bottom panel). In 
undifferentiated cells the level of viral B-globin transcript was approximately 12-fold 
higher than the endogenous y gene (Fig. 8.2 B, second lane), while in hemin-induced 
cells the viral signal was 230% of the endogenous aiy genes (Fig. 8.2 B, fourth lane). 
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Figure 8.1. (A) Schematic map of the RRL.GATA.B-globin.W.PGK.AN (G.B.W/P.AN) 
vector in its proviral form. The FLAG-modified human B-globin cDNA is inserted .in 
place of the GFP cDNA in the G.W/P vector described in Fig 3.13 A. (B) Analysis of 
LNGFR expression in HEL cells transduced with the G.B.W/P.AN vector. HEL cells 
were infected with vector at a MOl of 5, grown as bulk cultures and analyzed for 
LNGFR expression by single-channel cytofluorimetry after staining with a FITC-
conjugated anti-LNGFR antibody (X axis). Expression profiles are indicated by red 
(mock infected cells) or green (infected cells) peaks respectively. Percentage of 
LNGFR expressing cells is indicated within the panel. 
179 
As expected, no viral B-globin signals were detected in non-transduced BEL cells (first 
and third lanes in Fig. 8.2 B). 
Human B-globin expression, driven by GATA-LTR, was evaluated also at the protein" 
level by Western blot analysis of the same BEL bulk cultures (Fig. 8.2 C). Since all the 
globin chains have a very similar protein structure with little difference in protein 
molecular weight, it is very hard to distinguish the viral derived protein from the 
endogenous globins. To overcome this limitation we decided to modify our B-globin 
cDNA by adding an identification tag. For this reason, a FLAG epitope was cloned in 
frame at the 5' end of the B-globin cDNA. This epitope allowed detection of viral B-
globin by a specific anti-FLAG antibody. Furthermore, due to the enhancement of the 
molecular weight of the Flag-B-globin, this allowed it to be distinguished from the 
endogenous band of globins also when we use a polyclonal antibody that recognize all 
the globin chains. This modification in the viral B-globin allowed us to perform 
quantification experiments, not only at the mRNA, but also at the protein level. Western 
blot analysis of BEL bulk cultures showed no globin signals in both transduced and 
non-transduced, non-induced HEL cells (first and second lanes in Fig. 8.2 C). The 
absence of the Flag-B-globin signal in transduced, non-induced HEL cells was in 
contrast with the presence of the viral B-globin mRNA in the same BEL bulk culture 
(compare the second lane in Fig. 8.2 B and C). This is probably due to the absence of a-
globin chains in non-induced cells and to a high rate of B-globin degradation in the 
absence of its a-globin counterpart. Since in hemin-induced BEL cells the proportion of 
a-globin chains are consistently increased (Papayannopoulou et aI., 1987), this could 
enhance the stability of the viral B-globin by association with the induced a-globin in 
hemoglobin tetramers. Western blot analysis of BEL bulk cultures also showed that 
Flag-B-globin accumulated at a level of 42% with respect to the endogenous human 
globin chains (fourth lane in Fig. 8.2 C), while, as expected, no Flag-B-globin signal 
was detected in non-transduced, hemin-induced BEL cells (third lane in Fig. 8.2 C). The 
specificity of the Flag-B-globin signal was confirmed by Western" plot analysis of hemin 
induced BEL cells using a monoclonal antibody specific for the FLAG epitope (Fig. 
8.2C). 
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Figure 8.2. (A) Southern blot analysis of genomic DNA extracted from mock-transduce" (C) 
or G.B.W/P.AN-transduced (T) HEL cells, digested with AflII or with XbaI and hybridised 
with a WPRE probe. (B) Northern blot analysis of poly-A + RNA extracted from the same 
HEL cells with or without induction of differentiation with hemin, hybridised with a B-globin 
(upper panel) or a GAPDH (lower panel) probe. Viral and endogenous globin bands are 
indicated on the right. (C) Western blot analysis of proteins extracted from the same HEL 
cells and bound with a polyclonal anti-globin or monoclonal anti-FLAG antibody. Bands 
relative to the Flag-B-globin and to the a/y globins were indicated on the right. Molecular 
weights in kilobase (A and B) and in kilodalton (C) are indicated on the left. 
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To normalize Flag-B-globin expression per vector copy, the average proviral copy 
number of the HEL bulk cultures infected with G.B. W /P .~N, was determined by 
quantitative peR analysis. Results were confirmed by Southern blot analysis after. 
phosphorimage quantification of the AflII band relative to the HEL bulk culture in 
comparison with the AflII band relative to a standard HEL clone carrying 5 copies of 
integrated proviruses (not shown). The average proviral copy number of the 
G.B.W/P.~N-transduced HEL cells was 5.3 copies/cell. When normalized to single 
vector copy the level of viral B-globin mRNA expression in hemin-induced HEL cells, 
reduces to 43% of endogenous globin mRNA and the level of Flag-B-globin protein to 
8% of endogenous globin chains. Due to the triploid genotype of HEL cells, after 
correction to ex and y-globin content/allele, the proportion of viral B-globin expression is 
126% (at the mRNA level) and to 24% (at the protein level). 
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8.2 Expression of human B-gJobin in the MEL cell line. 
Similar results were obtained when we use the murine erythroleukemia (MEL) cell line 
as an erythroid expression system. MEL cells are erythroid progenitor cells derived. 
from the spleens of susceptible mice infected with the Friend virus complex. These 
virally transformed cells are arrested at the proerytroblast stage of development and can 
be maintained in culture indefinitely (Singer et aI., 1974). Most MEL cell lines show a 
low «1 %) level o(spontaneous erythroid differentiation, however, upon treatment with 
various chemical agents, MEL cells can be induced to undergo erythroid differentiation 
at much higher levels (30-100%). Among the most potent inducers of differentiation are 
polar-planar compounds (such as dimethyl sulfoxide, hexamethylene bisacetamide, 
sodium butyrate and retinoic acid). Erythroid differentiation of MEL cells in culture 
recapitulates many aspects of the erythroid terminal differentiation program, including 
hemoglobin synthesis and growth arrest. For this reason, MEL cells are considered an 
excellent model system for studying changes in chromatin structure and coordinate 
globin gene expression associated with differentiation (Fraser and Curtis, 1987). 
To test the activity of the G.B.WIP.~N vector (Fig. 8.3 A), MEL cells were transduced 
with the viral supernatant at an MOl of 10, usi~g the spinoculation protocol (see 
Materials and Methods). Transduced cells were mantained as bulk cultures and three 
days after infection, transduction efficiency was evaluated by FACS analysis of ~NGFR 
expression (Fig. 8.3 A). Cells in the bulk culture were almost all transduced (99%) and 
vector DNA stability was determined by genomic Southern blot analysis (Fig 8.3 B). 
Genomic DNA digestion with AflII and hybridization with a WPRE probe, showed 
stable integration of intact provirus with the expected size of 4.5 kb (Fig. 8.3 B). End-
fragment analysis of genomic DNA with Xbal, which cuts once inside the vector, 
showed the polyclonal nature of the HEL bulk culture (Fig. 8.3 B) .. 
The transcriptional activity of the G.B.W/P.L\N vector in MEL cells was characterized 
-
by Northern blot analysis, with or without induction of differentiation in the presence of 
2% DMSO, after hybridization to. a B-globin probe (Fig. 8.4 A). ~Yl?ridization with a B-
globin probe allowed a comparison in the level of viral B-globin expression wito the 
endogenous murine a and B-globins in DMSO-induced MEL cells transduced with the 
G.B.WIP.~N vector. In contrast to HEL cells, no endogenous B-globin expression was 
detected in non-induced MEL cells (compare the first two lanes in Fig. 8.2 B and in Fig. 
8.4 A). However, after transduced MEL cells were induced with DMSO, the viral B-
globin transcripts accumulated at a level of 70% with respect to the level of endogenous 
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Figure 8.3. (A) Analysis of LNGFR expression in MEL cells transduced with · the 
G.B.W/P.AN vector. MEL cells were infected with the vector at a MOl of 10, grown as 
bulk cultures and analyzed for LNGFR expression by single-channel fluorescence 
cytometry after staining with a FITC-conjugated anti-LNGFR antibody (X axis). 
Expression profiles are indicated by red (mock infected cells) or green (infected cells) 
peaks, respectively. The percentage of LNGFR expressing cells is shown within the 
panel. (B) Southern blot analysis of g~nomic DNA extracted from mock-transduced (C) 
or G.B.WIP.AN-transduced MEL cells, digested with AflII or with XbaI and hybridized 
with a WPRE probe. 
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transcripts (Fig. 8.4 A, fourth lane), as quantified by phosphorimaging after 
normalization for GAPDH mRNA content. As expected, no human B-globin expression 
was detected in non-transduced, DMSO-induced MEL cells (Fig. 8.4 A, third lane). 
The activity of the G.B.WIP.~N vector was characterized at the protein level by Western 
blot analysis of the same bulk cultures of transduced MEL cells, with or without 
induction of differentiation with 2% of DMSO (Fig. '8.4 B). As with the HEL cells, a 
FLAG-modified human B-globin was used to distinguish viral B-globin signal from the 
endogenous murine globin chains. During protein analysis, we used a polyclonal 
antibody against all the human globin chains. This antibody showed a strong cross-
reactivity with murine globin chains and allowed us to perform quantitative experiments 
between viral human and endogenous murine globin proteins. As expected, no 
endogenous globin signal was detected in non-induced MEL cells (first and second lane 
in Fig. 8.4 B), while a signal, representing a level of 30% with respect to the 
endogenous globins, was detected in transduced, DMSO-induced MEL cells (third lane 
in Fig. 8.4 B). Obviously, no viral human B-globin signal was detected in non-
transduced, DMSO-induced MEL cells (fourth lane in Fig. 8.4 B). The specificity of the 
viral human B-globin signal was confirmed by Western blot analysis of DMSO-induced 
MEL cells using the monoclonal antibody specific for the FLAG epitope (8.4 B, lower 
panel). 
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Figure 8.4. (A) Northern blot analysis of poly-A + RNA extracted from mock-transduced 
(C) and G.B.W/P.~-transduced ME~ cells (T), with or without induction of differention 
with 2% DMSO, hybridised with B-globin (upper panel) and GAPDH (lower panel) 
probes. Viral and endogenous globin bands are indicated on the right. (B) Western blot 
analysis of proteins extracted from the same MEL cells and revealed using a polyc1onal 
anti-globin or monoclonal anti-FLAG antibody. Bands relative to the Rag-B-globin and 
to the endogenous alB globins are indicated on the right. Molecular weights in kilobase 
(A) and in kilodalton (B) are indicated on the left. 
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8.3 Expression of human 8-globin in CD34+ cells. 
Human CD34+ stem/progenitor cells were purified from cord blood-derived 
mononuclear cells by positive immunoselection using beads-conjugated anti-human. 
CD34 (see Materials and Methods). These cells were cultured for 24 hours in serum-
free medium in the presence of cytokines and transduced with the G.BWIP.dN vector at 
an MOl of 100. Two days after infection, cells were sorted by immunoselection for 
LNGFR expression (Fig. 8.5 A). Efficiency of both transduction and immunomagnetic 
sorting were monitored by FACS analysis, after sorting (Fig. 8.5 A). More than 40% of 
CD34 + cells were transduced as measured by the expression of LNGFR driven by the 
internal PGK promoter (red peak in Fig. 8.5 A) while, after sorting, more than 90% 
were LNGFR positive (green peak in Fig. 8.4 A). To test the biological activity of the 
G.BWIP.dN vector in differentiated cells, mock-transduced and G.BWIP.dN-transduced 
CD34 + progenitor cells were induced to differentiate in liquid culture into either 
myeloid or erythroid lineages (see Material and Methods). Starting from 7 to 13 days 
after induction of differentiation, expression of LNGFR was evaluated by double-
immunofluorescence FACS analysis of cells stained with antibodies against either 
erythroid (GpA) or myeloid (CD13) lineage-specifIc surface markers (Fig. 8.5 B). The 
proportion of GpA + and CD 13+ cells in mock-transduced and transduced cells was 
comparable (51 % vs 62% inGpA + cells and 46% vs 36 % in CD 13+ cells, respectively), 
indicating that the presence of the G.BWIP.~N vector did not interfere with erythroid or 
myeloid differentiation of CD34+ cells (Fig. 8.5 B). Furthermore, LNGFR expression 
was comparable in the member of erythroid and myeloid induced progeny of transduced 
CD34 + cells (95% and 86%, respectively), showing that expression from the PGK 
promoter is mantained at the same level under both differentiative conditions (Fig. 8.5 
B). 
To test the efficiency of the GATA-LTR to drive expression of the B-globin gene, both 
erythroid and myeloid-differentiated progeny of mock-transduced and transduced 
CD34+ cells were collected thirteen days after induction of differentiation and analyzed 
II .' • 
by Northern and Western blotting (Fig. 8.6). Total RNA extracted from differentiated 
CD34+ cells were analyzed by Northern blot after hybridization with a B-globin or a 
GAPDH probe (Fig. 8.6 A). The results show a strong activation of endogenous globin 
gene expression during erythroid differentiation, while no globin signals were detected 
in myeloid-differentiated CD34+ cells (Fig. 8.6 A, upper panel). The viral B-globin 
~ 
transcript was detected only in transduced, erythroid-differentiated CD34+ cells (third 
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Figure 8.5. (A) F ACS analysis of LNGFR expression in liquid cultures of human 
CD34+ hematopoietic stem/progenitor cells transduced with the G.BWIP.~N vector 
and analyzed 2 days after infection, before (red peak) and after immunomagnetic 
sorting (green peak) of LNGFR-expressing cells. (B) FACS analysis of the mock-
transduced (NT) and G.BWIP.~-transduced (T) CD34+ cells 7 or 13 days after 
induction of erythroblastic (left panels) or myelomonocytic (right panels) 
differentiation. Cells were analyzed by double-immunofluorescence flow cytometry 
after staining with a FITC-conjugated anti-LNGFR antibody and PE-conjugated 
antibodies against specific surface markers for erythroid (GpA, left panels) and 
myeloid (CDI3, right panels) progeny. % values were indicate in each quadrant. 
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lane in Fig. 8.6 A). In fact, no viral B-globin signals were present in myeloid-
differentiated CD34+ cells (fourth lane in Fig. 8.6 A) and, as expected, in mock-
transduced cells (first and second lane in Fig. 8.6 A). This confirmed the erythroi~ 
specific expression of the GATA-LTR in transduced human HSCs. Quantitative 
experiments were performed to determine the proportion of viral B-globin expression 
with respect to the expression of endogenous globins. Viral B-globin transcripts 
accumulated in erythroid-differentiated cells at a level of 2.2% with respect to the 
endogenous a and B-globins, as quantified by phosphorimaging of Northern blots after 
normalization for GAPDH mRNA content (Fig. 8.6 A, bottom panel). 
The activity of the G.B.WIP.L\N vector was characterized at the protein level by Western 
blot analysis of the same bulk cultures of mock-transduced and transduced CD34+ cells, 
after induction of erythroid or myeloid differentiation (Fig. 8.6 B). As with the stable 
cell lines, a FLAG-modified human B-globin was used to distinguish viral B-globin 
signal from the endogenous globins. Protein analysis was performed using a polyclonal 
antibody against all the human globin chains. As expected, no endogenous globin signal 
was detected in myeloid-differentiated CD34+ cells (second lane in Fig. 8.6 B), while a 
signal, quantified at a level of 3.4% with respect to 'endogenous globins, was detected in 
transduced, erythroid-differentiated CD34+ cells (third lane in Fig. 8.6 B). Obviously, no 
viral human B-globin signal was detected in mock-transduced, erythroid-differentiated 
CD34+ cells (first lane in Fig. 8.6 B). As before, the specificity of the viral human B-
globin signal was confirmed by Western blot analysis of erytroid-differentiated CD34+ 
cells using a monoclonal antibody specific for the FLAG epitope (8.6 B, lower panel). 
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Figure 8.6. (A) Northern blot analysis of total RNA extracted from mock-transduced (C) 
and G.B.W/P.AN-transduced (T) CD34+ cells, 13 days after induction of erythroid (E) or 
myeloid (M) differentiation. The membrane was hybridised to a B-globin (upper panel) 
or a GAPDH (lower panel) probe. Viral and endogenous globin bands are indicated on 
the right. (B) Western blot analysis of proteins extracted from the same cells revealed 
using a polyclonal anti-human globin or a monoclonal anti-FALAG antibody. Bands 
relative to the Flag-B-globin and to the endogenous alB globins are indicated on the 
right. Molecular weights in kilobase (A) and in kilodalton (B) are shown on the left. 
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Chapter 9 
DISCUSSION 
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The prospect of effectively transducing HSCs creates a number of potential novel 
opportunities for the treatment of inherited and acquired diseases (Bordignon and 
Roncarolo, 2002). However, the successful implementation of stem cell gene therapy' 
will require safe and efficient gene transfer procedures as well as controlled and 
regulated transgene expression. Lentiviral vectors are emerging as the gene delivery 
system of choice for transducing HSCs without compromising their repopulating 
capacity after BM transplantation (Follenzi et aI., 2000; Miyoshi et aI., 1999; Woods et 
aI., 2000). Until now, the investigation of transgene regulation in hematopoietic cells 
has mostly focused on non-specific promoter/enhancer elements. These include 
elements of viral origin, such as retroviral LTRs and mammalian promoters. These 
promoters function in all hematopoietic lineages, albeit with variable strength. 
Accordingly, current clinical applications are limited to diseases where non-specific and 
relatively low-level expression of a vector-encoded product is sufficient. In disorders 
such as adenosine deaminase deficiency, Gaucher's disease or X-linked severe 
combined immunodeficiency (SCID), it seems acceptable to indiscriminately express 
the transgene product in lymphoid and myeloid lineages, irrespective of whether the 
pathology prevails in, for example, T lymphocytes or macrophages (Cavazzana-Calvo et 
aI., 2000); Aiuti et aI., 2002; Cavazzana-Calvo and Hacein-Bey-Abina, 2001). In the 
case of enzyme deficiencies, expression of a small fraction of physiological enzyme 
levels tends to suffice to yield therapeutic responses. In these settings, the 
transcriptional constraints for achieving clinical benefits without toxicity due to 
overexpression or ectopic expression are thus favourable. However, gene therapy of 
most blood genetic disorders (for example, chronic granoulomatosu disease amd 
thalasseamia) requires ex vivo gene transfer transplantable, self-renewing HSCs and 
regulation of transgene expression in one or more differentiated cell lineages (Sadelain, 
2002). At present, there are very few reports on how to deliver the gene product 
specifically to only one lineage, differentiating from the transduced HSCs, or how to 
regulate the level of expression, or its differentiation stage spe~.ifi9ity within a single 
lineage. Targeted transduction could theoretically be achieved by manipulating the 
vector envelope, so that binding and i~fection is confined to a specific cell lineage. 
However, this form of targeting has proven ineffective so far (reviewed in Larochelle et 
aI., 2002). To date, the only surface-targeting strategies that have allowed efficient 
infection by retroviral vectors in vivo are those in which the normal retroviral surface 
protein (SU) participates in receptor binding and fusion (Martin et aI., 2002; Peng et aI., 
192 
1999). However, while the potential of this virus-entry targeting approach could have a 
clear impact on cancer gene therapy, it seems less attractive for clinical application 
requiring a lineage-restricted expression of the therapeutic gene. On the other hand, 
transcriptional targeting by insertion of regulatory sequences into the vector to control 
transcription and confine expression of the transgene to a specific lineage after stem cell 
differentiation looks more promising. The work of thIs PhD thesis attempted to address 
basic issues in stem-cell gene therapy from the perspective of regulating transgene 
expression, taking globin gene transfer for the treatment of ~-thalassemia as a paradigm. 
One way to target transgene transcription is to drive an internal expression cassette with 
specific enhancer/promoter combinations. With this simple design, expression of a 
reporter or a therapeutic transgene has been effectively restricted to erythroblasts, 
antigen presenting cells and, very recently, to CD4+ cells derived from murine or human 
HSCs (Cui et aI., 2002; Marodon et aI., 2003; Moreau-Gaudry et aI., 2001; Richard et 
aI., 2001). For some gene therapy applications, for example, the correction of globin 
chain imbalance in human J3-thalassemia, a high protein output is just as important as its 
restricted expression, which makes practically inadequate the use of intronless J3-globin 
cDNAs expressed by internal promoters. This problem has been partially resolved by 
placing the entire human J3-globin gene under the control of its own promoter and a 
reduced version of the ~-globin locus control region (LCR) in opposite orientation 
within a first-generation LV vector. With this design, potentially therapeutic levels of 
human J3-globin have been obtained for the first time in a murine model of J3-
thalassemia (May et aI., 2000; May et aI., 2002; Rivella et aI., 2003). 
As an alternative strategy of transcriptional targeting, we have attempted to re-direct the 
activity of the HIV-1 promoter in our lentiviral vector by LTR enhancer replacement 
(Lotti et aI., 2002). Most of the U3 region of the HIV-1 3'LTR (from position -418 to-
40 from the transcription start site) has been deleted and replaced with a 200-bp auto-
regulatory enhancer (HS2) of the erythroid-specific GATA-1 transcription factor (Tsai 
et aI., 1989). In this design, the modified GATA-LTR controls the expression of a GFP 
cDNA as a reporter gene. Analysis of GFP expression showed the erythroid lineage 
specificity of the GATA-LTR upon transduction of a large panel of human and murine 
erythroid and non-erythoid cell lines (see Figs. 4.3 and 4.4). 
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As a general strategy, modification of the viral LTR offers a number of potential 
advantages that have been addressed one by one in this study. Firstly, the LTR enhancer 
replacement provides a more efficient vector design, which allows the use of the major 
viral transcription unit to express the gene of interest under the form of a genomic, 
spliceable RNA. This is a particularly suitable feature in gene therapy vectors aimed to 
clinical applications, such as human ~-thalassemia, where a high protein output is as 
important as its restricted expression. In order to test the efficacy of this advantage, we 
have directly compared the expression of the GFP reporter gene driven by the modified 
GAT A-LTR (in the G vector) with that obtained by the same enhancer/promoter 
combination placed in the conventional internal position in the context of a SIN 
lentiviral vector (in the -18/G vector). Transduction of HEL cells with the two different 
vectors showed that expression from the genomic transcript is higher than that obtained 
from an un spliced transcript driven by an internal promoter (see Figs. 5.1 A and 5.2). 
Secondly, the presence of two copies of a genomic enhancer flanking the integrated 
provirus could reduce the chances of chromatin-mediated inactivation of transcription, 
which is known to affect the long-term maintenance of retroviral transgene expression 
in vivo, particularly in stem cells (Challita and Kohn, 1994). Expression of integrated 
provirus is affected by chromatin structure. Because the bulk of the mammalian genome 
is packaged into transcriptionally silent heterochromatin (Karpen, 1994), and murine 
leukemia virus-based vectors insert at random sites in the genome, a large portion of 
murine leukemia virus insertions result in gene silencing. This can lead to highly 
variable expression among clones, with complete silencing of provirus expression in a 
significant fraction of clones either immediately after insertion or after following cell 
expansion. The progeny of a single clone containing a unique integration event can also 
be affected by the surrounding chromatin to varying degrees (Karpen, 1994), a 
phenomenon known as position effect variegation (PEV). The'mammalian genome is 
organised into discrete chromosomal domains, in part using sequences termed 
chromatin insulators (Bell and Felsenfeld, 1999). These elements, first described in 
Drosophila and more recently in several vertebrate species, help define the boundary 
between. differentially regulated loci and serve to shield promoters from the influence of 
neighbouring regulatory elements (P,!ioleau et aI., 1999). Insulators function in a polar 
manner (e.g., they must be located between the cis effectors and promoter) and do not 
194 
have stimulatory or inhibitory transcriptional effects on their own, distinguishing them 
from classical enhancers and silencers. The first and best-characterised vertebrate 
chromatin insulator is located within the chicken B-globin locus control region. This 
element, which contains a DNase-I hypersensitive site (cHS4), appears to constitute the 
5' boundary of the chicken B-globin locus. A 1.2-kb fragment containing the cHS4 
element displays classic insulator activities, including the ability to block the interaction 
of globin gene promoters and enhancers in cell lines (Chung et al., 1993), and the ability 
to protect expression cassettes in Drosophila and transgenic mammals from position 
effects. It is noteworthy though that tandem flanking copies of the 5'HS4 element are 
required for full insulating activity (Chung et al., 1993). Other elements exist in the 
eukaryotic genome that are believed to contribute toward delimiting the topological 
borders between chromatin domains (Bode et al., 1992). Termed scaffold or matrix 
attached regions (SIMARs), these elements have been proposed to anchor chromatin to 
a skeleton of protein cross-ties called the nuclear scaffold (in metaphase) or nuclear 
matrix (in interphase), forming chromosomal loops (Namciu et al., 1998; Schubeler et 
al., 1996). It has been proposed that SIMARs may function by bringing enhancers and 
others distal regulatory elements in close proximity to their corresponding promoter 
sequences. While insulator function has been attributed to some SIMARs, this does not 
appear to be a general property of these elements (Namciu et al., 1998). Based on the 
assumption that insulator elements may play a useful role in attenuating chromatin 
position effects, a series of retroviral and lentiviral vectors carrying these elements were 
generated (Agarwal et al., 1998; Auten et al., 1999; Dang et al., 2000; Emery et al., 
2000; Rivella et al., 2000). While all the reports showed an improved performance in 
gene expression of the viral vectors, these elements fail in shielding transgene 
expression from transcriptional silencing (Emery et al., 2002; Murray et al., 2000; 
Rivella et al., 2000). Very recently, by combinatorial association of the 5' cHS4 
insulator and the human interferon-B scaffold attachment region (INT -SAR), position-
effect protection of LV vector-mediated transgene expression in human KG1a 
hematopoietic progenitor cell line and in primary human CD34+ has been reported' (Ma 
et al., 2003; Ramezani et al., 2003). ,However, two findings seem to reshape the 
relevance of these data. Firstly, the introduction of GFP+ cell sorting by FACS during 
KG 1a cells cloning would eliminate integration sites where viral expression is silenced 
or very weak, introducing a non-acc~eptable bias in this type of analysis (Rivella and 
Sadelain, 1998). Secondly, KG 1a clonal analysis showed the persistance of a high 
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variabily in trangene expression also in the presence within the vector of the 5'HS4 and 
INF-SAR. The predominant effect of these two elements is in the increase of the mean 
fluorescence intensity (MFI) of the transgene. Persistance of expression reported by 
Ramezani et al. could be explained by the overall enhancement in transgene expression 
of 5'HS4IINF-SAR-carrying clones (Ramezani et aI., 2003). Nevertheless, suppression 
of repressive position effects by transcriptional enhancer has been extensively reported 
(Francastel et aI., 1999; Sutherland et aI., 1997; Walters et aI., 1996). Chromatin 
opening by pioneer transcription factors may be an integral part of transcriptional 
activation in a situation, such as cell differentiation, where silencing is used as a means 
of gene regulation (Francastel et aI., 2000; Martin, 2001). This function in some ways 
resembles chromatin insulation. Indeed, very recently, chromatin insulation by a 
transcriptional activator has been reported for a GFP reporter construct carrying 
multiple binding sites for a metal-inducible activator MTF (Sutter et aI., 2003). 
Induction makes silent transgenes more likely to become active and active transgenes 
less likely to become silent. Thus, the transcriptional activator suppresses both stable 
and variegating position effects in a manner that resembles chromatin insulation (Sutter 
et aI., 2003). Binding of erythroid-specific transcription factors, such as GAT A-I , to 
enhancers of erythroid-specific genes early in development or differentiation could be a 
key factor in initiation and maintenance of active chromatin structures (Martin et aI., 
1996). GAT A-I orchestrates multiple programs of erythroid development, including 
control of the cell cycle and apoptosis, as well as differentiation (see Section 1.4.3.1). 
At the biochemical level, GAT A-I is thought to recruit critical proteins to target sites. 
The interaction of GAT A-I with CBP/p300 suggests at least one mechanism by which 
histone acetylases might be brought to specific site (Blobel, 2000; Blobel et aI., 1998). 
By modifying chromatin-bound histones or perhaps by modification of GATA-1 itself, 
acetylases could enhance transcriptional activity of erythroid-specific loci (Boyes et aI., 
1998). In this context, GATA-1 might be viewed more as an "architectural" factor 
rather than a traditional transcriptional activator. Very recently, the essential role of 
GAT A-I and its cofactor CBP for the formation of an erythroid-specific acetylation 
pattern that is permissive for high level~ of gene expression has been reported (Letting 
et aI., 2003). Using chromatin immunoprecipitation (ChIP) experiments, Letting et al. 
found that GAT A-I stimulates acetylation of both histones H3 and H4 at the LCR and 
the B-major globin gene promoter. 'Time course experiments further demonstrated a 
correlation between GAT A-I occupancy at GATA elements, recruitment of CBP, 
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histone acetylation, and globin gene expression. These results suggest that one essential 
function of GAT A-I is to establish an erythroid-specific pattern of histone 
hyperacetylation at the globin gene cluster and very likely other erythroid-expressed 
genes (Letting et aI., 2003). The ability of GATA-I to disrupt a subset of histone-DNA 
contacts on a mononucleosome (Boyes et aI., 1998) may relate to the ability of GATA-
4, a similar protein enriched in the liver, to bind and open chromatin (Cirillo et aI., 
2002). The highly conserved zinc finger motif of this class of factors may generally 
possess a chromatin disrupting function. 
All these observations provide a strong rationale for using transcriptionally targeted 
vectors based on GATA binding sites as described in this study, to restrict expression of 
transgenes to the erythroid lineage and to shield its expression from repressive effects of 
flanking chromatin. Indeed, our results show persistent expression driven by the GAT A-
LTR is at uniformly high levels in individual clones of transduced HEL cells, showing 
remarkably less position effect variegation than a vector based on the same 
enhancer/promoter combination placed in an internal posi,tion (see Chapter 5). This 
vector design could therefore be applicable in all cases where long-term persistence of 
gene expression, tight gene regulation and high-level protein production are required in 
specific progeny of transduced HSCs, such as in gene therapy of thalassemia. 
Thirdly, another advantage of our transcriptional targeting design derives from the 
possibility to use an internal transcription unit to control a second gene providing an 
additional function to the transduced cells, generating bi-functionallentiviral vectors. 
For clinical applications, gene transfer vectors must be able to transduce HSCs at high 
efficiency without affecting their long-term repopulating capacity. Furthermore, since 
drastic myeloablation is an undesirable procedure' for thalassemic 'patients, the vectors 
should carry an in vivo positive selection function to favour engraftment and expansion 
of genetically modified HSCs. The ideal vector for gene therapy of ~-thalassemia 
should therefore drive constitutive expression of a positive selection function in long-
term repopulating HSCs and restricted expression of therapeutic levels of p-globin in 
their erythroblastic progeny. These req~irements complicate vector design, because the 
inclusion of a second transcription unit increases the size of the vector, may alter its 
genomi~ stability or decrease vector titer and the juxtaposition of two transcription units 
raises the possibility for transcrip~ional interference. Moreover, the two adjacent 
transcription units must function independently: one erythroid-specific and the other 
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pan-specific, directing expression in stem cells themselves and eventually their progeny 
in all lineages. All these issues have been addressed in this study by insertion of a 
second transcriptional cassette, containing the ~LNGFR cDNA under the control of a 
constitutive PGK promoter, downstream of the GFP gene in both G and -40 vectors. In 
this design, the modified GAT A-LTR controls expression of the gene of interest (GFP 
or ~-globin in this study), while the internal PGK promoter drives the constitutive 
expression of a second reporter gene (~LNGFR). Insertion of the second transcriptional 
cassette had no effect on titer, infectivity and genomic stability of the vector (see Fig. 
6.2). Gene expression analysis carried out on cells transduced with the G/P vector 
showed that the two transgenes are independently expressed in an erythroid-specific 
fashion (GFP) or consitutively in all cell lineages (~LNGFR). Unfortunately, GFP 
expression analysis of the same cells revealed that the internal promoter negatively 
interferes with the activity of the targeted LTR, thereby reducing the overall output of 
the vector genomic transcript with respect to single-gene vectors. The cause of this 
phenomenon comes from possible transcriptional inte~ference between the two 
enhancer/promoter elements in the vector or from a reduced stability of the genomic 
transcripts. Both mechanisms can influence accumulation of the genomic transcripts in 
infected cells. Although transcriptional interference could partially account for this 
reduction on genomic transcript accumulation, mRNA stability could also play an 
important role to this outcome. This possibility arises from the observation that the 
genomic transcript contains an internal stop codon, which could mimic a premature 
translation termination codon. All eukaryotes possess the ability to detect and degrade 
transcripts harbouring premature signals for the termination of translation (Lykke-
Andersen, 2001). This surveillance mechanism, known as nonsense-mediated decay 
(NMD), is thought to protect the organism from the deleterious' effects of truncated 
proteins that could result if nonsense transcripts were stable. Thus, genomic transcripts 
could be prone to NMD and degraded soon after transcription. Nevertheless, human 8-
globin mRNA decay in erythroid cells has been reported (Stevens et aI., 2002). Another 
step that plays a crucial role in transcript stability during mRNA processing is the 
efficiency of polyadenylation. Since in ,all retroviruses transcript polyadenylation occurs 
within the 3'LTR, the insertion of a transcriptional cassette between the 3'LTR and the 
reporter gene could reduce its efficiency. 
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Despite the mechanisms responsible of this phenomenon, we tried to overcome this 
problem by introducing a regulatory sequence from the genome of the woodchuck 
hepatitis virus (WPRE) at different positions within the vector construct (see Fig. 6.SA). 
This element acts at a post-transcriptional level, most likely promoting the efficiency of 
polyadenylation of the nascent transcript and increasing its total amount in cells 
(Donello et aI., 1998). A WPRE positioned at the 3' end of the vector was transcribed in 
both the genomic and the sub-genomic RNA and accordingly increased expression of 
both GFP and ~LNGFR. Conversely, a WPRE downstream of the GFP gene but 
upstream of the PGK promoter was incorporated only in the genomic transcript, and 
caused a selective increase of the GATA-LTR-driven GFP expression with no effect on 
its transcriptional restriction. Use of a WPRE therefore allows modulation of the 
relative abundance of two different gene products within a single lentiviral vector, and 
to restore high-level expression of a modified LTR even in the presence of an 
interfering internal promoter (6.5 B). 
Human cord blood-derived CD34+ stem/progenitor cells and murine repopulating HSCs 
were transduced at high efficiency (up to 70%) with this type of vector. This is shown 
by the expression of the constitutively regulated reporter gene in undifferentiated 
progenitors as well as in differentiated progenies (myeloid, lymphoid and erythroid) 
obtained in vitro and in vivo upon transplantation into NOD/SCID (human cells) or co-
isogenic (murine cells) mice. Expression of the transgene driven by the modified LTR 
was successfully restricted to the erythroblastic progeny of CD34+ progenitors in vitro 
and of human SCID-repopulating cells and murine HSCs in vivo. Transcription from the 
chimeric GATA-LTR was active at low levels in a subpopulation of transduced CD34+ 
cells (probably cycling progenitors), down regulated in myelo-monocytic cells and up 
regulated and maintained at sustained levels in erythroblastic cells, strictly paralleling 
the expression pattern of the GATA-1 gene during differentiation of human primary 
hematopoietic cells (Sposi et aI., 1992). Nevertheless, the G,AT A-LTR expression 
potential is maintained throughout differentiation, from transduced hematopoietic' cells 
to erythroid cell, even after 9 months ,in vivo. These results strongly suggest that the 
vector-encoded GFP expression resists trangene silencing at almost all integration sites 
(see Fig. 7.9). Interestingly, expression from the hybrid LTR does not require co-
expression of TAT and therefore app~ears to be relatively insensitive to the presence of a 
TAR secondary structure in the genomic transcript produced by the integrated provirus. 
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Overall, these experiments show that in our vectors the internal promoter is transcribed 
at approximately constant levels in undifferentiated HSCs and all their differentiated 
progeny in vitro and in vivo and that transcription from the modified LTR is effectively 
restricted to the erythroblastic lineage. This design is therefore suitable for expressing a 
constitutive in vivo selection marker, instead of the ~LNGFR gene, and a 
transcriptionally targeted therapeutic gene, instead of the GFP gene, in a single vector. 
Transcription factors, regulators of cell survival or cell proliferation may be used to 
enhance HSC functions. These novel approaches may be helpful in controlling post-
transplantation expansion and maybe in increasing donor chimerism in non-myelo-
ablated recipients (Sadelain et aI., 2000). However, the challenge is to enhance HSC 
function without impairing differentiation, without accelerating HSC exhaustion and 
without favouring leukemogenesis. Among the numerous in vivo selection strategies, a 
promising approach is the use of genes encoding modifi~d growth factor receptors 
conferring ligand-dependent, selective growth advantage to transduced cells. A number 
of recent reports indicate that reasonable candidates for this function are the receptors 
for hematopoietic growth factors and particularly that of erythropoietin (EpoR). 
Deletion of the carboxyl-terminal 91 amino acids of EpoR enhances the sensitivity of 
the receptor for the ligand, leading to an increase in the proliferative response to Epo 
stimulation in cells expressing this variant (D'Andrea and Koo, 1991). Transgenic mice 
carrying the tEpoR gene are phenotypically normal, but show an increase in multi potent 
clonogenic progenitors upon administration of exogenous Epo (Kirby et aI., 1996). 
Competitive repopulating experiments carried out by transplanting BM from tEpoR 
transgenic mice into wild-type recipients showed that stem cells ex·pressing tEpoR have 
a selective growth advantage over wild-type cells in Epo-treated animals (Kirby et aI., 
2000). Interestingly, similar naturally occurring EpoR mutants have been reported in 
humans, where they cause benign erythroid proliferation .but no malignant 
transformation (Arcasoy et aI., 1997; de la Chapelle et aI., 1993; Watowich et aI., 1999). 
The tEpoR gene appears therefore to be non-toxic, non-tumorigenic and non 
immunogenic in both mice and men. Nevertheless, it remains to be established whether 
such beneficial properties are maintained when the transgene is introduced into the 
genome of HSCs in the context of a ~iral vector, and whartype of regulation is required 
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to provide appropriate ligand response and selective advantage to transduced cells upon 
transplantation in vivo. 
An inherent limitation of our vector design is the persistence of a potentially active, 
TAT-responsive mv promoter in the integrated provirus. The TAT protein binds to the 
TAR region in the nascent genomic transcript and tethers the cyclin T -CDK9 complex 
to polymerase II, leading to increased transcriptional elongation (Wei et aI., 1998). By 
this action, TAT acts as a transcriptional activator and therefore plays a pivotal role in 
the exceedingly high replication rates that characterise HIV -induced diseases (Cullen, 
1998). The chimeric GATA-LTR HIV enhancer/promoter could theoretically be 
activated by super infection of wild-type mY, for instance in the T cell or macrophage 
progeny of transduced HSCs, thereby leading to mobilisation of the vector genome into 
infective mv particles. Although the occurrence of such an event should be practically 
verified in an appropriate in vivo model, vector mobilisation would be an undesirable 
effect, potentially affecting the safety characteristics of the gene transfer system for 
clinical applications. However, the latest generation of lentiviral packaging systems no 
longer rely on TAT for expression of the transfer vector into the packaging cell line 
(Klages et aI., 2000). This allows a design of lentiviral vectors, which do not 
incorporate a TAR element in the primary transcript. Mutation of the TAR element 
downstream the targeted LTR should abolish the possibility of HIV -induced 
mobilisation of the vector and therefore restore a degree of safety comparable to that of 
the currently used, fully U3-deleted SIN vectors. 
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The fl-thalassaemias are a group of inherited anaemias characterised by a reduction or a 
total absence in the production of haemoglobin B-chains (Weatherall, 2001; Weatherall, 
2001). The resulting imbalance of B-globin to a-globin chains results in a severe anemia 
that is generally treated by repeated blood transfusions. A consequense of such regular 
blood transfusion is the increased risk of exposure to virus-infected blood supplies and 
eventually leads to iron overload that can cause organ failure unless treated by iron 
chelation drug therapy (Olivieri, 1999; Olivieri et al., 1998). The only existing cure is 
allogeneic bone marrow transplantation (BMT), which is however available for less 
than 30% of thalassemic patients (Giardini and Lucarelli, 1994). Gene therapy is an 
attractive potential alternative to BMT (Sorrentino and Nienhuis, Gene Therapy for 
hematopoietic diseases. In: Stamatoyannopoulos G et al., 2001). 
Gene therapy of thalassaemias requires a restricted expression of a globin transgene 
only to the erythropoietic progeny of the hematopoietic stem cell and represents one of 
the most challanging models to test the efficiency and efficcacy of transcriptional 
targeting of viral vectors. The clinical history of t~e disease and over 15 years of BMT 
experience indicate that even a mild correction (>15%) of the globin chain imbalance in 
a fraction (>25%) of maturing erythroblasts is sufficient to reduce the morbidity caused 
by ineffective erythropoiesis, to improve the clinical management of the disease and to 
increase the patients' life expectancy (Gaziev and Lucarelli, 2003). For therapeutic 
purposes, reproducing the full pattern of the complex regulation of fl-globin gene 
expression might be unnecessary. However, the ideal fl-globin gene therapy vector 
should stably integrate into an HSC at high efficiency and be expressed to near 
endogenous levels at single copy. Position-dependent silencing and position effect 
variegation are particularly ~roublesome for retrovirus vectors containing the human B-
or y-globin gen~s (Raftopoulos et al., 1997; Rivella and Sadelain, 1998). Over the years, 
a number of scientists have tried to obtain lineage-restricted, high-level transcription of 
the fl-globin gene under control of minimal sized (200-300bp) LCR elements within the 
framework of MoMLV -derived retroviral (Sadelain et al., 1995) or adeno-associted 
viral vectors (Einrhand et al., 1995) (Dong et al., 2002; Tang and Qian, 1998). 
Expression studies in retrovirally transduced cells demonstrated that B-globin vectors 
harbouring a 1.0-kb LCR element, made up of the juxtaposed HS2, HS3, and HS4 core 
elements, could enhance the average B-globin expression in an erythroid-specific 
fashion, but failed to reduce positional variability of expression (Sadelain et al., 1995). 
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Moreover, in vivo studies in long-term bone marrow chimeras transplanted with B-
globin vectors harbouring the HS2, HS3, and HS4 core sites, demonstrated that this 
minimal LCR failed to sustain elevated and long-term expression (Raftopoulos et aI., 
1997; Rivella and Sadelain, 1998). Thus, the data suggested that the 1.0-kb LCR merely 
functioned like a classic enhancer rather than a chromatin regulator able to confer 
position-independent expression. The in vivo data showed relatively low (less than 3% 
of an endogenous globin gene), variable, and rarely persistent levels of vector-encoded 
human B-globin expression. Likewise, the results obtained with AA V vectors 
harbouring globin genes linked to LCR elements have been disappointing. Furthermore, 
the ability of AA V to integrate efficiently into hematopoietic stem cells has been 
controversial, with conflicting results reported from a number of groups (Russell and 
Kay, 1999). The results achieved with the minimal 1.0-kb LCR are consistent with 
transgenic studies that show the hypersensitive site cores are necessary for expression, 
but require additional sequences lying outside the hypersensitive site cores for full LCR 
function (Hardison et aI., 1997). In an effort to improve upon previous vectors, attempts 
have been made to effectively increase the size of the LCR element, incorporating the 
LCR core elements along with additional flanking sequences. Unfortunately, 
incorporation of the larger genomic fragments in retroviral vectors proved problematic. 
This was due in part to the inability of vectors to incorporate large LCR elements in a 
stable manner. Vector rearrangements frequently ensued, precluding introduction of 
intact unrearranged copies of the B-globin transcription unit into target cells at a high 
frequency. The difficulty to transfer large genomic sequences by using oncoretroviral 
vector systems, such as ML V -derived vectors, has limited their usefulness in gene 
therapy approaches to treat severe hemoglobin disorders. The combined effect of high 
gene transfer efficiency, and absence of vector rearrangements afforded by the 
recombinant lentivirus harboring the B-globin gene and LCR configuration, yielded 
remarkably high levels of human B-globin expression. In fact, the synthesis of 
potentially therapeutic levels of human ~-globin was achieved in the erythrocytes of 
bone marrow chimeras transplanted with ~-thalassemic bone marrow or foetal liver 
cells, transduced with the 1st generation lentiviral vector TNS9 (May et aI., 2000; May 
et aI., 2002). The TNS9 lentiviral vector contains the human ~-globin gene, including 
extended promoter sequences, the ~-globin 3' proximal enhancer and LCR elements 
HS2,3 and 4 as a 3.2kb combination, cloned in opposite'orientation in respect to HIV 
LTR transcriptional direction. Although these results showed that appropriate regulation 
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of a globin gene can be technically achieved, intrinsic limitations to this system are the 
lacking of position-independent expression of virally encoded ~-globin, demonstrated 
by clonal analysis of transduced MEL cells (May et aI., 2000) and the size of the vector, 
which is unlikely to allow the insertion of a second transgene for selection of transduced 
stem cells. Moreover, the TNS9 vector has been done in the backbone of a first-
generation lentiviral vector containing two intact HIV -1 LTRs. A SIN version of the 
TNS9 lentiviral vector must be developed using the third-generation packaging system 
to prevent recombination events generating replication-competent mv -1 virus. 
Another alternative approach addressing the problem of vector silencing involves the 
use of selection schemes to enrich for stem or progenitor cells that have provirus 
integrated at transcriptionally permissive sites. In one application, Kalberer et al 
transduced mouse marrow with an oncoretrovirus vector for human B-globin and a OFP 
reporter gene and preselected OFP-expressing cells before transplantation by flow 
cytometry (Kalberer et aI., 2000). As a result of preselection, they observed that the 
fraction of RBCs expressing OFP remained constant f9r up to 9.5 months after 
transplantation, and all mice expressed human B-globin in at least some peripheral 
RBCs. However, the levels of human B-globin expression were highly variable, and the 
published analysis did not include a serial assessment of human B-globin expression 
over time or a correlation between the fraction of RBCs expressing human B-globin and 
the level of provirus for individual animals. Thus, the effects of preselection on 
silencing of the therapeutic B-globin cassette in their study are difficult to assess. 
A third approach to overcoming silencing of globin gene vectors involves replacing the 
promoter for the globin gene cassette with a enhancer/promoter from other genes known 
to be expressed at high levels in RBCs. In one promising application of this approach, 
Sabatino et al demonstrate that fusion of a minimal ankyrin promoter to a B-globin gene 
allowed for expression in a copy number-dependent fashion in transgenic mice and at 
low levels in virtually all peripheral RBCs following retrovirus vector-mediated 
transduction of bone marrow in mice, indicating that this cassette is relatively resistant 
to silencing and position effects (Sabatino et aI., 2000; Sabatino et aI., 2000). Adapting 
this last strategy to our transcriptional targeting design allowed us to exploit and benefit 
of the chromatin opening function attributed to pioneer transcription factor, such as 
OATA~1. Since our OATA-LTR vector possess all the safety features common to the 
latest generation of lentiviral vecto~rs and seems to have a high probability to direct 
expression at all integration sites, using our targeting design we will probably be able to 
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overcome the major concerns regarding the ideal J3-globin gene therapy vector. Based 
on this optimistic assumption we decided to develop GATA-LTR lentiviral for human 
J3-globin expression. 
The goal of our lentiviral vectors for J3-globin expression was to reach a potentially 
therapeutic level of J3-globin polypeptides (at least 10-20 % of that present in normal red 
blood cells) in thalassemic erythroblasts. On the basis of results obtained by using 
transcriptionally targeted lentiviral vectors expressing GFP under the control of GATA-
LTR, we replaced the marker gene with a FLAG epitope tagged-440-bp J3-globin 
cDNA. HIV -1 cPPT and WPRE sequences were added within the framework of the 
vector to increase the efficiency of target cell transduction and RNA stability. The 
FLAG epitope was cloned in frame at the 5' end of the J3-globin cDNA to allow 
transgene detection with a specific anti-FLAG antibody. Gene expression obtainable 
with these modifications was measured at the level of RNA accumulation by Northern 
blot analysis and protein synthesis by Western blot analysis. 
HEL and MEL cells, expressing endogenous human a/y and murine alJ3 globins 
respectively, were transduced with lentiviral vectors and induce to differentiate in the 
presence of 50 p.M hemin and 2% DMSO respectively. The results from the Northern 
blot analysis showed that in hemin-induced HEL cells, the viral J3-globin transcripts 
accumulated at 230% of the level of endogenous globin mRNAs. The same analysis in 
DMSO-induced MEL cells showed that the viral J3-globin signal was 70% with respect 
to the endogenous murine globin signal. Similar results were obtained with the TNS9 
lentiviral vector by May and collegues who repo~ed that, after no:malization to vector 
copy number and to endogenous B-globin expression per allele, human B-globin levels 
were 71.3 ± 2.3jn pooled MEL cells (May et aI., 2000). Western blot analysis of hemin-
induced HEL cells showed that Flag-J3-globin was produced at a level of 42% with 
respect to endogenous human globin chains. In DMSO-indiced MEL cells, the leyel of 
vector derived Flag-J3-globin was 30% with respect to the endogenous murine signal. 
The comparison of viral transcripts accumulated in induced and non-induced cells 
showed that the GATA-LTR is already activated in non-induced cells and down-
regulated in induced cells. This suggests that the GATA-l transcription factor is not 
involved in the late phase of erythroid differentiation in HEL and MEL cells. Therefore, 
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both HEL and MEL cells seem to be useful to study the activity of our vectors in 
systems with an inducible production of hemoglobin. However, within these cell lines 
our GATA-LTR vector does not appear to mimic the transcriptional activation 
dependence of GAT A-I observed during erythroid differentiation of the human HSCs. 
For this reason, we decided to test the activity of our G.B.W/p.~N vector upon 
transduction and differentiation of human HSCs in vitro. Results from Northern blot 
analysis after normalization to endogenous a and ~-globin expression per allele, 
showed that viral ~-globin transcrips in erythroid-differentiated CD34+ cells 
accumulated at a level of 8.8% with respect to the endogenous globins. At the protein 
level, a signal quantified as 3.4% of endogenous globins was detected in erythroid-
differentiated CD34+ cells. After correction to endogenous a and f3-globin expression 
per allele, the proportion of Flag-f3-globin expression is 13.6%. Based on the data 
published from Persons and collegues (Persons et aI., 2001), a significant therapeutic 
benefit could be achieved with expression of a transferred gene at about 15% of the 
level of total a-globin in patients with severe ~-thalassaemia in whom 20% of erythroid 
precursors express the vector genome. With our vector we are very near to this 
therapeutic level and these results are particularly encouraging because they were 
obtained using CD34+ cells from healthy donors, where a strong competition between 
viral and endogenous ~-globin genes is present. For this reason, the real therapeutic 
efficacy of our vector should be tested in a ~-thalassemic context. On the other hand, 
the full potential of our design remains unexplored, since the use of a second gene as an 
in vivo selectable marker could be crucial for the treatment of severe f3-thalassaemia. 
Indeed, application of gene therapy approaches to treat severe ~- is likely to occur 
initially within the context of minimal myeloablation. Treated individuals are therefore 
likely to have a mixture of a small minority of genetically modified autologous cells, in 
which vector-mediated globin transgene expression is significantly less than the output 
of the normal human ~-globin gene locus, in a background with a majority of 
unmodified, diseased cells. With this approach, to provide an in" vi~o selection function 
to transduced cells could be essential. 
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In conclusion, we report a new lentiviral vector design based on the use of an enhancer-
replaced, transcriptionally targeted HIV LTR to express a therapeutic gene and of a 
second, independently regulated internal promoter to drive the expression of an 
accessory function such as an in vivo selection marker. This vector combines the 
advantages of using the spliced, genomic viral transcript to obtain high-level protein 
expression with the possibility to direct gene expression in a tissue- or cell-specific 
function through the use of a cellular enhancer to restrict the activity of the LTR 
promoter. The possibility to insert a second, independently regulated, transcription 
cassette in this backbone renders such a vector design particularly suited for gene 
therapy applications based on genetic modification of pluripotent HSCs with a 
transcriptionally targeted trans gene, in the context of a minimal or absent myeloablation 
of the patient. 
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